ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

Medicinal product no longer authorised
1. NAME OF THE MEDICINAL PRODUCT

Imprida HCT 5 mg/160 mg/12.5 mg film-coated tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film-coated tablet contains 5 mg of amlodipine (as amlodipine besylate), 160 mg of valsartan, and 12.5 mg of hydrochlorothiazide.

For a full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Film-coated tablet (tablet)

White, ovaloid, biconvex tablets with bevelled edge, debossed “NVR” on one side and “VCL” on the other side.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.

4.2 Posology and method of administration

Posology
The recommended dose of Imprida HCT is one tablet per day, to be taken preferably in the morning.

Before switching to Imprida HCT patients should be controlled on stable doses of the monocomponents taken at the same time. The dose of Imprida HCT should be based on the doses of the individual components of the combination at the time of switching.

The maximum recommended dose of Imprida HCT is 10 mg/320 mg/25 mg.

Special populations
Renal impairment
No adjustment of the initial dose is required for patients with mild to moderate renal impairment (see sections 4.4 and 5.2). Due to the hydrochlorothiazide component, Imprida HCT is contraindicated for use in patients with anuria (see section 4.3) and in patients with severe renal impairment (glomerular filtration rate (GFR) <30 ml/min/1.73 m²) (see sections 4.3, 4.4 and 5.2).

Hepatic impairment
Due to the valsartan component, Imprida HCT is contraindicated in patients with severe hepatic impairment (see section 4.3). In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan and therefore Imprida HCT is not suitable in this group of patients (see sections 4.3, 4.4 and 5.2).
Heart failure and coronary artery disease
There is limited experience with the use of Imprida HCT, particularly at the maximum dose, in patients with heart failure and coronary artery disease. Caution is advised in patients with heart failure and coronary artery disease, particularly at the maximum dose of Imprida HCT, 10 mg/320 mg/25 mg.

Elderly (age 65 years or over)
Caution, including more frequent monitoring of blood pressure, is recommended in elderly patients, particularly at the maximum dose of Imprida HCT, 10 mg/320 mg/25 mg, since available data in this patient population are limited.

Paediatric population
There is no relevant use of Imprida HCT in the paediatric population (patients below age 18 years) for the indication of essential hypertension.

Method of administration
Imprida HCT can be taken with or without food. The tablets should be swallowed whole with some water, at the same time of the day and preferably in the morning.

4.3 Contraindications
- Hypersensitivity to the active substances, to other sulphonamide derivatives, to dihydropyridine derivatives, or to any of the excipients.
- Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
- Hepatic impairment, biliary cirrhosis or cholestasis.
- Severe renal impairment (GFR <30 ml/min/1.73 m²), anuria and patients undergoing dialysis.
- Refractory hypokalaemia, hyponatraemia, hypercalcaemia, and symptomatic hyperuricaemia.

4.4 Special warnings and precautions for use
Sodium- and/or volume-depleted patients
Excessive hypotension, including orthostatic hypotension, was seen in 1.7% of patients treated with the maximum dose of Imprida HCT (10 mg/320 mg/25 mg) compared to 1.8% of valsartan/hydrochlorothiazide (320 mg/25 mg) patients, 0.4% of amlodipine/valsartan (10 mg/320 mg) patients, and 0.2% of hydrochlorothiazide/amlodipine (25 mg/10 mg) patients in a controlled trial in patients with moderate to severe uncomplicated hypertension.

In sodium-depleted and/or volume-depleted patients, such as those receiving high doses of diuretics, symptomatic hypotension may occur after initiation of treatment with Imprida HCT. Imprida HCT should be used only after correction of any pre-existing sodium and/or volume depletion.

If excessive hypotension occurs with Imprida HCT, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline. Treatment can be continued once blood pressure has been stabilised.

Serum electrolyte changes
Amlodipine/valsartan/hydrochlorothiazide
In the controlled trial of Imprida HCT, the counteracting effects of valsartan 320 mg and hydrochlorothiazide 25 mg on serum potassium approximately balanced each other in many patients. In other patients, one or the other effect may be dominant. Periodic determinations of serum electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals.

Periodic determination of serum electrolytes and potassium in particular should be performed at appropriate intervals to detect possible electrolyte imbalance, especially in patients with other risk factors such as impaired renal function, treatment with other medicinal products or history of prior electrolyte imbalances.
Valsartan
Concomitant use with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other medicinal products that may increase potassium levels (heparin, etc.) is not recommended. Monitoring of potassium should be undertaken as appropriate.

Hydrochlorothiazide
Treatment with Imprida HCT should only start after correction of hypokalaemia and any coexisting hypomagnesaemia. Thiazide diuretics can precipitate new onset hypokalaemia or exacerbate pre-existing hypokalaemia. Thiazide diuretics should be administered with caution in patients with conditions involving enhanced potassium loss, for example salt-losing nephropathies and prerenal (cardiogenic) impairment of kidney function. If hypokalaemia develops during hydrochlorothiazide therapy, Imprida HCT should be discontinued until stable correction of the potassium balance.

Thiazide diuretics can precipitate new onset hyponatraemia and hypochloroaemic alkalosis or exacerbate pre-existing hyponatraemia. Hyponatraemia, accompanied by neurological symptoms (nausea, progressive disorientation, apathy) has been observed. Treatment with hydrochlorothiazide should only be started after correction of pre-existing hyponatraemia. In case severe or rapid hyponatraemia develops during Imprida HCT therapy, the treatment should be discontinued until normalisation of natraemia.

All patients receiving thiazide diuretics should be periodically monitored for imbalances in electrolytes, particularly potassium, sodium and magnesium.

Renal impairment
Thiazide diuretics may precipitate azotaemia in patients with chronic kidney disease. When Imprida HCT is used in patients with renal impairment periodic monitoring of serum electrolytes (including potassium), creatinine and uric acid serum levels is recommended. Imprida HCT is contraindicated in patients with severe renal impairment, anuria or undergoing dialysis (see section 4.3).

No dosage adjustment of Imprida HCT is required for patients with mild to moderate renal impairment (GFR ≥30 ml/min/1.73 m²).

Renal artery stenosis
No data are available on the use of Imprida HCT in patients with unilateral or bilateral renal artery stenosis or stenosis to a solitary kidney.

Kidney transplantation
To date there is no experience of the safe use of Imprida HCT in patients who have had a recent kidney transplantation.

Hepatic impairment
Valsartan is mostly eliminated unchanged via the bile, whereas amlodipine is extensively metabolised by the liver. In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan, and therefore, Imprida HCT is not suitable in this group of patients (see sections 4.2, 4.3 and 5.2).

Heart failure and coronary artery disease
As a consequence of the inhibition of the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients with severe heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotaemia and (rarely) with acute renal failure and/or death. Similar outcomes have been reported with valsartan.
In a long-term, placebo-controlled study (PRAISE-2) of amlodipine in patients with NYHA (New York Heart Association Classification) III and IV heart failure of non-ischaemic aetiology, amlodipine was associated with increased reports of pulmonary oedema despite no significant difference in the incidence of worsening heart failure as compared to placebo.

Caution is advised in patients with heart failure and coronary artery disease, particularly at the maximum dose of Imprida HCT, 10 mg/320 mg/25 mg, since available data in these patient populations is limited.

Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy
As with all other vasodilators, special caution is indicated in patients with aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.

Pregnancy
Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).

Primary hyperaldosteronism
Patients with primary hyperaldosteronism should not be treated with the angiotensin II antagonist valsartan as their renin-angiotensin system is not activated. Therefore, Imprida HCT is not recommended in this population.

Systemic lupus erythematosus
Thiazide diuretics, including hydrochlorothiazide, have been reported to exacerbate or activate systemic lupus erythematosus.

Other metabolic disturbances
Thiazide diuretics, including hydrochlorothiazide, may alter glucose tolerance and raise serum levels of cholesterol, triglycerides and uric acid. In diabetic patients dosage adjustments of insulin or oral hypoglycaemic agents may be required.

Due to the hydrochlorothiazide component, Imprida HCT is contraindicated in symptomatic hyperuricaemia. Hydrochlorothiazide may raise the serum uric acid level due to reduced clearance of uric acid and may cause or exacerbate hyperuricaemia as well as precipitate gout in susceptible patients.

Thiazides reduce urinary calcium excretion and may cause intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Imprida HCT is contraindicated in patients with hypercalcaemia and should only be used after correction of any pre-existing hypercalcaemia. Imprida HCT should be discontinued if hypercalcaemia develops during treatment. Serum levels of calcium should be periodically monitored during treatment with thiazides. Marked hypercalcaemia may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function.

Photosensitivity
Cases of photosensitivity reactions have been reported with thiazide diuretics (see section 4.8). If photosensitivity reaction occurs during treatment with Imprida HCT, it is recommended to stop the treatment. If a readministration of the diuretic is deemed necessary, it is recommended to protect exposed areas to the sun or to artificial UVA.
Acute angle-closure glaucoma
Hydrochlorothiazide, a sulphonamide, has been associated with an idiosyncratic reaction resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to a week of treatment initiation. Untreated acute-angle closure glaucoma can lead to permanent vision loss.

The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatment may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle closure glaucoma may include a history of sulphonamide or penicillin allergy.

General
Caution should be exercised in patients who have shown prior hypersensitivity to other angiotensin II receptor antagonists. Hypersensitivity reactions to hydrochlorothiazide are more likely in patients with allergy and asthma.

Elderly (age 65 years or over)
Caution, including more frequent monitoring of blood pressure, is recommended in elderly patients, particularly at the maximum dose of Imprida HCT, 10 mg/320 mg/25 mg, since available data in this patient population are limited.

4.5 Interaction with other medicinal products and other forms of interaction

No formal interaction studies with other medicinal products were performed with Imprida HCT. Thus, only information on interactions with other medicinal products that are known for the individual active substances is provided in this section.

However, it is important to take into account that Imprida HCT may increase the hypotensive effect of other antihypertensive agents.
### Known interactions with the following agents

<table>
<thead>
<tr>
<th>Medicinal Product</th>
<th>Known interactions</th>
<th>Effect of the interaction with other medicinal products</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Concomitant use not recommended</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Imprida HCT individual component</strong></td>
<td>Lithium</td>
<td>Reversible increases in serum lithium concentrations and toxicity have been reported during concurrent use of ACE inhibitors and thiazides such as hydrochlorothiazide. Despite the lack of experience with concomitant use of valsartan and lithium, this combination is not recommended. If the combination proves necessary, careful monitoring of serum lithium levels is recommended (see section 4.4).</td>
</tr>
<tr>
<td><strong>Known interactions</strong></td>
<td>Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may increase potassium levels</td>
<td>If a medicinal product that affects potassium levels is considered necessary in combination with valsartan, frequent monitoring of potassium plasma levels is advised.</td>
</tr>
<tr>
<td><strong>Amlodipine</strong></td>
<td>Grapefruit or grapefruit juice</td>
<td>Administration of amlodipine with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients, resulting in increased blood pressure lowering effects.</td>
</tr>
<tr>
<td><strong>Caution required with concomitant use</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Imprida HCT individual component</strong></td>
<td><strong>CYP3A4 inhibitors</strong> (i.e. ketoconazole, itraconazole, ritonavir)</td>
<td>Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors, azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem) may give rise to significant increase in amlodipine exposure. The clinical translation of these pharmacokinetic variations may be more pronounced in the elderly. Clinical monitoring and dose adjustment may thus be required.</td>
</tr>
<tr>
<td></td>
<td><strong>CYP3A4 inducers</strong> (anticonvulsant agents [e.g. carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone], rifampicin, <em>Hypericum perforatum</em> [St. John’s wort])</td>
<td>There is no data available regarding the effect of CYP3A4 inducers on amlodipine. The concomitant use of CYP3A4 inducers (e.g. rifampicin, <em>Hypericum perforatum</em>) may give a lower plasma concentration of amlodipine. Amlodipine should be used with caution together with CYP3A4 inducers.</td>
</tr>
<tr>
<td><strong>Simvastatin</strong></td>
<td>Co-administration of multiple doses of 10 mg amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. It is recommended to limit the dose of simvastatin to 20 mg daily in patients on amlodipine.</td>
<td></td>
</tr>
<tr>
<td><strong>Dantrolene (infusion)</strong></td>
<td>In animals, lethal ventricular fibrillation and cardiovascular collapse are observed in association with hyperkalaemia after administration of verapamil and intravenous dantrolene. Due to risk of hyperkalaemia, it is recommended that the co-administration of calcium channel blockers such as amlodipine be avoided in patients susceptible to malignant hyperthermia and in the management of malignant hyperthermia.</td>
<td></td>
</tr>
<tr>
<td><strong>Valsartan</strong></td>
<td><strong>Non-steroidal anti-inflammatory medicines (NSAIDs), including selective cyclooxygenase-2 inhibitors (COX-2 inhibitors), acetylsalicylic acid (&gt;3 g/day), and non-selective NSAIDs</strong> NSAIDS can attenuate the antihypertensive effect of both angiotensin II antagonists and hydrochlorothiazide when administered simultaneously. Furthermore, concomitant use of Imprida HCT and NSAIDs may lead to worsening of renal function and an increase in serum potassium. Therefore, monitoring of renal function at the beginning of the treatment is recommended, as well as adequate hydration of the patient.</td>
<td></td>
</tr>
<tr>
<td><strong>Valsartan</strong></td>
<td><strong>Inhibitors of the uptake transporter (rifampicin, ciclosporin) or efflux transporter (ritonavir)</strong> The results of an <em>in vitro</em> study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1 and of the hepatic efflux transporter MRP2. Co-administration of inhibitors of the uptake transporter (rifampicin, ciclosporin) or efflux transporter (ritonavir) may increase the systemic exposure to valsartan.</td>
<td></td>
</tr>
<tr>
<td><strong>HCT</strong></td>
<td><strong>Alcohol, barbiturates or narcotics</strong> Concomitant administration of thiazide diuretics with substances that also have a blood pressure lowering effect (e.g. by reducing sympathetic central nervous system activity or direct vasodilatation) may potentiate orthostatic hypotension.</td>
<td></td>
</tr>
<tr>
<td><strong>Amantadine</strong></td>
<td>Thiazides, including hydrochlorothiazide, may increase the risk of adverse reactions caused by amantadine.</td>
<td></td>
</tr>
<tr>
<td><strong>Anticholinergic agents and other medicinal products affecting gastric motility</strong></td>
<td>The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents (e.g. atropine, biperiden), apparently due to a decrease in gastrointestinal motility and the stomach emptying rate. Conversely, it is anticipated that prokinetic substances such as cisapride may decrease the bioavailability of thiazide-type diuretics.</td>
<td></td>
</tr>
<tr>
<td><strong>Antidiabetic agents</strong> (e.g. insulin and oral antidiabetic agents)</td>
<td>Thiazides may alter glucose tolerance. Dose adjustment of the antidiabetic medicinal product may be necessary.</td>
<td></td>
</tr>
<tr>
<td>– <strong>Metformin</strong></td>
<td>Metformin should be used with caution because of the risk of lactic acidosis induced by possible functional renal failure linked to hydrochlorothiazide.</td>
<td></td>
</tr>
<tr>
<td><strong>Beta blockers and diazoxide</strong></td>
<td>Concomitant use of thiazide diuretics, including hydrochlorothiazide, with beta blockers may increase the risk of hyperglycaemia. Thiazide diuretics, including hydrochlorothiazide, may enhance the hyperglycaemic effect of diazoxide.</td>
<td></td>
</tr>
<tr>
<td>Medicinal Product Category</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>----------------------------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td><strong>Ciclosporin</strong></td>
<td>Concomitant treatment with ciclosporin may increase the risk of hyperuricaemia and gout-type complications.</td>
<td></td>
</tr>
<tr>
<td><strong>Cytotoxic agents</strong></td>
<td>Thiazides, including hydrochlorothiazide, may reduce the renal excretion of cytotoxic agents (e.g. cyclophosphamide, methotrexate) and potentiate their myelosuppressive effects.</td>
<td></td>
</tr>
<tr>
<td><strong>Digitalis glycosides</strong></td>
<td>Thiazide-induced hypokalaemia or hypomagnesaemia may occur as undesirable effects, favouring the onset of digitalis-induced cardiac arrhythmias.</td>
<td></td>
</tr>
<tr>
<td><strong>Iodine contrasting agents</strong></td>
<td>In case of diuretic-induced dehydration, there is an increased risk of acute renal failure, especially with high doses of iodine products. Patients should be re-hydrated before the administration.</td>
<td></td>
</tr>
<tr>
<td><strong>Ion exchange resins</strong></td>
<td>Absorption of thiazide diuretics, including hydrochlorothiazide, is decreased by cholestyramine or colestipol. This could result in sub-therapeutic effects of thiazide diuretics. However, staggering the dosage of hydrochlorothiazide and resin such that hydrochlorothiazide is administered at least 4 hours before or 4-6 hours after the administration of resins would potentially minimise the interaction.</td>
<td></td>
</tr>
<tr>
<td><strong>Medicinal products affecting serum potassium level</strong></td>
<td>The hypokalaemic effect of hydrochlorothiazide may be increased by concomitant administration of kaliuretic diuretics, corticosteroids, laxatives, adrenocorticotropic hormone (ACTH), amphotericin, carbenoxolone, penicillin G and salicylic acid derivatives or antiarrhythmics. If these medicinal products are to be prescribed with the amlodipine /valsartan /hydrochlorothiazide combination, monitoring of potassium plasma levels is advised.</td>
<td></td>
</tr>
<tr>
<td><strong>Medicinal products affecting serum sodium level</strong></td>
<td>The hyponatraemic effect of diuretics may be intensified by concomitant administration of medicinal products such as antidepressants, antipsychotics, antiepileptics, etc. Caution is indicated in long-term administration of these medicinal products.</td>
<td></td>
</tr>
<tr>
<td><strong>Medicinal products that could induce torsades de pointes</strong></td>
<td>Due to the risk of hypokalaemia, hydrochlorothiazide should be administered with caution when associated with medicinal products that could induce torsades de pointes, in particular Class Ia and Class III antiarrhythmics and some antipsychotics.</td>
<td></td>
</tr>
<tr>
<td><strong>Medicinal products used in the treatment of gout (probenecid, sulfinpyrazone and allopurinol)</strong></td>
<td>Dose adjustment of uricosuric medicinal products may be necessary as hydrochlorothiazide may raise the level of serum uric acid. Increase of dose of probenecid or sulfinpyrazone may be necessary. Co-administration of thiazide diuretics, including hydrochlorothiazide, may increase the incidence of hypersensitivity reactions to allopurinol.</td>
<td></td>
</tr>
<tr>
<td><strong>Methyldopa</strong></td>
<td>There have been isolated reports of haemolytic anaemia occurring with concomitant use of hydrochlorothiazide and methyldopa.</td>
<td></td>
</tr>
<tr>
<td><strong>Non-depolarising skeletal muscle relaxants (e.g. tubocurarine)</strong></td>
<td>Thiazides, including hydrochlorothiazide, potentiate the action of curare derivatives.</td>
<td></td>
</tr>
</tbody>
</table>
**Other anti-hypertensive drugs**

Thiazides potentiate the antihypertensive action of other antihypertensive drugs (e.g. guanethidine, methyldopa, beta-blockers, vasodilators, calcium channel blockers, ACE inhibitors, ARBs and Direct Renin Inhibitors (DRIs)).

**Pressor amines (e.g. noradrenaline, adrenaline)**

Hydrochlorothiazide may reduce the response to pressor amines such as noradrenaline. The clinical significance of this effect is uncertain and not sufficient to preclude their use.

**Vitamin D and calcium salts**

Administration of thiazide diuretics, including hydrochlorothiazide, with vitamin D or with calcium salts may potentiate the rise in serum calcium. Concomitant use of thiazide type diuretics may lead to hypercalcaemia in patients pre-disposed for hypercalcaemia (e.g. hyperparathyroidism, malignancy or vitamin-D-mediated conditions) by increasing tubular calcium reabsorption.

<table>
<thead>
<tr>
<th>No interaction</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Imprida HCT individual component</strong></td>
</tr>
<tr>
<td><strong>Known interactions with the following agents</strong></td>
</tr>
<tr>
<td><strong>Effect of the interaction with other medicinal products</strong></td>
</tr>
</tbody>
</table>

| Valsartan | Others | In monotherapy with valsartan, no interactions of clinical significance have been found with the following substances: cimetidine, warfarin, furosemide, digoxin, atenolol, indomethacin, hydrochlorothiazide, amlodipine, glibenclamide. Some of these substances could interact with the hydrochlorothiazide component of Imprida HCT (see interactions related to HCT). |
| Amlodipine | Others | In clinical interaction studies, amlodipine did not affect the pharmacokinetics of atorvastatin, digoxin, warfarin or ciclosporin. |

### 4.6 Fertility, pregnancy and lactation

#### Pregnancy Amlodipine

The safety of amlodipine in human pregnancy has not been established. In animal studies, reproductive toxicity was observed at high doses (see section 5.3). Use in pregnancy is only recommended when there is no safer alternative and when the disease itself carries greater risk for the mother and foetus.
Valsartan

The use of Angiotensin II Receptor Antagonists (AIIRAs) is not recommended during the first trimester of pregnancy (see section 4.4). The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 and 4.4).

Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and if appropriate, alternative therapy should be started.

Exposure to AIIRAs therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3).

Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.

Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3 and 4.4).

Hydrochlorothiazide

There is limited experience with hydrochlorothiazide during pregnancy, especially during the first trimester. Animal studies are insufficient.

Hydrochlorothiazide crosses the placenta. Based on the pharmacological mechanism of action of hydrochlorothiazide, its use during the second and third trimester may compromise foeto-placental perfusion and may cause foetal and neonatal effects like icterus, disturbance of electrolyte balance and thrombocytopenia.

Amlodipine/valsartan/hydrochlorothiazide

There is no experience on the use of Imprida HCT in pregnant women. Based on the existing data with the components, the use of Imprida HCT is not recommended during first trimester and contraindicated during the second and third trimester of pregnancy (see sections 4.3 and 4.4).

Breast-feeding

No information is available regarding the use of valsartan and/or amlodipine during breast-feeding. Hydrochlorothiazide is excreted in human milk in small amounts. Thiazides in high doses causing intense diuresis can inhibit milk production. The use of Imprida HCT during breast-feeding is not recommended. If Imprida HCT is used during breast-feeding, doses should be kept as low as possible. Alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.

Fertility

There are no clinical studies on fertility with Imprida HCT.

Valsartan

Valsartan had no adverse effects on the reproductive performance of male or female rats at oral doses up to 200 mg/kg/day. This dose is 6 times the maximum recommended human dose on a mg/m² basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).
**Amlodipine**

Reversible biochemical changes in the head of spermatozoa have been reported in some patients treated by calcium channel blockers. Clinical data are insufficient regarding the potential effect of amlodipine on fertility. In one rat study, adverse effects were found on male fertility (see section 5.3).

### 4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. When driving vehicles or using machines it should be taken into account that occasionally dizziness or weariness may occur.

### 4.8 Undesirable effects

The safety profile of Imprida HCT presented below is based on clinical studies performed with Imprida HCT and the known safety profile of the individual components amlodipine, valsartan and hydrochlorothiazide.

#### Information on Imprida HCT

The safety of Imprida HCT has been evaluated at its maximum dose of 10 mg/320 mg/25 mg in one controlled short-term (8 weeks) clinical study with 2,271 patients, 582 of whom received valsartan in combination with amlodipine and hydrochlorothiazide. Adverse reactions were generally mild and transient in nature and only infrequently required discontinuation of therapy. In this active controlled clinical trial, the most common reasons for discontinuation of therapy with Imprida HCT were dizziness and hypotension (0.7%).

In the 8-week controlled clinical study, no significant new or unexpected adverse reactions were observed with triple therapy treatment compared to the known effects of the monotherapy or dual therapy components.

In the 8-week controlled clinical study, changes in laboratory parameters observed with the combination of Imprida HCT were minor and consistent with the pharmacological mechanism of action of the monotherapy agents. The presence of valsartan in the triple combination attenuated the hypokalaemic effect of hydrochlorothiazide.

The following adverse reactions, listed by MedDRA System Organ Class and frequency, concern Imprida HCT (amlodipine/valsartan/HCT) and amlodipine, valsartan and HCT individually. Very common: ≥1/10; common: ≥1/100 to <1/10; uncommon: ≥1/1,000 to <1/100; rare: ≥1/10,000 to <1/1,000; very rare: <1/10,000, not known (cannot be estimated from the available data).

<table>
<thead>
<tr>
<th>MedDRA System Organ Class</th>
<th>Adverse reactions</th>
<th>Frequency</th>
<th>Imprida HCT</th>
<th>Amlodipine</th>
<th>Valsartan</th>
<th>HCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>Agranulocytosis, bone marrow depression</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Very rare</td>
</tr>
<tr>
<td></td>
<td>Decrease in haemoglobin and in haematocrit</td>
<td>--</td>
<td>--</td>
<td>Not known</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Haemolytic anaemia</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Very rare</td>
</tr>
<tr>
<td></td>
<td>Leukopenia</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>Very rare</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Neutropenia</td>
<td>--</td>
<td></td>
<td>Not known</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thrombocytopenia, sometimes with purpura</td>
<td>--</td>
<td>Very rare</td>
<td>Not known</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aplastic anaemia</td>
<td>--</td>
<td></td>
<td>--</td>
<td>--</td>
<td>Not known</td>
</tr>
<tr>
<td>Disorder</td>
<td>Frequency</td>
<td>Immune system disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-----------</td>
<td>-------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypersensitivity</td>
<td>--</td>
<td>Very rare</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anorexia</td>
<td>Uncommon</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypercalcaemia</td>
<td>Uncommon</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperglycaemia</td>
<td>--</td>
<td>Very rare</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperlipidaemia</td>
<td>Uncommon</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperuricaemia</td>
<td>Uncommon</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypochloreaemic alkalosis</td>
<td>--</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypokalaemia</td>
<td>Common</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypomagnesaemia</td>
<td>--</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyponatraemia</td>
<td>Uncommon</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Worsening of diabetic metabolic state</td>
<td>--</td>
<td>Rare</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression</td>
<td>--</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anorexia</td>
<td>Uncommon</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypercalcaemia</td>
<td>Uncommon</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperglycaemia</td>
<td>--</td>
<td>Very rare</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperlipidaemia</td>
<td>Uncommon</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperuricaemia</td>
<td>Uncommon</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypochloreaemic alkalosis</td>
<td>--</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypokalaemia</td>
<td>Common</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypomagnesaemia</td>
<td>--</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyponatraemia</td>
<td>Uncommon</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Worsening of diabetic metabolic state</td>
<td>--</td>
<td>Rare</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression</td>
<td>--</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insomnia/sleep disturbances</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mood swings</td>
<td>--</td>
<td>Uncommon</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coordination abnormal</td>
<td>Uncommon</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td>Common</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dizziness postural, dizziness exertional</td>
<td>Uncommon</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyseusia</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Extrapyramidal syndrome</td>
<td>--</td>
<td>Not known</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>Common</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertonia</td>
<td>Very rare</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lethargy</td>
<td>Uncommon</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paraesthesia</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peripheral neuropathy, neuropathy</td>
<td>Uncommon</td>
<td>Very rare</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Somnolence</td>
<td>Uncommon</td>
<td>Common</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Syncope</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tremor</td>
<td>--</td>
<td>Uncommon</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute angle-closure glaucoma</td>
<td>--</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visual impairment</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ear and labyrinth disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tinnitus</td>
<td>--</td>
<td>Uncommon</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vertigo</td>
<td>Uncommon</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Palpitations</td>
<td>--</td>
<td>Common</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tachycardia</td>
<td>Uncommon</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arrhythmias (including bradycardia, ventricular tachycardia, and atrial fibrillation)</td>
<td>--</td>
<td>Very rare</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>--</td>
<td>Very rare</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vascular disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flushing</td>
<td>--</td>
<td>Common</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypotension</td>
<td>Common</td>
<td>Uncommon</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Orthostatic hypotension</td>
<td>Uncommon</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phlebitis, thrombophlebitis</td>
<td>Uncommon</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vasculitis</td>
<td>--</td>
<td>Very rare</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Not known
--
Rare
<table>
<thead>
<tr>
<th>Respiratory, thoracic and mediastinal disorders</th>
<th>Cough</th>
<th>Uncommon</th>
<th>Very rare</th>
<th>Uncommon</th>
<th>--</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dyspnoea</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Respiratory distress, pulmonary oedema, pneumonitis</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Very rare</td>
<td></td>
</tr>
<tr>
<td>Rhinitis</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Throat irritation</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Abdominal discomfort, abdominal pain upper</td>
<td>Uncommon</td>
<td>Common</td>
<td>Uncommon</td>
<td>Rare</td>
</tr>
<tr>
<td>Breath odour</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Change of bowel habit</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Constipation</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Common</td>
<td></td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td>Dry mouth</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>Common</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Gastritis</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Gingival hyperplasia</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Nausea</td>
<td>Uncommon</td>
<td>Common</td>
<td>--</td>
<td>Common</td>
<td></td>
</tr>
<tr>
<td>Pancreatitis</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>Very rare</td>
<td></td>
</tr>
<tr>
<td>Vomiting</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>Common</td>
<td></td>
</tr>
<tr>
<td>Hepatobiliary disorders</td>
<td>Hepatic enzyme elevation, including increase of serum bilirubin</td>
<td>--</td>
<td>Very rare</td>
<td>Not known</td>
<td>--</td>
</tr>
<tr>
<td>Hepatitis</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Intrahepatic cholestasis, jaundice</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>Alopecia</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Angioedema</td>
<td>--</td>
<td>Very rare</td>
<td>Not known</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Cutaneous lupus erythematosus-like reactions, reactivation of cutaneous lupus erythematosus</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Very rare</td>
<td></td>
</tr>
<tr>
<td>Erythema multiforme</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>Not known</td>
<td>--</td>
</tr>
<tr>
<td>Exanthema</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Hyperhidrosis</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Photosensitivity reaction*</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td>Purpura</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>Not known</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Rash</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td>Skin discoloration</td>
<td>--</td>
<td>Uncommon</td>
<td>Not known</td>
<td>Common</td>
<td></td>
</tr>
<tr>
<td>Urticaria and other forms of rash</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>Common</td>
<td></td>
</tr>
<tr>
<td>Vasculitis necrotising and toxic epidermal necrolysis</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Very rare</td>
<td></td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td>Arthralgia</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Back pain</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Joint swelling</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Muscle spasm</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>Not known</td>
<td>--</td>
</tr>
<tr>
<td>Muscular weakness</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Myalgia</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>Not known</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Pain in extremity</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
</tbody>
</table>
### Renal and urinary disorders

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Frequency</th>
<th>Note</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elevation of serum creatinine</td>
<td>Uncommon</td>
<td>--</td>
<td>Not known</td>
</tr>
<tr>
<td>Micturition disorder</td>
<td></td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Nocturia</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
</tr>
<tr>
<td>Pollakiuria</td>
<td>Common</td>
<td>Uncommon</td>
<td></td>
</tr>
<tr>
<td>Renal dysfunction</td>
<td></td>
<td>--</td>
<td>Not known</td>
</tr>
<tr>
<td>Renal failure acute</td>
<td>Uncommon</td>
<td>--</td>
<td>Not known</td>
</tr>
<tr>
<td>Renal failure and impairment</td>
<td></td>
<td>--</td>
<td>Rare</td>
</tr>
</tbody>
</table>

### Reproductive system and breast disorders

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Frequency</th>
<th>Note</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>Impotence</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>Common</td>
</tr>
<tr>
<td>Gynaecomastia</td>
<td></td>
<td>Uncommon</td>
<td></td>
</tr>
</tbody>
</table>

### General disorders and administration site conditions

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Frequency</th>
<th>Note</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abasia, gait disturbance</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Asthenia</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>Not known</td>
</tr>
<tr>
<td>Discomfort, malaise</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
</tr>
<tr>
<td>Fatigue</td>
<td>Common</td>
<td>Common</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Non cardiac chest pain</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td></td>
</tr>
<tr>
<td>Oedema</td>
<td>Common</td>
<td>Common</td>
<td>--</td>
</tr>
<tr>
<td>Pain</td>
<td></td>
<td>Uncommon</td>
<td>--</td>
</tr>
<tr>
<td>Pyrexia</td>
<td></td>
<td>--</td>
<td>Not known</td>
</tr>
</tbody>
</table>

### Investigations

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Frequency</th>
<th>Note</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lipids increased</td>
<td></td>
<td>Very common</td>
<td></td>
</tr>
<tr>
<td>Blood urea nitrogen increased</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Blood uric acid increased</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Glycosuria</td>
<td></td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td>Serum potassium decreased</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Serum potassium increased</td>
<td></td>
<td>--</td>
<td>Not known</td>
</tr>
<tr>
<td>Weight increase</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
</tr>
<tr>
<td>Weight decrease</td>
<td></td>
<td>Uncommon</td>
<td>--</td>
</tr>
</tbody>
</table>

* See section 4.4 Photosensitivity

### 4.9 Overdose

**Symptoms**

There is no experience of overdose with Imprida HCT. The major symptom of overdose with valsartan is possibly pronounced hypotension with dizziness. Overdose with amlodipine may result in excessive peripheral vasodilatation and, possibly, reflex tachycardia. Marked and potentially prolonged systemic hypotension, including shock with fatal outcome, have been reported with amlodipine.

**Treatment**

*Amlodipine/Valsartan/Hydrochlorothiazide*

Clinically significant hypotension due to Imprida HCT overdose calls for active cardiovascular support, including frequent monitoring of cardiac and respiratory function, elevation of extremities, and attention to circulating fluid volume and urine output. A vasoconstrictor may be helpful in restoring vascular tone and blood pressure, provided that there is no contraindication to its use. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade.

*Amlodipine*

If ingestion is recent, induction of vomiting or gastric lavage may be considered. Administration of activated charcoal to healthy volunteers immediately or up to two hours after ingestion of amlodipine has been shown to significantly decrease amlodipine absorption. Amlodipine is unlikely to be removed by haemodialysis.
**Valsartan**
Valsartan is unlikely to be removed by haemodialysis.

**Hydrochlorothiazide**
Overdose with hydrochlorothiazide is associated with electrolyte depletion (hypokalaemia, hypochloraemia) and hypovolaemia resulting from excessive diuresis. The most common signs and symptoms of overdose are nausea and somnolence. Hypokalaemia may result in muscle spasms and or accentuate arrhythmia associated with the concomitant use of digitalis glycosides or certain anti-arrhythmic medicinal products. The degree to which hydrochlorothiazide is removed by haemodialysis has not been established.

5. **PHARMACOLOGICAL PROPERTIES**

5.1 **Pharmacodynamic properties**

Pharmacotherapeutic group: Angiotensin II antagonists, plain (valsartan), combinations with dihydropyridine derivatives (amlodipine) and thiazide diuretics (hydrochlorothiazide), ATC code: C09DX01 valsartan, amlodipine and hydrochlorothiazide.

Imprida HCT combines three antihypertensive compounds with complementary mechanisms to control blood pressure in patients with essential hypertension: amlodipine belongs to the calcium antagonist class and valsartan to the angiotensin II antagonist class of medicines and hydrochlorothiazide belongs to the thiazide diuretics class of medicines. The combination of these substances has an additive antihypertensive effect.

**Amlodipine/Valsartan/Hydrochlorothiazide**

Imprida HCT was studied in a double-blind, active controlled study in hypertensive patients. A total of 2,271 patients with moderate to severe hypertension (mean baseline systolic/diastolic blood pressure was 170/107 mmHg) received treatments of amlodipine/valsartan/hydrochlorothiazide 10 mg/320 mg/25 mg, valsartan/hydrochlorothiazide 320 mg/25 mg, amlodipine/valsartan 10 mg/320 mg, or hydrochlorothiazide/amlodipine 25 mg/10 mg. At study initiation patients were assigned lower doses of their treatment combination and were titrated to their full treatment dose by week 2.

At week 8, the mean reductions in systolic/diastolic blood pressure were 39.7/24.7 mmHg with Imprida HCT, 32.0/19.7 mmHg with valsartan/hydrochlorothiazide, 33.5/21.5 mmHg with amlodipine/valsartan and 31.5/19.5 mmHg with amlodipine/hydrochlorothiazide. The triple combination therapy was statistically superior to each of the three dual combination treatments in reduction of diastolic and systolic blood pressures. The reductions in systolic/diastolic blood pressure with Imprida HCT were 7.6/5.0 mmHg greater than with valsartan/hydrochlorothiazide, 6.2/3.3 mmHg greater than with amlodipine/valsartan, and 8.2/5.3 mmHg greater than with amlodipine/hydrochlorothiazide. The full blood pressure lowering effect was achieved 2 weeks after being on their maximal dose of Imprida HCT. Statistically greater proportions of patients achieved blood pressure control (<140/90 mmHg) with Imprida HCT (71%) compared to each of the three dual combination therapies (45-54%) (p<0.0001).

In a subgroup of 283 patients focusing on ambulatory blood pressure monitoring, clinically and statistically superior reductions in 24-hour systolic and diastolic blood pressures were observed with the triple combination compared to valsartan/hydrochlorothiazide, valsartan/amlodipine, and hydrochlorothiazide/amlodipine.
Amlodipine
The amlodipine component of Imprida HCT inhibits the transmembrane entry of calcium ions into cardiac and vascular smooth muscle. The mechanism of the antihypertensive action of amlodipine is due to a direct relaxant effect on vascular smooth muscle, causing reductions in peripheral vascular resistance and in blood pressure. Experimental data suggest that amlodipine binds to both dihydropyridine and non-dihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels.

Following administration of therapeutic doses to patients with hypertension, amlodipine produces vasodilation, resulting in a reduction of supine and standing blood pressures. These decreases in blood pressure are not accompanied by a significant change in heart rate or plasma catecholamine levels with chronic dosing.

Plasma concentrations correlate with effect in both young and elderly patients.

In hypertensive patients with normal renal function, therapeutic doses of amlodipine resulted in a decrease in renal vascular resistance and increases in glomerular filtration rate and effective renal plasma flow, without change in filtration fraction or proteinuria.

Valsartan
Valsartan is an orally active, potent and specific angiotensin II receptor antagonist. It acts selectively on the receptor subtype AT1, which is responsible for the known actions of angiotensin II.

Administration of valsartan to patients with hypertension results in a drop in blood pressure without affecting pulse rate.

In most patients, after administration of a single oral dose, onset of antihypertensive activity occurs within 2 hours, and the peak drop in blood pressure is achieved within 4-6 hours. The antihypertensive effect persists over 24 hours after administration. During repeated administration, the maximum reduction in blood pressure with any dose is generally attained within 2-4 weeks.

Hydrochlorothiazide
The site of action of thiazide diuretics is primarily in the renal distal convoluted tubule. It has been shown that there is a high-affinity receptor in the renal cortex as the primary binding site for the thiazide diuretic action and inhibition of NaCl transport in the distal convoluted tubule. The mode of action of thiazides is through inhibition of the Na\(^+\)Cl\(^-\) symporter perhaps by competing for the Cl\(^-\) site, thereby affecting electrolyte reabsorption mechanisms: directly increasing sodium and chloride excretion to an approximately equal extent, and indirectly, by this diuretic action, reducing plasma volume, with consequent increases in plasma renin activity, aldosterone secretion and urinary potassium loss, and a decrease in serum potassium.

The European Medicines Agency has waived the obligation to submit the results of studies with Imprida HCT in all subsets of the paediatric population in essential hypertension. See section 4.2 for information on paediatric use.

5.2 Pharmacokinetic properties

Linearity
Amlodipine, valsartan and hydrochlorothiazide exhibit linear pharmacokinetics.

Amlodipine/valsartan/hydrochlorothiazide
Following oral administration of Imprida HCT in normal healthy adults, peak plasma concentrations of amlodipine, valsartan and hydrochlorothiazide are reached in 6-8 hours, 3 hours, and 2 hours, respectively. The rate and extent of absorption of amlodipine, valsartan and hydrochlorothiazide from Imprida HCT are the same as when administered as individual dosage forms.
**Amlodipine**

**Absorption:** After oral administration of therapeutic doses of amlodipine alone, peak plasma concentrations of amlodipine are reached in 6-12 hours. Absolute bioavailability has been calculated as between 64% and 80%. Amlodipine bioavailability is unaffected by food ingestion.

**Distribution:** Volume of distribution is approximately 21 l/kg. *In vitro* studies with amlodipine have shown that approximately 97.5% of circulating drug is bound to plasma proteins.

**Biotransformation:** Amlodipine is extensively (approximately 90%) metabolised in the liver to inactive metabolites.

**Elimination:** Amlodipine elimination from plasma is biphasic, with a terminal elimination half-life of approximately 30 to 50 hours. Steady-state plasma levels are reached after continuous administration for 7-8 days. Ten per cent of original amlodipine and 60% of amlodipine metabolites are excreted in urine.

**Valsartan**

**Absorption:** Following oral administration of valsartan alone, peak plasma concentrations of valsartan are reached in 2-4 hours. Mean absolute bioavailability is 23%. Food decreases exposure (as measured by AUC) to valsartan by about 40% and peak plasma concentration (C_{max}) by about 50%, although from about 8 h post dosing plasma valsartan concentrations are similar for the fed and fasted groups. This reduction in AUC is not, however, accompanied by a clinically significant reduction in the therapeutic effect, and valsartan can therefore be given either with or without food.

**Distribution:** The steady-state volume of distribution of valsartan after intravenous administration is about 17 litres, indicating that valsartan does not distribute into tissues extensively. Valsartan is highly bound to serum proteins (94-97%), mainly serum albumin.

**Biotransformation:** Valsartan is not transformed to a high extent as only about 20% of dose is recovered as metabolites. A hydroxy metabolite has been identified in plasma at low concentrations (less than 10% of the valsartan AUC). This metabolite is pharmacologically inactive.

**Elimination:** Valsartan is primarily eliminated in faeces (about 83% of dose) and urine (about 13% of dose), mainly as unchanged drug. Following intravenous administration, plasma clearance of valsartan is about 2 l/h and its renal clearance is 0.62 l/h (about 30% of total clearance). The half-life of valsartan is 6 hours.

**Hydrochlorothiazide**

**Absorption:** The absorption of hydrochlorothiazide, after an oral dose, is rapid (T_{max} about 2 hours). The increase in mean AUC is linear and dose proportional in the therapeutic range.

The effect of food on hydrochlorothiazide absorption, if any, has little clinical significance. Absolute bioavailability of hydrochlorothiazide is 70% after oral administration.

**Distribution:** The apparent volume of distribution is 4-8 l/kg. Circulating hydrochlorothiazide is bound to serum proteins (40-70%), mainly serum albumin. Hydrochlorothiazide also accumulates in erythrocytes at approximately 3 times the level in plasma.

**Biotransformation:** Hydrochlorothiazide is eliminated predominantly as unchanged compound.

**Elimination:** Hydrochlorothiazide is eliminated from plasma with a half-life averaging 6 to 15 hours in the terminal elimination phase. There is no change in the kinetics of hydrochlorothiazide on repeated dosing, and accumulation is minimal when dosed once daily. More than 95% of the absorbed dose is being excreted as unchanged compound in the urine. The renal clearance is composed of passive filtration and active secretion into the renal tubule.
**Special populations**

**Paediatric patients (age below 18 years)**
No pharmacokinetic data are available in the paediatric population.

**Elderly (age 65 years or over)**
Time to peak plasma amlodipine concentrations is similar in young and elderly patients. In elderly patients, amlodipine clearance tends to decline, causing increases in the area under the curve (AUC) and elimination half-life. Mean systemic AUC of valsartan is higher by 70% in the elderly than in the young, therefore caution is required when increasing the dosage.

Systemic exposure to valsartan is slightly elevated in the elderly as compared to the young, but this has not been shown to have any clinical significance.

Limited data suggest that the systemic clearance of hydrochlorothiazide is reduced in both healthy and hypertensive elderly subjects compared to young healthy volunteers.

Since the three components are equally well tolerated in younger and elderly patients, normal dose regimens are recommended (see section 4.2).

**Renal impairment**
The pharmacokinetics of amlodipine are not significantly influenced by renal impairment. As expected for a compound where renal clearance accounts for only 30% of total plasma clearance, no correlation was seen between renal function and systemic exposure to valsartan.

Patients with mild to moderate renal impairment may therefore receive the usual initial dose (see sections 4.2 and 4.4).

In the presence of renal impairment, mean peak plasma levels and AUC values of hydrochlorothiazide are increased and the urinary excretion rate is reduced. In patients with mild to moderate renal impairment, a 3-fold increase in hydrochlorothiazide AUC has been observed. In patients with severe renal impairment an 8-fold increase in AUC has been observed. Imprida HCT is contraindicated in patients with severe renal impairment, anuria or undergoing dialysis (see section 4.3).

**Hepatic impairment**
Patients with hepatic insufficiency have decreased clearance of amlodipine with resulting increase of approximately 40–60% in AUC. On average, in patients with mild to moderate chronic liver disease, exposure (measured by AUC values) to valsartan is twice that found in healthy volunteers (matched by age, sex and weight). Due to the valsartan component, Imprida HCT is contraindicated in patients with hepatic impairment (see sections 4.2 and 4.3).

### 5.3 Preclinical safety data

**Amlodipine/Valsartan/Hydrochlorothiazide**
In a variety of preclinical safety studies conducted in several animal species with amlodipine, valsartan, hydrochlorothiazide, valsartan/hydrochlorothiazide, amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide (Imprida HCT), there was no evidence of systemic or target organ toxicity that would adversely affect the development of Imprida HCT for clinical use in humans.

Preclinical safety studies of up to 13 weeks in duration were conducted with amlodipine/valsartan/hydrochlorothiazide in rats. The combination resulted in expected reduction of red blood cell mass (erythrocytes, haemoglobin, haematocrit, and reticulocytes), increase in serum urea, increase in serum creatinine, increase in serum potassium, juxtaglomerular (JG) hyperplasia in the kidney and focal erosions in the glandular stomach in rats. All these changes were reversible after a 4-week recovery period and were considered to be exaggerated pharmacological effects.
The amlodipine/valsartan/hydrochlorothiazide combination was not tested for genotoxicity or carcinogenicity as there was no evidence of any interaction between these substances, which have been on the market for a long time. However, amlodipine, valsartan and hydrochlorothiazide have been tested individually for genotoxicity and carcinogenicity with negative results.

**Amlodipine**

**Reproductive toxicology**

Reproductive studies in rats and mice have shown delayed date of delivery, prolonged duration of labour and decreased pup survival at dosages approximately 50 times greater than the maximum recommended dosage for humans based on mg/kg.

**Impairment of fertility**

There was no effect on the fertility of rats treated with amlodipine (males for 64 days and females 14 days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human dose of 10 mg on a mg/m² basis). In another rat study in which male rats were treated with amlodipine besilate for 30 days at a dose comparable with the human dose based on mg/kg, decreased plasma follicle-stimulating hormone and testosterone were found as well as decreases in sperm density and in the number of mature spermatids and Sertoli cells.

**Carcinogenesis, mutagenesis**

Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity. The highest dose (for mice, similar to, and for rats twice* the maximum recommended clinical dose of 10 mg on a mg/m² basis) was close to the maximum tolerated dose for mice but not for rats.

Mutagenicity studies revealed no drug related effects at either the gene or chromosome levels.

* Based on patient weight of 50 kg

**Valsartan**

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential.

In rats, maternally toxic doses (600 mg/kg/day) during the last days of gestation and lactation led to lower survival, lower weight gain and delayed development (pinna detachment and ear-canal opening) in the offspring (see section 4.6). These doses in rats (600 mg/kg/day) are approximately 18 times the maximum recommended human dose on a mg/m² basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).

In non-clinical safety studies, high doses of valsartan (200 to 600 mg/kg body weight) caused in rats a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit) and evidence of changes in renal haemodynamics (slightly raised plasma urea, and renal tubular hyperplasia and basophilia in males). These doses in rats (200 and 600 mg/kg/day) are approximately 6 and 18 times the maximum recommended human dose on a mg/m² basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).

In marmosets at similar doses, the changes were similar though more severe, particularly in the kidney where the changes developed to a nephropathy which included raised urea and creatinine.

Hypertrophy of the renal juxtaglomerular cells was also seen in both species. All changes were considered to be caused by the pharmacological action of valsartan which produces prolonged hypotension, particularly in marmosets. For therapeutic doses of valsartan in humans, the hypertrophy of the renal juxtaglomerular cells does not seem to have any relevance.
6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core
Cellulose microcrystalline
Crospovidone
Silica, colloidal anhydrous
Magnesium stearate

Coating
Hypromellose
Titanium dioxide (E171)
Macrogol 4000
Talc

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

2 years

6.4 Special precautions for storage

Do not store above 30°C.
Store in the original package in order to protect from moisture.

6.5 Nature and contents of container

PVC/PVDC blisters. One blister contains 7, 10 or 14 film-coated tablets.
Pack sizes: 14, 28, 30, 56, 90, 98 or 280 film-coated tablets.
Multipacks of 280 tablets, comprising 20 cartons, each containing 14 tablets.

PVC/PVDC perforated unit dose blisters for hospital use:
Pack sizes: 56, 98 or 280 film-coated tablets
Multipacks of 280 tablets, comprising 4 cartons, each containing 70 tablets.

Not all pack sizes or strengths may be marketed.

6.6 Special precautions for disposal and other handling

No special requirements.

7. MARKETING AUTHORISATION HOLDER

Novartis Europharm Limited
Wimblehurst Road
Horsham
West Sussex, RH12 5AB
United Kingdom
8. MARKETING AUTHORISATION NUMBER(S)

EU/1/09/570/001-012

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

15.10.2009

10. DATE OF REVISION OF THE TEXT

Detailed information on this product is available on the website of the European Medicines Agency http://www.ema.europa.eu

Medicinal product no longer authorised
1. **NAME OF THE MEDICINAL PRODUCT**

Imprida HCT 10 mg/160 mg/12.5 mg film-coated tablets

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each film-coated tablet contains 10 mg of amlodipine (as amlodipine besylate), 160 mg of valsartan, and 12.5 mg of hydrochlorothiazide.

For a full list of excipients, see section 6.1.

3. **PHARMACEUTICAL FORM**

Film-coated tablet (tablet)

Pale yellow, ovaloid, biconvex tablets with bevelled edge, debossed “NVR” on one side and “VDL” on the other side.

4. **CLINICAL PARTICULARS**

4.1 **Therapeutic indications**

Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.

4.2 **Posology and method of administration**

**Posology**

The recommended dose of Imprida HCT is one tablet per day, to be taken preferably in the morning.

Before switching to Imprida HCT patients should be controlled on stable doses of the monocomponents taken at the same time. The dose of Imprida HCT should be based on the doses of the individual components of the combination at the time of switching.

The maximum recommended dose of Imprida HCT is 10 mg/320 mg/25 mg.

**Special populations**

**Renal impairment**

No adjustment of the initial dose is required for patients with mild to moderate renal impairment (see sections 4.4 and 5.2). Due to the hydrochlorothiazide component, Imprida HCT is contraindicated for use in patients with anuria (see section 4.3) and in patients with severe renal impairment (glomerular filtration rate (GFR) <30 ml/min/1.73 m²) (see sections 4.3, 4.4 and 5.2).

**Hepatic impairment**

Due to the valsartan component, Imprida HCT is contraindicated in patients with severe hepatic impairment (see section 4.3). In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan and therefore Imprida HCT is not suitable in this group of patients (see sections 4.3, 4.4 and 5.2).
Heart failure and coronary artery disease
There is limited experience with the use of Imprida HCT, particularly at the maximum dose, in patients with heart failure and coronary artery disease. Caution is advised in patients with heart failure and coronary artery disease, particularly at the maximum dose of Imprida HCT, 10 mg/320 mg/25 mg.

Elderly (age 65 years or over)
Caution, including more frequent monitoring of blood pressure, is recommended in elderly patients, particularly at the maximum dose of Imprida HCT, 10 mg/320 mg/25 mg, since available data in this patient population are limited.

Paediatric population
There is no relevant use of Imprida HCT in the paediatric population (patients below age 18 years) for the indication of essential hypertension.

Method of administration
Imprida HCT can be taken with or without food. The tablets should be swallowed whole with some water, at the same time of the day and preferably in the morning.

4.3 Contraindications
- Hypersensitivity to the active substances, to other sulphonamide derivatives, to dihydropyridine derivatives, or to any of the excipients.
- Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
- Hepatic impairment, biliary cirrhosis or cholestasis.
- Severe renal impairment (GFR <30 ml/min/1.73 m²), anuria and patients undergoing dialysis.
- Refractory hypokalaemia, hyponatraemia, hypercalcaemia, and symptomatic hyperuricaemia.

4.4 Special warnings and precautions for use
Sodium- and/or volume-depleted patients
Excessive hypotension, including orthostatic hypotension, was seen in 1.7% of patients treated with the maximum dose of Imprida HCT (10 mg/320 mg/25 mg) compared to 1.8% of valsartan/hydrochlorothiazide (320 mg/25 mg) patients, 0.4% of amlodipine/valsartan (10 mg/320 mg) patients, and 0.2% of hydrochlorothiazide/amlodipine (25 mg/10 mg) patients in a controlled trial in patients with moderate to severe uncomplicated hypertension.

In sodium-depleted and/or volume-depleted patients, such as those receiving high doses of diuretics, symptomatic hypotension may occur after initiation of treatment with Imprida HCT. Imprida HCT should be used only after correction of any pre-existing sodium and/or volume depletion.

If excessive hypotension occurs with Imprida HCT, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline. Treatment can be continued once blood pressure has been stabilised.

Serum electrolyte changes
Amlodipine/valsartan/hydrochlorothiazide
In the controlled trial of Imprida HCT, the counteracting effects of valsartan 320 mg and hydrochlorothiazide 25 mg on serum potassium approximately balanced each other in many patients. In other patients, one or the other effect may be dominant. Periodic determinations of serum electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals.

Periodic determination of serum electrolytes and potassium in particular should be performed at appropriate intervals to detect possible electrolyte imbalance, especially in patients with other risk factors such as impaired renal function, treatment with other medicinal products or history of prior electrolyte imbalances.
**Valsartan**

Concomitant use with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other medicinal products that may increase potassium levels (heparin, etc.) is not recommended. Monitoring of potassium should be undertaken as appropriate.

**Hydrochlorothiazide**

Treatment with Imprida HCT should only start after correction of hypokalaemia and any coexisting hypomagnesaemia. Thiazide diuretics can precipitate new onset hypokalaemia or exacerbate pre-existing hypokalaemia. Thiazide diuretics should be administered with caution in patients with conditions involving enhanced potassium loss, for example salt-losing nephropathies and prerenal (cardiogenic) impairment of kidney function. If hypokalaemia develops during hydrochlorothiazide therapy, Imprida HCT should be discontinued until stable correction of the potassium balance.

Thiazide diuretics can precipitate new onset hyponatraemia and hypochloroaemic alkalosis or exacerbate pre-existing hyponatraemia. Hyponatraemia, accompanied by neurological symptoms (nausea, progressive disorientation, apathy) has been observed. Treatment with hydrochlorothiazide should only be started after correction of pre-existing hyponatraemia. In case severe or rapid hyponatraemia develops during Imprida HCT therapy, the treatment should be discontinued until normalisation of natraemia.

All patients receiving thiazide diuretics should be periodically monitored for imbalances in electrolytes, particularly potassium, sodium and magnesium.

**Renal impairment**

Thiazide diuretics may precipitate azotaemia in patients with chronic kidney disease. When Imprida HCT is used in patients with renal impairment periodic monitoring of serum electrolytes (including potassium), creatinine and uric acid serum levels is recommended. Imprida HCT is contraindicated in patients with severe renal impairment, anuria or undergoing dialysis (see section 4.3).

No dosage adjustment of Imprida HCT is required for patients with mild to moderate renal impairment (GFR ≥30 ml/min/1.73 m²).

**Renal artery stenosis**

No data are available on the use of Imprida HCT in patients with unilateral or bilateral renal artery stenosis or stenosis to a solitary kidney.

**Kidney transplantation**

To date there is no experience of the safe use of Imprida HCT in patients who have had a recent kidney transplantation.

**Hepatic impairment**

Valsartan is mostly eliminated unchanged via the bile, whereas amlodipine is extensively metabolised by the liver. In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan, and therefore, Imprida HCT is not suitable in this group of patients (see sections 4.2, 4.3 and 5.2).

**Heart failure and coronary artery disease**

As a consequence of the inhibition of the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients with severe heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotaemia and (rarely) with acute renal failure and/or death. Similar outcomes have been reported with valsartan.
In a long-term, placebo-controlled study (PRAISE-2) of amlodipine in patients with NYHA (New York Heart Association Classification) III and IV heart failure of non-ischaemic aetiology, amlodipine was associated with increased reports of pulmonary oedema despite no significant difference in the incidence of worsening heart failure as compared to placebo.

Caution is advised in patients with heart failure and coronary artery disease, particularly at the maximum dose of Imprida HCT, 10 mg/320 mg/25 mg, since available data in these patient populations is limited.

Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy
As with all other vasodilators, special caution is indicated in patients with aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.

Pregnancy
Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).

Primary hyperaldosteronism
Patients with primary hyperaldosteronism should not be treated with the angiotensin II antagonist valsartan as their renin-angiotensin system is not activated. Therefore, Imprida HCT is not recommended in this population.

Systemic lupus erythematosus
Thiazide diuretics, including hydrochlorothiazide, have been reported to exacerbate or activate systemic lupus erythematosus.

Other metabolic disturbances
Thiazide diuretics, including hydrochlorothiazide, may alter glucose tolerance and raise serum levels of cholesterol, triglycerides and uric acid. In diabetic patients dosage adjustments of insulin or oral hypoglycaemic agents may be required.

Due to the hydrochlorothiazide component, Imprida HCT is contraindicated in symptomatic hyperuricaemia. Hydrochlorothiazide may raise the serum uric acid level due to reduced clearance of uric acid and may cause or exacerbate hyperuricaemia as well as precipitate gout in susceptible patients.

Thiazides reduce urinary calcium excretion and may cause intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Imprida HCT is contraindicated in patients with hypercalcaemia and should only be used after correction of any pre-existing hypercalcaemia. Imprida HCT should be discontinued if hypercalcaemia develops during treatment. Serum levels of calcium should be periodically monitored during treatment with thiazides. Marked hypercalcaemia may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function.

Photosensitivity
Cases of photosensitivity reactions have been reported with thiazide diuretics (see section 4.8). If photosensitivity reaction occurs during treatment with Imprida HCT, it is recommended to stop the treatment. If a readministration of the diuretic is deemed necessary, it is recommended to protect exposed areas to the sun or to artificial UVA.
Acute angle-closure glaucoma
Hydrochlorothiazide, a sulphonamide, has been associated with an idiosyncratic reaction resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to a week of treatment initiation. Untreated acute-angle closure glaucoma can lead to permanent vision loss.

The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatment may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle closure glaucoma may include a history of sulphonamide or penicillin allergy.

General
Caution should be exercised in patients who have shown prior hypersensitivity to other angiotensin II receptor antagonists. Hypersensitivity reactions to hydrochlorothiazide are more likely in patients with allergy and asthma.

Elderly (age 65 years or over)
Caution, including more frequent monitoring of blood pressure, is recommended in elderly patients, particularly at the maximum dose of Imprida HCT, 10 mg/320 mg/25 mg, since available data in this patient population are limited.

4.5 Interaction with other medicinal products and other forms of interaction

No formal interaction studies with other medicinal products were performed with Imprida HCT. Thus, only information on interactions with other medicinal products that are known for the individual active substances is provided in this section.

However, it is important to take into account that Imprida HCT may increase the hypotensive effect of other antihypertensive agents.
## Concomitant use not recommended

<table>
<thead>
<tr>
<th>Imprida HCT individual component</th>
<th>Known interactions with the following agents</th>
<th>Effect of the interaction with other medicinal products</th>
</tr>
</thead>
<tbody>
<tr>
<td>Valsartan and HCT</td>
<td>Lithium</td>
<td>Reversible increases in serum lithium concentrations and toxicity have been reported during concurrent use of ACE inhibitors and thiazides such as hydrochlorothiazide. Despite the lack of experience with concomitant use of valsartan and lithium, this combination is not recommended. If the combination proves necessary, careful monitoring of serum lithium levels is recommended (see section 4.4).</td>
</tr>
<tr>
<td>Valsartan</td>
<td>Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may increase potassium levels</td>
<td>If a medicinal product that affects potassium levels is considered necessary in combination with valsartan, frequent monitoring of potassium plasma levels is advised.</td>
</tr>
<tr>
<td>Amlodipine</td>
<td>Grapefruit or grapefruit juice</td>
<td>Administration of amlodipine with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients, resulting in increased blood pressure lowering effects.</td>
</tr>
</tbody>
</table>

## Caution required with concomitant use

<table>
<thead>
<tr>
<th>Imprida HCT individual component</th>
<th>Known interactions with the following agents</th>
<th>Effect of the interaction with other medicinal products</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amlodipine</td>
<td>CYP3A4 inhibitors (i.e. ketoconazole, itraconazole, ritonavir)</td>
<td>Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors, azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem) may give rise to significant increase in amlodipine exposure. The clinical translation of these pharmacokinetic variations may be more pronounced in the elderly. Clinical monitoring and dose adjustment may thus be required.</td>
</tr>
<tr>
<td></td>
<td>CYP3A4 inducers (anticonvulsant agents [e.g. carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone], rifampicin, Hypericum perforatum [St. John’s wort])</td>
<td>There is no data available regarding the effect of CYP3A4 inducers on amlodipine. The concomitant use of CYP3A4 inducers (e.g. rifampicin, Hypericum perforatum) may give a lower plasma concentration of amlodipine. Amlodipine should be used with caution together with CYP3A4 inducers.</td>
</tr>
</tbody>
</table>
### Simvastatin

Co-administration of multiple doses of 10 mg amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. It is recommended to limit the dose of simvastatin to 20 mg daily in patients on amlodipine.

### Dantrolene (infusion)

In animals, lethal ventricular fibrillation and cardiovascular collapse are observed in association with hyperkalaemia after administration of verapamil and intravenous dantrolene. Due to risk of hyperkalaemia, it is recommended that the co-administration of calcium channel blockers such as amlodipine be avoided in patients susceptible to malignant hyperthermia and in the management of malignant hyperthermia.

<table>
<thead>
<tr>
<th>Valsartan and HCT</th>
<th>Non-steroidal anti-inflammatory medicines (NSAIDs), including selective cyclooxygenase-2 inhibitors (COX-2 inhibitors), acetylsalicylic acid (&gt;3 g/day), and non-selective NSAIDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Valsartan</td>
<td>Inhibitors of the uptake transporter (rifampicin, ciclosporin) or efflux transporter (ritonavir)</td>
</tr>
<tr>
<td>HCT</td>
<td>Alcohol, barbiturates or narcotics</td>
</tr>
<tr>
<td></td>
<td>Amantadine</td>
</tr>
<tr>
<td></td>
<td>Anticholinergic agents and other medicinal products affecting gastric motility</td>
</tr>
<tr>
<td></td>
<td>Antidiabetic agents (e.g. insulin and oral antidiabetic agents)</td>
</tr>
<tr>
<td></td>
<td>– Metformin</td>
</tr>
<tr>
<td></td>
<td>Beta blockers and diazoxide</td>
</tr>
</tbody>
</table>

NSAIDS can attenuate the antihypertensive effect of both angiotensin II antagonists and hydrochlorothiazide when administered simultaneously. Furthermore, concomitant use of Imprida HCT and NSAIDs may lead to worsening of renal function and an increase in serum potassium. Therefore, monitoring of renal function at the beginning of the treatment is recommended, as well as adequate hydration of the patient.

The results of an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1 and of the hepatic efflux transporter MRP2. Co-administration of inhibitors of the uptake transporter (rifampicin, ciclosporin) or efflux transporter (ritonavir) may increase the systemic exposure to valsartan.

Concomitant administration of thiazide diuretics with substances that also have a blood pressure lowering effect (e.g. by reducing sympathetic central nervous system activity or direct vasodilatation) may potentiate orthostatic hypotension.

Thiazides, including hydrochlorothiazide, may increase the risk of adverse reactions caused by amantadine.

The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents (e.g. atropine, biperiden), apparently due to a decrease in gastrointestinal motility and the stomach emptying rate. Conversely, it is anticipated that prokinetic substances such as cisapride may decrease the bioavailability of thiazide-type diuretics.

Thiazides may alter glucose tolerance. Dose adjustment of the antidiabetic medicinal product may be necessary.

Metformin should be used with caution because of the risk of lactic acidosis induced by possible functional renal failure linked to hydrochlorothiazide.

Concomitant use of thiazide diuretics, including hydrochlorothiazide, with beta blockers may increase the risk of hyperglycaemia. Thiazide diuretics, including hydrochlorothiazide, may enhance the hyperglycaemic effect of diazoxide.
<table>
<thead>
<tr>
<th>Medicinal Product Category</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ciclosporin</td>
<td>Concomitant treatment with ciclosporin may increase the risk of hyperuricaemia and gout-type complications.</td>
</tr>
<tr>
<td>Cytotoxic agents</td>
<td>Thiazides, including hydrochlorothiazide, may reduce the renal excretion of cytotoxic agents (e.g. cyclophosphamide, methotrexate) and potentiate their myelosuppressive effects.</td>
</tr>
<tr>
<td>Digitalis glycosides</td>
<td>Thiazide-induced hypokalaemia or hypomagnesaemia may occur as undesirable effects, favouring the onset of digitalis-induced cardiac arrhythmias.</td>
</tr>
<tr>
<td>Iodine contrasting agents</td>
<td>In case of diuretic-induced dehydration, there is an increased risk of acute renal failure, especially with high doses of iodine products. Patients should be re-hydrated before the administration.</td>
</tr>
<tr>
<td>Ion exchange resins</td>
<td>Absorption of thiazide diuretics, including hydrochlorothiazide, is decreased by cholestyramine or colestipol. This could result in sub-therapeutic effects of thiazide diuretics. However, staggering the dosage of hydrochlorothiazide and resin such that hydrochlorothiazide is administered at least 4 hours before or 4-6 hours after the administration of resins would potentially minimise the interaction.</td>
</tr>
<tr>
<td>Medicinal products affecting serum potassium level</td>
<td>The hypokalaemic effect of hydrochlorothiazide may be increased by concomitant administration of kaliuretic diuretics, corticosteroids, laxatives, adrenocorticotropic hormone (ACTH), amphotericin, carbadoxolone, penicillin G and salicylic acid derivatives or antiarrhythmics. If these medicinal products are to be prescribed with the amlodipine /valsartan /hydrochlorothiazide combination, monitoring of potassium plasma levels is advised.</td>
</tr>
<tr>
<td>Medicinal products affecting serum sodium level</td>
<td>The hyponatraemic effect of diuretics may be intensified by concomitant administration of medicinal products such as antidepressants, antipsychotics, antiepileptics, etc. Caution is indicated in long-term administration of these medicinal products.</td>
</tr>
<tr>
<td>Medicinal products that could induce torsades de pointes</td>
<td>Due to the risk of hypokalaemia, hydrochlorothiazide should be administered with caution when associated with medicinal products that could induce torsades de pointes, in particular Class Ia and Class III antiarrhythmics and some antipsychotics.</td>
</tr>
<tr>
<td>Medicinal products used in the treatment of gout (probenecid, sulfinpyrazone and allopurinol)</td>
<td>Dose adjustment of uricosuric medicinal products may be necessary as hydrochlorothiazide may raise the level of serum uric acid. Increase of dose of probenecid or sulfinpyrazone may be necessary. Co-administration of thiazide diuretics, including hydrochlorothiazide, may increase the incidence of hypersensitivity reactions to allopurinol.</td>
</tr>
<tr>
<td>Methyldopa</td>
<td>There have been isolated reports of haemolytic anaemia occurring with concomitant use of hydrochlorothiazide and methyldopa.</td>
</tr>
<tr>
<td>Non-depolarising skeletal muscle relaxants (e.g. tubocurarine)</td>
<td>Thiazides, including hydrochlorothiazide, potentiate the action of curare derivatives.</td>
</tr>
<tr>
<td><strong>Other anti-hypertensive drugs</strong></td>
<td>Thiazides potentiate the antihypertensive action of other antihypertensive drugs (e.g. guanethidine, methyldopa, beta-blockers, vasodilators, calcium channel blockers, ACE inhibitors, ARBs and Direct Renin Inhibitors [DRIs]).</td>
</tr>
<tr>
<td><strong>Pressor amines (e.g. noradrenaline, adrenaline)</strong></td>
<td>Hydrochlorothiazide may reduce the response to pressor amines such as noradrenaline. The clinical significance of this effect is uncertain and not sufficient to preclude their use.</td>
</tr>
<tr>
<td><strong>Vitamin D and calcium salts</strong></td>
<td>Administration of thiazide diuretics, including hydrochlorothiazide, with vitamin D or with calcium salts may potentiate the rise in serum calcium. Concomitant use of thiazide type diuretics may lead to hypercalcaemia in patients pre-disposed for hypercalcaemia (e.g. hyperparathyroidism, malignancy or vitamin-D-mediated conditions) by increasing tubular calcium reabsorption.</td>
</tr>
</tbody>
</table>

**No interaction**

<table>
<thead>
<tr>
<th><strong>Imprida HCT individual component</strong></th>
<th><strong>Known interactions with the following agents</strong></th>
<th><strong>Effect of the interaction with other medicinal products</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Valsartan</strong></td>
<td><strong>Others</strong> (cimetidine, warfarin, furosemide, digoxin, atenolol, indomethacin, hydrochlorothiazide, amlodipine, glibenclamide)</td>
<td>In monotherapy with valsartan, no interactions of clinical significance have been found with the following substances: cimetidine, warfarin, furosemide, digoxin, atenolol, indomethacin, hydrochlorothiazide, amlodipine, glibenclamide. Some of these substances could interact with the hydrochlorothiazide component of Imprida HCT (see interactions related to HCT).</td>
</tr>
<tr>
<td><strong>Amlodipine</strong></td>
<td><strong>Others</strong></td>
<td>In clinical interaction studies, amlodipine did not affect the pharmacokinetics of atorvastatin, digoxin, warfarin or ciclosporin.</td>
</tr>
</tbody>
</table>

**4.6 Fertility, pregnancy and lactation**

**Pregnancy**

**Amlodipine**

The safety of amlodipine in human pregnancy has not been established. In animal studies, reproductive toxicity was observed at high doses (see section 5.3). Use in pregnancy is only recommended when there is no safer alternative and when the disease itself carries greater risk for the mother and foetus.
The use of Angiotensin II Receptor Antagonists (AIIRAs) is not recommended during the first trimester of pregnancy (see section 4.4). The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 and 4.4).

Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and if appropriate, alternative therapy should be started.

Exposure to AIIRAs therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3).

Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.

Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3 and 4.4).

**Hydrochlorothiazide**

There is limited experience with hydrochlorothiazide during pregnancy, especially during the first trimester. Animal studies are insufficient.

Hydrochlorothiazide crosses the placenta. Based on the pharmacological mechanism of action of hydrochlorothiazide, its use during the second and third trimester may compromise foeto-placental perfusion and may cause foetal and neonatal effects like icterus, disturbance of electrolyte balance and thrombocytopenia.

**Amlodipine/valsartan/hydrochlorothiazide**

There is no experience on the use of Imprida HCT in pregnant women. Based on the existing data with the components, the use of Imprida HCT is not recommended during first trimester and contraindicated during the second and third trimester of pregnancy (see sections 4.3 and 4.4).

**Breast-feeding**

No information is available regarding the use of valsartan and/or amlodipine during breast-feeding. Hydrochlorothiazide is excreted in human milk in small amounts. Thiazides in high doses causing intense diuresis can inhibit milk production. The use of Imprida HCT during breast-feeding is not recommended. If Imprida HCT is used during breast-feeding, doses should be kept as low as possible. Alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.

**Fertility**

There are no clinical studies on fertility with Imprida HCT.

**Valsartan**

Valsartan had no adverse effects on the reproductive performance of male or female rats at oral doses up to 200 mg/kg/day. This dose is 6 times the maximum recommended human dose on a mg/m² basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).
Amlodipine
Reversible biochemical changes in the head of spermatozoa have been reported in some patients treated by calcium channel blockers. Clinical data are insufficient regarding the potential effect of amlodipine on fertility. In one rat study, adverse effects were found on male fertility (see section 5.3).

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. When driving vehicles or using machines it should be taken into account that occasionally dizziness or weariness may occur.

4.8 Undesirable effects

The safety profile of Imprida HCT presented below is based on clinical studies performed with Imprida HCT and the known safety profile of the individual components amlodipine, valsartan and hydrochlorothiazide.

Information on Imprida HCT
The safety of Imprida HCT has been evaluated at its maximum dose of 10 mg/320 mg/25 mg in one controlled short-term (8 weeks) clinical study with 2,271 patients, 582 of whom received valsartan in combination with amlodipine and hydrochlorothiazide. Adverse reactions were generally mild and transient in nature and only infrequently required discontinuation of therapy. In this active controlled clinical trial, the most common reasons for discontinuation of therapy with Imprida HCT were dizziness and hypotension (0.7%).

In the 8-week controlled clinical study, no significant new or unexpected adverse reactions were observed with triple therapy treatment compared to the known effects of the monotherapy or dual therapy components.

In the 8-week controlled clinical study, changes in laboratory parameters observed with the combination of Imprida HCT were minor and consistent with the pharmacological mechanism of action of the monotherapy agents. The presence of valsartan in the triple combination attenuated the hypokalaemic effect of hydrochlorothiazide.

The following adverse reactions, listed by MedDRA System Organ Class and frequency, concern Imprida HCT (amlodipine/valsartan/HCT) and amlodipine, valsartan and HCT individually. Very common: ≥1/10; common: ≥1/100 to <1/10; uncommon: ≥1/1,000 to <1/100; rare: ≥1/10,000 to <1/1,000; very rare: <1/10,000, not known (cannot be estimated from the available data).

<table>
<thead>
<tr>
<th>MedDRA System Organ Class</th>
<th>Adverse reactions</th>
<th>Frequency</th>
<th>Imprida HCT</th>
<th>Amlodipine</th>
<th>Valsartan</th>
<th>HCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>Agranulocytosis, bone marrow depression</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Very rare</td>
</tr>
<tr>
<td></td>
<td>Decrease in haemoglobin and in haematocrit</td>
<td>--</td>
<td>--</td>
<td>Not known</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Haemolytic anaemia</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Very rare</td>
</tr>
<tr>
<td></td>
<td>Leukopenia</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>--</td>
<td>Very rare</td>
</tr>
<tr>
<td></td>
<td>Neutropenia</td>
<td>--</td>
<td>--</td>
<td>Not known</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thrombocytopenia, sometimes with purpura</td>
<td>--</td>
<td>Very rare</td>
<td>Not known</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aplastic anaemia</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Not known</td>
<td></td>
</tr>
<tr>
<td>Immune system disorders</td>
<td>Hypersensitivity</td>
<td>--</td>
<td>Very rare</td>
<td>Not known</td>
<td>Very rare</td>
<td></td>
</tr>
<tr>
<td>-------------------------</td>
<td>-----------------</td>
<td>----</td>
<td>-----------</td>
<td>-----------</td>
<td>-----------</td>
<td></td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td>Anorexia</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>Very rare</td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td>Hypercalcaemia</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Common</td>
</tr>
<tr>
<td></td>
<td>Hyperglycaemia</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hyperlipidaemia</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Hyperuricaemia</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>Common</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Hypochloraeic alkalosis</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Very rare</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hypokalaemia</td>
<td>Common</td>
<td>--</td>
<td>--</td>
<td>Very common</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Hypomagnesaemia</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Common</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hyponatraemia</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>Common</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Worsening of diabetic metabolic state</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td>Depression</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Insomnia/sleep disturbances</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mood swings</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Coordination abnormal</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dizziness</td>
<td>Common</td>
<td>Common</td>
<td>--</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dizziness postural, dizziness exertional</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dysgeusia</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Extrapyramidal syndrome</td>
<td>--</td>
<td>Not known</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Headache</td>
<td>Common</td>
<td>Common</td>
<td>--</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hypertonia</td>
<td>Very rare</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lethargy</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Paraesthesia</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Peripheral neuropathy, neuropathy</td>
<td>Uncommon</td>
<td>Very rare</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Somnolence</td>
<td>Uncommon</td>
<td>Common</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Syncope</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tremor</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Eye disorders</td>
<td>Acute angle-closure glaucoma</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Not known</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Visual impairment</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td>Ear and labyrinth disorders</td>
<td>Tinnitus</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Vertigo</td>
<td>Uncommon</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td>Palpitations</td>
<td>--</td>
<td>Common</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tachycardia</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Arrhythmias (including bradycardia, ventricular tachycardia, and atrial fibrillation)</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Myocardial infarction</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>Flushing</td>
<td>--</td>
<td>Common</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hypotension</td>
<td>Common</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Orthostatic hypotension</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>Common</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Phlebitis, thrombophlebitis</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Vasculitis</td>
<td>--</td>
<td>Very rare</td>
<td>Not known</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>Cough</td>
<td>Uncommon</td>
<td>Very rare</td>
<td>Uncommon</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>-------</td>
<td>----------</td>
<td>-----------</td>
<td>----------</td>
<td>----</td>
<td></td>
</tr>
<tr>
<td>Dyspnoea</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Respiratory distress, pulmonary oedema, pneumonitis</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Rhinitis</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Throat irritation</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Abdominal discomfort, abdominal pain upper</td>
<td>Uncommon</td>
<td>Common</td>
<td>Uncommon</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td>Breath odour</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Change of bowel habit</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Constipation</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Rare</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Common</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>Rare</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Dry mouth</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>Common</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Gastritis</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Gingival hyperplasia</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>Uncommon</td>
<td>Common</td>
<td>--</td>
<td>Common</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Pancreatitis</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Vomiting</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>Common</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Hepatobiliary disorders</td>
<td>Hepatic enzyme elevation, including increase of serum bilirubin</td>
<td>--</td>
<td>Very rare</td>
<td>Not known</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Hepatitis</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Intrahepatic cholestasis, jaundice</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>Rare</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>Alopecia</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Angioedema</td>
<td>--</td>
<td>Very rare</td>
<td>Not known</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Cutaneous lupus erythematosus-like reactions, reactivation of cutaneous lupus erythematosus</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Erythema multiforme</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>Not known</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Exanthema</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Hyperhidrosis</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Photosensitivity reaction*</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Rare</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Puritus</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>Not known</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Purpura</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>Rare</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Rash</td>
<td>--</td>
<td>Uncommon</td>
<td>Not known</td>
<td>Common</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Skin discoloration</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Urticaria and other forms of rash</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>Common</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Vasculitis necrotising and toxic epidermal necrolysis</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td>Arthralgia</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Back pain</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Joint swelling</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Muscle spasm</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>Not known</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Muscular weakness</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Myalgia</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>Not known</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Pain in extremity</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Renal and urinary disorders</td>
<td>Elevation of serum creatinine</td>
<td>Uncommon</td>
<td>--</td>
<td>Not known</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>---------------------------</td>
<td>-----------------------------</td>
<td>----------</td>
<td>-----</td>
<td>-----------</td>
<td>-----</td>
<td></td>
</tr>
<tr>
<td>Micturition disorder</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nocturia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pollakiuria</td>
<td>Common</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Renal dysfunction</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal failure acute</td>
<td>Uncommon</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal failure and impairment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reproductive system and breast disorders</td>
<td>Impotence</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>Common</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gynaecomastia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>Abasia, gait disturbance</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Asthenia</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>Not known</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Discomfort, malaise</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fatigue</td>
<td>Common</td>
<td>Common</td>
<td>Uncommon</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Non cardiac chest pain</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oedema</td>
<td>Common</td>
<td>Common</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pain</td>
<td></td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pyrexia</td>
<td></td>
<td>--</td>
<td>--</td>
<td>Not known</td>
<td></td>
</tr>
<tr>
<td>Investigations</td>
<td>Lipids increased</td>
<td></td>
<td></td>
<td>Very common</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Blood urea nitrogen increased</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Blood uric acid increased</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Glycosuria</td>
<td></td>
<td></td>
<td>Rare</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Serum potassium decreased</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Serum potassium increased</td>
<td>--</td>
<td>--</td>
<td>Not known</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Weight increase</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Weight decrease</td>
<td></td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
</tbody>
</table>

* See section 4.4 Photosensitivity

### 4.9 Overdose

**Symptoms**
There is no experience of overdose with Imprida HCT. The major symptom of overdose with valsartan is possibly pronounced hypotension with dizziness. Overdose with amlodipine may result in excessive peripheral vasodilation and, possibly, reflex tachycardia. Marked and potentially prolonged systemic hypotension, including shock with fatal outcome, have been reported with amlodipine.

**Treatment**

**Amlodipine/Valsartan/Hydrochlorothiazide**
Clinically significant hypotension due to Imprida HCT overdose calls for active cardiovascular support, including frequent monitoring of cardiac and respiratory function, elevation of extremities, and attention to circulating fluid volume and urine output. A vasoconstrictor may be helpful in restoring vascular tone and blood pressure, provided that there is no contraindication to its use. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade.

**Amlodipine**
If ingestion is recent, induction of vomiting or gastric lavage may be considered. Administration of activated charcoal to healthy volunteers immediately or up to two hours after ingestion of amlodipine has been shown to significantly decrease amlodipine absorption. Amlodipine is unlikely to be removed by haemodialysis.
Valsartan
Valsartan is unlikely to be removed by haemodialysis.

Hydrochlorothiazide
Overdose with hydrochlorothiazide is associated with electrolyte depletion (hypokalaemia, hypochloraemia) and hypovolaemia resulting from excessive diuresis. The most common signs and symptoms of overdose are nausea and somnolence. Hypokalaemia may result in muscle spasms and or accentuate arrhythmia associated with the concomitant use of digitalis glycosides or certain anti-arrhythmic medicinal products.

The degree to which hydrochlorothiazide is removed by haemodialysis has not been established.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Angiotensin II antagonists, plain (valsartan), combinations with dihydropyridine derivatives (amlodipine) and thiazide diuretics (hydrochlorothiazide), ATC code: C09DX01 valsartan, amlodipine and hydrochlorothiazide.

Imprida HCT combines three antihypertensive compounds with complementary mechanisms to control blood pressure in patients with essential hypertension: amlodipine belongs to the calcium antagonist class and valsartan to the angiotensin II antagonist class of medicines and hydrochlorothiazide belongs to the thiazide diuretics class of medicines. The combination of these substances has an additive antihypertensive effect.

Amlodipine/Valsartan/Hydrochlorothiazide
Imprida HCT was studied in a double-blind, active controlled study in hypertensive patients. A total of 2,271 patients with moderate to severe hypertension (mean baseline systolic/diastolic blood pressure was 170/107 mmHg) received treatments of amlodipine/valsartan/hydrochlorothiazide 10 mg/320 mg/25 mg, valsartan/hydrochlorothiazide 320 mg/25 mg, amlodipine/valsartan 10 mg/320 mg, or hydrochlorothiazide/amlodipine 25 mg/10 mg. At study initiation patients were assigned lower doses of their treatment combination and were titrated to their full treatment dose by week 2.

At week 8, the mean reductions in systolic/diastolic blood pressure were 39.7/24.7 mmHg with Imprida HCT, 32.0/19.7 mmHg with valsartan/hydrochlorothiazide, 33.5/21.5 mmHg with amlodipine/valsartan, and 31.5/19.5 mmHg with amlodipine/hydrochlorothiazide. The triple combination therapy was statistically superior to each of the three dual combination treatments in reduction of diastolic and systolic blood pressures. The reductions in systolic/diastolic blood pressure with Imprida HCT were 7.6/5.0 mmHg greater than with valsartan/hydrochlorothiazide, 6.2/3.3 mmHg greater than with amlodipine/valsartan, and 8.2/5.3 mmHg greater than with amlodipine/hydrochlorothiazide. The full blood pressure lowering effect was achieved 2 weeks after being on their maximal dose of Imprida HCT. Statistically greater proportions of patients achieved blood pressure control (<140/90 mmHg) with Imprida HCT (71%) compared to each of the three dual combination therapies (45-54%) (p<0.0001).

In a subgroup of 283 patients focusing on ambulatory blood pressure monitoring, clinically and statistically superior reductions in 24-hour systolic and diastolic blood pressures were observed with the triple combination compared to valsartan/hydrochlorothiazide, valsartan/amlodipine, and hydrochlorothiazide/amlodipine.
**Amlodipine**

The amlodipine component of Imprida HCT inhibits the transmembrane entry of calcium ions into cardiac and vascular smooth muscle. The mechanism of the antihypertensive action of amlodipine is due to a direct relaxant effect on vascular smooth muscle, causing reductions in peripheral vascular resistance and in blood pressure. Experimental data suggest that amlodipine binds to both dihydropyridine and non-dihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels.

Following administration of therapeutic doses to patients with hypertension, amlodipine produces vasodilation, resulting in a reduction of supine and standing blood pressures. These decreases in blood pressure are not accompanied by a significant change in heart rate or plasma catecholamine levels with chronic dosing.

Plasma concentrations correlate with effect in both young and elderly patients.

In hypertensive patients with normal renal function, therapeutic doses of amlodipine resulted in a decrease in renal vascular resistance and increases in glomerular filtration rate and effective renal plasma flow, without change in filtration fraction or proteinuria.

**Valsartan**

Valsartan is an orally active, potent and specific angiotensin II receptor antagonist. It acts selectively on the receptor subtype AT\(_1\), which is responsible for the known actions of angiotensin II.

Administration of valsartan to patients with hypertension results in a drop in blood pressure without affecting pulse rate.

In most patients, after administration of a single oral dose, onset of antihypertensive activity occurs within 2 hours, and the peak drop in blood pressure is achieved within 4-6 hours. The antihypertensive effect persists over 24 hours after administration. During repeated administration, the maximum reduction in blood pressure with any dose is generally attained within 2-4 weeks.

**Hydrochlorothiazide**

The site of action of thiazide diuretics is primarily in the renal distal convoluted tubule. It has been shown that there is a high-affinity receptor in the renal cortex as the primary binding site for the thiazide diuretic action and inhibition of NaCl transport in the distal convoluted tubule. The mode of action of thiazides is through inhibition of the Na\(^+\)-Cl\(^-\) symporter perhaps by competing for the Cl\(^-\) site, thereby affecting electrolyte reabsorption mechanisms: directly increasing sodium and chloride excretion to an approximately equal extent, and indirectly, by this diuretic action, reducing plasma volume, with consequent increases in plasma renin activity, aldosterone secretion and urinary potassium loss, and a decrease in serum potassium.

The European Medicines Agency has waived the obligation to submit the results of studies with Imprida HCT in all subsets of the paediatric population in essential hypertension. See section 4.2 for information on paediatric use.

5.2 Pharmacokinetic properties

**Linearity**

Amlodipine, valsartan and hydrochlorothiazide exhibit linear pharmacokinetics.

**Amlodipine/valsartan/hydrochlorothiazide**

Following oral administration of Imprida HCT in normal healthy adults, peak plasma concentrations of amlodipine, valsartan and hydrochlorothiazide are reached in 6-8 hours, 3 hours, and 2 hours, respectively. The rate and extent of absorption of amlodipine, valsartan and hydrochlorothiazide from Imprida HCT are the same as when administered as individual dosage forms.
**Amlodipine**

**Absorption:** After oral administration of therapeutic doses of amlodipine alone, peak plasma concentrations of amlodipine are reached in 6-12 hours. Absolute bioavailability has been calculated as between 64% and 80%. Amlodipine bioavailability is unaffected by food ingestion.

**Distribution:** Volume of distribution is approximately 21 l/kg. *In vitro* studies with amlodipine have shown that approximately 97.5% of circulating drug is bound to plasma proteins.

**Biotransformation:** Amlodipine is extensively (approximately 90%) metabolised in the liver to inactive metabolites.

**Elimination:** Amlodipine elimination from plasma is biphasic, with a terminal elimination half-life of approximately 30 to 50 hours. Steady-state plasma levels are reached after continuous administration for 7-8 days. Ten per cent of original amlodipine and 60% of amlodipine metabolites are excreted in urine.

**Valsartan**

**Absorption:** Following oral administration of valsartan alone, peak plasma concentrations of valsartan are reached in 2-4 hours. Mean absolute bioavailability is 23%. Food decreases exposure (as measured by AUC) to valsartan by about 40% and peak plasma concentration (Cmax) by about 50%, although from about 8 h post dosing plasma valsartan concentrations are similar for the fed and fasted groups. This reduction in AUC is not, however, accompanied by a clinically significant reduction in the therapeutic effect, and valsartan can therefore be given either with or without food.

**Distribution:** The steady-state volume of distribution of valsartan after intravenous administration is about 17 litres, indicating that valsartan does not distribute into tissues extensively. Valsartan is highly bound to serum proteins (94-97%), mainly serum albumin.

**Biotransformation:** Valsartan is not transformed to a high extent as only about 20% of dose is recovered as metabolites. A hydroxy metabolite has been identified in plasma at low concentrations (less than 10% of the valsartan AUC). This metabolite is pharmacologically inactive.

**Elimination:** Valsartan is primarily eliminated in faeces (about 83% of dose) and urine (about 13% of dose), mainly as unchanged drug. Following intravenous administration, plasma clearance of valsartan is about 2 l/h and its renal clearance is 0.62 l/h (about 30% of total clearance). The half-life of valsartan is 6 hours.

**Hydrochlorothiazide**

**Absorption:** The absorption of hydrochlorothiazide, after an oral dose, is rapid (Tmax about 2 hours). The increase in mean AUC is linear and dose proportional in the therapeutic range. The effect of food on hydrochlorothiazide absorption, if any, has little clinical significance. Absolute bioavailability of hydrochlorothiazide is 70% after oral administration.

**Distribution:** The apparent volume of distribution is 4-8 l/kg. Circulating hydrochlorothiazide is bound to serum proteins (40-70%), mainly serum albumin. Hydrochlorothiazide also accumulates in erythrocytes at approximately 3 times the level in plasma.

**Biotransformation:** Hydrochlorothiazide is eliminated predominantly as unchanged compound.

**Elimination:** Hydrochlorothiazide is eliminated from plasma with a half-life averaging 6 to 15 hours in the terminal elimination phase. There is no change in the kinetics of hydrochlorothiazide on repeated dosing, and accumulation is minimal when dosed once daily. More than 95% of the absorbed dose is being excreted as unchanged compound in the urine. The renal clearance is composed of passive filtration and active secretion into the renal tubule.
Special populations

Paediatric patients (age below 18 years)
No pharmacokinetic data are available in the paediatric population.

Elderly (age 65 years or over)
Time to peak plasma amlodipine concentrations is similar in young and elderly patients. In elderly patients, amlodipine clearance tends to decline, causing increases in the area under the curve (AUC) and elimination half-life. Mean systemic AUC of valsartan is higher by 70% in the elderly than in the young, therefore caution is required when increasing the dosage.

Systemic exposure to valsartan is slightly elevated in the elderly as compared to the young, but this has not been shown to have any clinical significance.

Limited data suggest that the systemic clearance of hydrochlorothiazide is reduced in both healthy and hypertensive elderly subjects compared to young healthy volunteers.

Since the three components are equally well tolerated in younger and elderly patients, normal dose regimens are recommended (see section 4.2).

Renal impairment
The pharmacokinetics of amlodipine are not significantly influenced by renal impairment. As expected for a compound where renal clearance accounts for only 30% of total plasma clearance, no correlation was seen between renal function and systemic exposure to valsartan.

Patients with mild to moderate renal impairment may therefore receive the usual initial dose (see sections 4.2 and 4.4).

In the presence of renal impairment, mean peak plasma levels and AUC values of hydrochlorothiazide are increased and the urinary excretion rate is reduced. In patients with mild to moderate renal impairment, a 3-fold increase in hydrochlorothiazide AUC has been observed. In patients with severe renal impairment an 8-fold increase in AUC has been observed. Imprida HCT is contraindicated in patients with severe renal impairment, anuria or undergoing dialysis (see section 4.3).

Hepatic impairment
Patients with hepatic insufficiency have decreased clearance of amlodipine with resulting increase of approximately 40–60% in AUC. On average, in patients with mild to moderate chronic liver disease, exposure (measured by AUC values) to valsartan is twice that found in healthy volunteers (matched by age, sex and weight). Due to the valsartan component, Imprida HCT is contraindicated in patients with hepatic impairment (see sections 4.2 and 4.3).

5.3 Preclinical safety data

Amlodipine/Valsartan/Hydrochlorothiazide
In a variety of preclinical safety studies conducted in several animal species with amlodipine, valsartan, hydrochlorothiazide, valsartan/hydrochlorothiazide, amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide (Imprida HCT), there was no evidence of systemic or target organ toxicity that would adversely affect the development of Imprida HCT for clinical use in humans.

Preclinical safety studies of up to 13 weeks in duration were conducted with amlodipine/valsartan/hydrochlorothiazide in rats. The combination resulted in expected reduction of red blood cell mass (erythrocytes, haemoglobin, haematocrit, and reticulocytes), increase in serum urea, increase in serum creatinine, increase in serum potassium, juxtaglomerular (JG) hyperplasia in the kidney and focal erosions in the glandular stomach in rats. All these changes were reversible after a 4-week recovery period and were considered to be exaggerated pharmacological effects.
The amlodipine/valsartan/hydrochlorothiazide combination was not tested for genotoxicity or carcinogenicity as there was no evidence of any interaction between these substances, which have been on the market for a long time. However, amlodipine, valsartan and hydrochlorothiazide have been tested individually for genotoxicity and carcinogenicity with negative results.

**Amlodipine**

**Reproductive toxicology**

Reproductive studies in rats and mice have shown delayed date of delivery, prolonged duration of labour and decreased pup survival at dosages approximately 50 times greater than the maximum recommended dosage for humans based on mg/kg.

**Impairment of fertility**

There was no effect on the fertility of rats treated with amlodipine (males for 64 days and females 14 days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human dose of 10 mg on a mg/m² basis). In another rat study in which male rats were treated with amlodipine besilate for 30 days at a dose comparable with the human dose based on mg/kg, decreased plasma follicle-stimulating hormone and testosterone were found as well as decreases in sperm density and in the number of mature spermatids and Sertoli cells.

**Carcinogenesis, mutagenesis**

Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity. The highest dose (for mice, similar to, and for rats twice* the maximum recommended clinical dose of 10 mg on a mg/m² basis) was close to the maximum tolerated dose for mice but not for rats.

Mutagenicity studies revealed no drug related effects at either the gene or chromosome levels.

* Based on patient weight of 50 kg

**Valsartan**

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential.

In rats, maternally toxic doses (600 mg/kg/day) during the last days of gestation and lactation led to lower survival, lower weight gain and delayed development (pinna detachment and ear-canal opening) in the offspring (see section 4.6). These doses in rats (600 mg/kg/day) are approximately 18 times the maximum recommended human dose on a mg/m² basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).

In non-clinical safety studies, high doses of valsartan (200 to 600 mg/kg body weight) caused in rats a reduction of red blood cell parameters (erythrocytes, haemoglobin, hematocrit) and evidence of changes in renal haemodynamics (slightly raised plasma urea, and renal tubular hyperplasia and basophilia in males). These doses in rats (200 and 600 mg/kg/day) are approximately 6 and 18 times the maximum recommended human dose on a mg/m² basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).

In marmosets at similar doses, the changes were similar though more severe, particularly in the kidney where the changes developed to a nephropathy which included raised urea and creatinine.

Hypertrophy of the renal juxtaglomerular cells was also seen in both species. All changes were considered to be caused by the pharmacological action of valsartan which produces prolonged hypotension, particularly in marmosets. For therapeutic doses of valsartan in humans, the hypertrophy of the renal juxtaglomerular cells does not seem to have any relevance.

Medicinal product no longer authorised.
6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core
Cellulose microcrystalline
Crosponvidone
Silica, colloidal anhydrous
Magnesium stearate

Coating
Hypromellose
Macrogol 4000
Talc
Titanium dioxide (E171)
Iron oxide, yellow (E172)
Iron oxide, red (E172)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

2 years

6.4 Special precautions for storage

Do not store above 30°C.

Store in the original package in order to protect from moisture.

6.5 Nature and contents of container

PVC/PVDC blisters. One blister contains 7, 10 or 14 film-coated tablets.
Pack sizes: 14, 28, 30, 56, 90, 98 or 280 film-coated tablets.
Multipacks of 280 tablets, comprising 20 cartons, each containing 14 tablets.

PVC/PVDC perforated unit dose blisters for hospital use:
Pack sizes: 56, 98 or 280 film-coated tablets
Multipacks of 280 tablets, comprising 4 cartons, each containing 70 tablets.

Not all pack sizes or strengths may be marketed.

6.6 Special precautions for disposal and other handling

No special requirements.

7. MARKETING AUTHORISATION HOLDER

Novartis Europharm Limited
Wimplehurst Road
Horsham
West Sussex, RH12 5AB
United Kingdom
8. MARKETING AUTHORISATION NUMBER(S)

EU/1/09/570/013-024

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

15.10.2009

10. DATE OF REVISION OF THE TEXT

Detailed information on this product is available on the website of the European Medicines Agency http://www.ema.europa.eu

Medicinal product no longer authorised
1. **NAME OF THE MEDICINAL PRODUCT**

Imprida HCT 5 mg/160 mg/25 mg film-coated tablets

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each film-coated tablet contains 5 mg of amlodipine (as amlodipine besylate), 160 mg of valsartan, and 25 mg of hydrochlorothiazide.

For a full list of excipients, see section 6.1.

3. **PHARMACEUTICAL FORM**

Film-coated tablet (tablet)

Yellow, ovaloid, biconvex tablets with bevelled edge, debossed “NVR” on one side and “VEL” on the other side.

4. **CLINICAL PARTICULARS**

4.1 Therapeutic indications

Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.

4.2 Posology and method of administration

**Posology**

The recommended dose of Imprida HCT is one tablet per day, to be taken preferably in the morning.

Before switching to Imprida HCT patients should be controlled on stable doses of the monocomponents taken at the same time. The dose of Imprida HCT should be based on the doses of the individual components of the combination at the time of switching.

The maximum recommended dose of Imprida HCT is 10 mg/320 mg/25 mg.

**Special populations**

**Renal impairment**

No adjustment of the initial dose is required for patients with mild to moderate renal impairment (see sections 4.4 and 5.2). Due to the hydrochlorothiazide component, Imprida HCT is contraindicated for use in patients with anuria (see section 4.3) and in patients with severe renal impairment (glomerular filtration rate (GFR) <30 ml/min/1.73 m²) (see sections 4.3, 4.4 and 5.2).

**Hepatic impairment**

Due to the valsartan component, Imprida HCT is contraindicated in patients with severe hepatic impairment (see section 4.3). In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan and therefore Imprida HCT is not suitable in this group of patients (see sections 4.3, 4.4 and 5.2).
Heart failure and coronary artery disease
There is limited experience with the use of Imprida HCT, particularly at the maximum dose, in patients with heart failure and coronary artery disease. Caution is advised in patients with heart failure and coronary artery disease, particularly at the maximum dose of Imprida HCT, 10 mg/320 mg/25 mg.

Elderly (age 65 years or over)
Caution, including more frequent monitoring of blood pressure, is recommended in elderly patients, particularly at the maximum dose of Imprida HCT, 10 mg/320 mg/25 mg, since available data in this patient population are limited.

Paediatric population
There is no relevant use of Imprida HCT in the paediatric population (patients below age 18 years) for the indication of essential hypertension.

Method of administration
Imprida HCT can be taken with or without food. The tablets should be swallowed whole with some water, at the same time of the day and preferably in the morning.

4.3 Contraindications
- Hypersensitivity to the active substances, to other sulphonamide derivatives, to dihydropyridine derivatives, or to any of the excipients.
- Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
- Hepatic impairment, biliary cirrhosis or cholestasis.
- Severe renal impairment (GFR <30 ml/min/1.73 m²), anuria and patients undergoing dialysis.
- Refractory hypokalaemia, hyponatraemia, hypercalcaemia, and symptomatic hyperuricaemia.

4.4 Special warnings and precautions for use
Sodium- and/or volume-depleted patients
Excessive hypotension, including orthostatic hypotension, was seen in 1.7% of patients treated with the maximum dose of Imprida HCT (10 mg/320 mg/25 mg) compared to 1.8% of valsartan/hydrochlorothiazide (320 mg/25 mg) patients, 0.4% of amlodipine/valsartan (10 mg/320 mg) patients, and 0.2% of hydrochlorothiazide/amlodipine (25 mg/10 mg) patients in a controlled trial in patients with moderate to severe uncomplicated hypertension.

In sodium-depleted and/or volume-depleted patients, such as those receiving high doses of diuretics, symptomatic hypotension may occur after initiation of treatment with Imprida HCT. Imprida HCT should be used only after correction of any pre-existing sodium and/or volume depletion.

If excessive hypotension occurs with Imprida HCT, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline. Treatment can be continued once blood pressure has been stabilised.

Serum electrolyte changes
Amlodipine/valsartan/hydrochlorothiazide
In the controlled trial of Imprida HCT, the counteracting effects of valsartan 320 mg and hydrochlorothiazide 25 mg on serum potassium approximately balanced each other in many patients. In other patients, one or the other effect may be dominant. Periodic determinations of serum electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals.

Periodic determination of serum electrolytes and potassium in particular should be performed at appropriate intervals to detect possible electrolyte imbalance, especially in patients with other risk factors such as impaired renal function, treatment with other medicinal products or history of prior electrolyte imbalances.
Valsartan
Concomitant use with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other medicinal products that may increase potassium levels (heparin, etc.) is not recommended. Monitoring of potassium should be undertaken as appropriate.

Hydrochlorothiazide
Treatment with Imprida HCT should only start after correction of hypokalaemia and any coexisting hypomagnesaemia. Thiazide diuretics can precipitate new onset hypokalaemia or exacerbate pre-existing hypokalaemia. Thiazide diuretics should be administered with caution in patients with conditions involving enhanced potassium loss, for example salt-losing nephropathies and prerenal (cardiogenic) impairment of kidney function. If hypokalaemia develops during hydrochlorothiazide therapy, Imprida HCT should be discontinued until stable correction of the potassium balance.

Thiazide diuretics can precipitate new onset hyponatraemia and hypochloroaemic alkalosis or exacerbate pre-existing hyponatraemia. Hyponatraemia, accompanied by neurological symptoms (nausea, progressive disorientation, apathy) has been observed. Treatment with hydrochlorothiazide should only be started after correction of pre-existing hyponatraemia. In case severe or rapid hyponatraemia develops during Imprida HCT therapy, the treatment should be discontinued until normalisation of natraemia.

All patients receiving thiazide diuretics should be periodically monitored for imbalances in electrolytes, particularly potassium, sodium and magnesium.

Renal impairment
Thiazide diuretics may precipitate azotaemia in patients with chronic kidney disease. When Imprida HCT is used in patients with renal impairment periodic monitoring of serum electrolytes (including potassium), creatinine and uric acid serum levels is recommended. Imprida HCT is contraindicated in patients with severe renal impairment, anuria or undergoing dialysis (see section 4.3).

No dosage adjustment of Imprida HCT is required for patients with mild to moderate renal impairment (GFR ≥30 ml/min/1.73 m²).

Renal artery stenosis
No data are available on the use of Imprida HCT in patients with unilateral or bilateral renal artery stenosis or stenosis to a solitary kidney.

Kidney transplantation
To date there is no experience of the safe use of Imprida HCT in patients who have had a recent kidney transplantation.

Hepatic impairment
Valsartan is mostly eliminated unchanged via the bile, whereas amlodipine is extensively metabolised by the liver. In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan, and therefore, Imprida HCT is not suitable in this group of patients (see sections 4.2, 4.3 and 5.2).

Heart failure and coronary artery disease
As a consequence of the inhibition of the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients with severe heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotaemia and (rarely) with acute renal failure and/or death. Similar outcomes have been reported with valsartan.
In a long-term, placebo-controlled study (PRAISE-2) of amlodipine in patients with NYHA (New York Heart Association Classification) III and IV heart failure of non-ischaemic aetiology, amlodipine was associated with increased reports of pulmonary oedema despite no significant difference in the incidence of worsening heart failure as compared to placebo.

Caution is advised in patients with heart failure and coronary artery disease, particularly at the maximum dose of Imprida HCT, 10 mg/320 mg/25 mg, since available data in these patient populations is limited.

Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy
As with all other vasodilators, special caution is indicated in patients with aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.

Pregnancy
Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).

Primary hyperaldosteronism
Patients with primary hyperaldosteronism should not be treated with the angiotensin II antagonist valsartan as their renin-angiotensin system is not activated. Therefore, Imprida HCT is not recommended in this population.

Systemic lupus erythematosus
Thiazide diuretics, including hydrochlorothiazide, have been reported to exacerbate or activate systemic lupus erythematosus.

Other metabolic disturbances
Thiazide diuretics, including hydrochlorothiazide, may alter glucose tolerance and raise serum levels of cholesterol, triglycerides and uric acid. In diabetic patients dosage adjustments of insulin or oral hypoglycaemic agents may be required.

Due to the hydrochlorothiazide component, Imprida HCT is contraindicated in symptomatic hyperuricaemia. Hydrochlorothiazide may raise the serum uric acid level due to reduced clearance of uric acid and may cause or exacerbate hyperuricaemia as well as precipitate gout in susceptible patients.

Thiazides reduce urinary calcium excretion and may cause intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Imprida HCT is contraindicated in patients with hypercalcaemia and should only be used after correction of any pre-existing hypercalcaemia. Imprida HCT should be discontinued if hypercalcaemia develops during treatment. Serum levels of calcium should be periodically monitored during treatment with thiazides. Marked hypercalcaemia may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function.

Photosensitivity
Cases of photosensitivity reactions have been reported with thiazide diuretics (see section 4.8). If photosensitivity reaction occurs during treatment with Imprida HCT, it is recommended to stop the treatment. If a readministration of the diuretic is deemed necessary, it is recommended to protect exposed areas to the sun or to artificial UVA.
Acute angle-closure glaucoma
Hydrochlorothiazide, a sulphonamide, has been associated with an idiosyncratic reaction resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to a week of treatment initiation. Untreated acute-angle closure glaucoma can lead to permanent vision loss.

The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatment may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle closure glaucoma may include a history of sulphonamide or penicillin allergy.

General
Caution should be exercised in patients who have shown prior hypersensitivity to other angiotensin II receptor antagonists. Hypersensitivity reactions to hydrochlorothiazide are more likely in patients with allergy and asthma.

Elderly (age 65 years or over)
Caution, including more frequent monitoring of blood pressure, is recommended in elderly patients, particularly at the maximum dose of Imprida HCT, 10 mg/320 mg/25 mg, since available data in this patient population are limited.

4.5 Interaction with other medicinal products and other forms of interaction

No formal interaction studies with other medicinal products were performed with Imprida HCT. Thus, only information on interactions with other medicinal products that are known for the individual active substances is provided in this section.

However, it is important to take into account that Imprida HCT may increase the hypotensive effect of other antihypertensive agents.
### Concomitant use not recommended

<table>
<thead>
<tr>
<th>Imprida HCT individual component</th>
<th>Known interactions with the following agents</th>
<th>Effect of the interaction with other medicinal products</th>
</tr>
</thead>
<tbody>
<tr>
<td>Valsartan and HCT</td>
<td>Lithium</td>
<td>Reversible increases in serum lithium concentrations and toxicity have been reported during concurrent use of ACE inhibitors and thiazides such as hydrochlorothiazide. Despite the lack of experience with concomitant use of valsartan and lithium, this combination is not recommended. If the combination proves necessary, careful monitoring of serum lithium levels is recommended (see section 4.4).</td>
</tr>
<tr>
<td>Valsartan</td>
<td>Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may increase potassium levels</td>
<td>If a medicinal product that affects potassium levels is considered necessary in combination with valsartan, frequent monitoring of potassium plasma levels is advised.</td>
</tr>
<tr>
<td>Amlodipine</td>
<td>Grapefruit or grapefruit juice</td>
<td>Administration of amlodipine with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients, resulting in increased blood pressure lowering effects.</td>
</tr>
</tbody>
</table>

### Caution required with concomitant use

<table>
<thead>
<tr>
<th>Imprida HCT individual component</th>
<th>Known interactions with the following agents</th>
<th>Effect of the interaction with other medicinal products</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amlodipine</td>
<td>CYP3A4 inhibitors (i.e. ketoconazole, itraconazole, ritonavir)</td>
<td>Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors, azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem) may give rise to significant increase in amlodipine exposure. The clinical translation of these pharmacokinetic variations may be more pronounced in the elderly. Clinical monitoring and dose adjustment may thus be required.</td>
</tr>
<tr>
<td></td>
<td>CYP3A4 inducers (anticonvulsant agents [e.g. carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone], rifampicin, Hypericum perforatum [St. John’s wort])</td>
<td>There is no data available regarding the effect of CYP3A4 inducers on amlodipine. The concomitant use of CYP3A4 inducers (e.g. rifampicin, Hypericum perforatum) may give a lower plasma concentration of amlodipine. Amlodipine should be used with caution together with CYP3A4 inducers.</td>
</tr>
<tr>
<td>Compound</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td><strong>Simvastatin</strong></td>
<td>Co-administration of multiple doses of 10 mg amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. It is recommended to limit the dose of simvastatin to 20 mg daily in patients on amlodipine.</td>
<td></td>
</tr>
<tr>
<td><strong>Dantrolene (infusion)</strong></td>
<td>In animals, lethal ventricular fibrillation and cardiovascular collapse are observed in association with hyperkalaemia after administration of verapamil and intravenous dantrolene. Due to risk of hyperkalaemia, it is recommended that the co-administration of calcium channel blockers such as amlodipine be avoided in patients susceptible to malignant hyperthermia and in the management of malignant hyperthermia.</td>
<td></td>
</tr>
<tr>
<td><strong>Valsartan and HCT</strong></td>
<td>NSAIDS can attenuate the antihypertensive effect of both angiotensin II antagonists and hydrochlorothiazide when administered simultaneously. Furthermore, concomitant use of Imprida HCT and NSAIDs may lead to worsening of renal function and an increase in serum potassium. Therefore, monitoring of renal function at the beginning of the treatment is recommended, as well as adequate hydration of the patient.</td>
<td></td>
</tr>
<tr>
<td><strong>Valsartan</strong></td>
<td><strong>Inhibitors of the uptake transporter</strong> (rifampicin, ciclosporin) or <strong>efflux transporter</strong> (ritonavir) The results of an <em>in vitro</em> study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1 and of the hepatic efflux transporter MRP2. Co-administration of inhibitors of the uptake transporter (rifampicin, ciclosporin) or efflux transporter (ritonavir) may increase the systemic exposure to valsartan.</td>
<td></td>
</tr>
<tr>
<td><strong>HCT</strong></td>
<td><strong>Alcohol, barbiturates or narcotics</strong> Concomitant administration of thiazide diuretics with substances that also have a blood pressure lowering effect (e.g. by reducing sympathetic central nervous system activity or direct vasodilatation) may potentiate orthostatic hypotension.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Amantadine</strong> Thiazides, including hydrochlorothiazide, may increase the risk of adverse reactions caused by amantadine.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Anticholinergic agents and other medicinal products affecting gastric motility</strong> The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents (e.g. atropine, biperiden), apparently due to a decrease in gastrointestinal motility and the stomach emptying rate. Conversely, it is anticipated that prokinetic substances such as cisapride may decrease the bioavailability of thiazide-type diuretics.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Antidiabetic agents</strong> (e.g. insulin and oral antidiabetic agents) Thiazides may alter glucose tolerance. Dose adjustment of the antidiabetic medicinal product may be necessary.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>– <strong>Metformin</strong> Metformin should be used with caution because of the risk of lactic acidosis induced by possible functional renal failure linked to hydrochlorothiazide.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Beta blockers and diazoxide</strong> Concomitant use of thiazide diuretics, including hydrochlorothiazide, with beta blockers may increase the risk of hyperglycaemia. Thiazide diuretics, including hydrochlorothiazide, may enhance the hyperglycaemic effect of diazoxide.</td>
<td></td>
</tr>
<tr>
<td><strong>Ciclosporin</strong></td>
<td>Concomitant treatment with ciclosporin may increase the risk of hyperuricaemia and gout-type complications.</td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td>-------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Cytotoxic agents</strong></td>
<td>Thiazides, including hydrochlorothiazide, may reduce the renal excretion of cytotoxic agents (e.g. cyclophosphamide, methotrexate) and potentiate their myelosuppressive effects.</td>
<td></td>
</tr>
<tr>
<td><strong>Digitalis glycosides</strong></td>
<td>Thiazide-induced hypokalaemia or hypomagnesaemia may occur as undesirable effects, favouring the onset of digitalis-induced cardiac arrhythmias.</td>
<td></td>
</tr>
<tr>
<td><strong>Iodine contrasting agents</strong></td>
<td>In case of diuretic-induced dehydration, there is an increased risk of acute renal failure, especially with high doses of iodine products. Patients should be re-hydrated before the administration.</td>
<td></td>
</tr>
<tr>
<td><strong>Ion exchange resins</strong></td>
<td>Absorption of thiazide diuretics, including hydrochlorothiazide, is decreased by cholestyramine or colestipol. This could result in sub-therapeutic effects of thiazide diuretics. However, staggering the dosage of hydrochlorothiazide and resin such that hydrochlorothiazide is administered at least 4 hours before or 4-6 hours after the administration of resins would potentially minimise the interaction.</td>
<td></td>
</tr>
<tr>
<td><strong>Medicinal products affecting serum potassium level</strong></td>
<td>The hypokalaemic effect of hydrochlorothiazide may be increased by concomitant administration of kaliuretic diuretics, corticosteroids, laxatives, adrenocorticotropic hormone (ACTH), amphotericin, carbenoxolone, penicillin G and salicylic acid derivatives or antiarrhythmics. If these medicinal products are to be prescribed with the amlodipine /valsartan /hydrochlorothiazide combination, monitoring of potassium plasma levels is advised.</td>
<td></td>
</tr>
<tr>
<td><strong>Medicinal products affecting serum sodium level</strong></td>
<td>The hyponatraemic effect of diuretics may be intensified by concomitant administration of medicinal products such as antidepressants, antipsychotics, antiepileptics, etc. Caution is indicated in long-term administration of these medicinal products.</td>
<td></td>
</tr>
<tr>
<td><strong>Medicinal products that could induce torsades de pointes</strong></td>
<td>Due to the risk of hypokalaemia, hydrochlorothiazide should be administered with caution when associated with medicinal products that could induce <em>torsades de pointes</em>, in particular Class Ia and Class III antiarrhythmics and some antipsychotics.</td>
<td></td>
</tr>
<tr>
<td><strong>Medicinal products used in the treatment of gout (probenecid, sulfinpyrazone and allopurinol)</strong></td>
<td>Dose adjustment of uricosuric medicinal products may be necessary as hydrochlorothiazide may raise the level of serum uric acid. Increase of dose of probenecid or sulfinpyrazone may be necessary. Co-administration of thiazide diuretics, including hydrochlorothiazide, may increase the incidence of hypersensitivity reactions to allopurinol.</td>
<td></td>
</tr>
<tr>
<td><strong>Methyldopa</strong></td>
<td>There have been isolated reports of haemolytic anaemia occurring with concomitant use of hydrochlorothiazide and methyldopa.</td>
<td></td>
</tr>
<tr>
<td><strong>Non-depolarising skeletal muscle relaxants (e.g. tubocurarine)</strong></td>
<td>Thiazides, including hydrochlorothiazide, potentiate the action of curare derivatives.</td>
<td></td>
</tr>
</tbody>
</table>
**Other anti-hypertensive drugs**  
Thiazides potentiate the antihypertensive action of other antihypertensive drugs (e.g. guanethidine, methyldopa, beta-blockers, vasodilators, calcium channel blockers, ACE inhibitors, ARBs and Direct Renin Inhibitors [DRIs]).

**Pressor amines (e.g. noradrenaline, adrenaline)**  
Hydrochlorothiazide may reduce the response to pressor amines such as noradrenaline. The clinical significance of this effect is uncertain and not sufficient to preclude their use.

**Vitamin D and calcium salts**  
Administration of thiazide diuretics, including hydrochlorothiazide, with vitamin D or with calcium salts may potentiate the rise in serum calcium. Concomitant use of thiazide type diuretics may lead to hypercalcaemia in patients pre-disposed for hypercalcaemia (e.g. hyperparathyroidism, malignancy or vitamin-D-mediated conditions) by increasing tubular calcium reabsorption.

<table>
<thead>
<tr>
<th>Medicinal product</th>
<th>Known interactions with the following agents</th>
<th>Effect of the interaction with other medicinal products</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Imprida HCT</strong></td>
<td><strong>Known interactions</strong></td>
<td><strong>Effect of the interaction with other medicinal products</strong></td>
</tr>
<tr>
<td><strong>individual component</strong></td>
<td><strong>others</strong></td>
<td>In monotherapy with valsartan, no interactions of clinical significance have been found with the following substances: cimetidine, warfarin, furosemide, digoxin, atenolol, indomethacin, hydrochlorothiazide, amlodipine, glibenclamide. Some of these substances could interact with the hydrochlorothiazide component of Imprida HCT (see interactions related to HCT).</td>
</tr>
<tr>
<td><strong>Valsartan</strong></td>
<td>(cimetidine, warfarin, furosemide, digoxin, atenolol, indomethacin, hydrochlorothiazide, amlodipine, glibenclamide)</td>
<td></td>
</tr>
<tr>
<td><strong>Amlodipine</strong></td>
<td><strong>Others</strong></td>
<td>In clinical interaction studies, amlodipine did not affect the pharmacokinetics of atorvastatin, digoxin, warfarin or ciclosporin.</td>
</tr>
</tbody>
</table>

### 4.6 Fertility, pregnancy and lactation

**Pregnancy Amlodipine**

The safety of amlodipine in human pregnancy has not been established. In animal studies, reproductive toxicity was observed at high doses (see section 5.3). Use in pregnancy is only recommended when there is no safer alternative and when the disease itself carries greater risk for the mother and foetus.
Valsartan

The use of Angiotensin II Receptor Antagonists (AIIRAs) is not recommended during the first trimester of pregnancy (see section 4.4). The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 and 4.4).

Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued AIIR therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and if appropriate, alternative therapy should be started.

Exposure to AIIRAs therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3).

Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.

Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3 and 4.4).

Hydrochlorothiazide

There is limited experience with hydrochlorothiazide during pregnancy, especially during the first trimester. Animal studies are insufficient.

Hydrochlorothiazide crosses the placenta. Based on the pharmacological mechanism of action of hydrochlorothiazide, its use during the second and third trimester may compromise foeto-placental perfusion and may cause foetal and neonatal effects like icterus, disturbance of electrolyte balance and thrombocytopenia.

Amlodipine/valsartan/hydrochlorothiazide

There is no experience on the use of Imprida HCT in pregnant women. Based on the existing data with the components, the use of Imprida HCT is not recommended during first trimester and contraindicated during the second and third trimester of pregnancy (see sections 4.3 and 4.4).

Breast-feeding

No information is available regarding the use of valsartan and/or amlodipine during breast-feeding. Hydrochlorothiazide is excreted in human milk in small amounts. Thiazides in high doses causing intense diuresis can inhibit milk production. The use of Imprida HCT during breast-feeding is not recommended. If Imprida HCT is used during breast-feeding, doses should be kept as low as possible. Alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.

Fertility

There are no clinical studies on fertility with Imprida HCT.

Valsartan

Valsartan had no adverse effects on the reproductive performance of male or female rats at oral doses up to 200 mg/kg/day. This dose is 6 times the maximum recommended human dose on a mg/m² basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).
**Amlodipine**
Reversible biochemical changes in the head of spermatozoa have been reported in some patients treated by calcium channel blockers. Clinical data are insufficient regarding the potential effect of amlodipine on fertility. In one rat study, adverse effects were found on male fertility (see section 5.3).

### 4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. When driving vehicles or using machines it should be taken into account that occasionally dizziness or weariness may occur.

### 4.8 Undesirable effects

The safety profile of Imprida HCT presented below is based on clinical studies performed with Imprida HCT and the known safety profile of the individual components amlodipine, valsartan and hydrochlorothiazide.

**Information on Imprida HCT**
The safety of Imprida HCT has been evaluated at its maximum dose of 10 mg/320 mg/25 mg in one controlled short-term (8 weeks) clinical study with 2,271 patients, 582 of whom received valsartan in combination with amlodipine and hydrochlorothiazide. Adverse reactions were generally mild and transient in nature and only infrequently required discontinuation of therapy. In this active controlled clinical trial, the most common reasons for discontinuation of therapy with Imprida HCT were dizziness and hypotension (0.7%).

In the 8-week controlled clinical study, no significant new or unexpected adverse reactions were observed with triple therapy treatment compared to the known effects of the monotherapy or dual therapy components.

In the 8-week controlled clinical study, changes in laboratory parameters observed with the combination of Imprida HCT were minor and consistent with the pharmacological mechanism of action of the monotherapy agents. The presence of valsartan in the triple combination attenuated the hypokalaemic effect of hydrochlorothiazide.

The following adverse reactions, listed by MedDRA System Organ Class and frequency, concern Imprida HCT (amlodipine/valsartan/HCT) and amlodipine, valsartan and HCT individually.

Very common: ≥1/10; common: ≥1/100 to <1/10; uncommon: ≥1/1,000 to <1/100; rare: ≥1/10,000 to <1/1,000; very rare: <1/10,000, not known (cannot be estimated from the available data).

<table>
<thead>
<tr>
<th>MedDRA System Organ Class</th>
<th>Adverse reactions</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>Agranulocytosis, bone marrow depression</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Decrease in haemoglobin and in haematocrit</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Haemolytic anaemia</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Leukopenia</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Neutropenia</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Thrombocytopenia, sometimes with purpura</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Aplastic anaemia</td>
<td>--</td>
</tr>
<tr>
<td>Immune system disorders</td>
<td>Hypersensitivity</td>
<td>--</td>
</tr>
<tr>
<td>------------------------</td>
<td>-----------------</td>
<td>-----</td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td>Anorexia</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Hypercalcaemia</td>
<td>Uncommon</td>
<td>--</td>
</tr>
<tr>
<td>Hyperglycaemia</td>
<td>--</td>
<td>Very rare</td>
</tr>
<tr>
<td>Hyperlipidaemia</td>
<td>Uncommon</td>
<td>--</td>
</tr>
<tr>
<td>Hyperuricaemia</td>
<td>Uncommon</td>
<td>--</td>
</tr>
<tr>
<td>Hypochloreaemic alkalosis</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Hypokalaemia</td>
<td>Common</td>
<td>--</td>
</tr>
<tr>
<td>Hypomagnesaemia</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Hypoanaemia</td>
<td>Uncommon</td>
<td>--</td>
</tr>
<tr>
<td>Worsening of diabetic metabolic state</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td>Depression</td>
<td>--</td>
</tr>
<tr>
<td>Insomnia/sleep disturbances</td>
<td>Uncommon</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Mood swings</td>
<td>--</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Coordination abnormal</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Dizziness</td>
<td>Common</td>
<td>Common</td>
</tr>
<tr>
<td>Dizziness postural, dizziness exertional</td>
<td>Uncommon</td>
<td>--</td>
</tr>
<tr>
<td>Dysgeusia</td>
<td>Uncommon</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Extrapyramidal syndrome</td>
<td>--</td>
<td>Not known</td>
</tr>
<tr>
<td>Headache</td>
<td>Common</td>
<td>Common</td>
</tr>
<tr>
<td>Hypertonia</td>
<td>--</td>
<td>Very rare</td>
</tr>
<tr>
<td>Lethargy</td>
<td>Uncommon</td>
<td>--</td>
</tr>
<tr>
<td>Paraesthesia</td>
<td>Uncommon</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Peripheral neuropathy, neuropathy</td>
<td>Uncommon</td>
<td>Very rare</td>
</tr>
<tr>
<td>Somnolence</td>
<td>Uncommon</td>
<td>Common</td>
</tr>
<tr>
<td>Syncope</td>
<td>Uncommon</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Tremor</td>
<td>--</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Eye disorders</td>
<td>Acute angle-closure glaucoma</td>
<td>--</td>
</tr>
<tr>
<td>Visual impairment</td>
<td>Uncommon</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Ear and labyrinth disorders</td>
<td>Tinnitus</td>
<td>--</td>
</tr>
<tr>
<td>Vertigo</td>
<td>Uncommon</td>
<td>--</td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td>Palpitations</td>
<td>--</td>
</tr>
<tr>
<td>Tachycardia</td>
<td>Uncommon</td>
<td>--</td>
</tr>
<tr>
<td>Arrhythmias (including bradycardia, ventricular tachycardia, and atrial fibrillation)</td>
<td>--</td>
<td>Very rare</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>--</td>
<td>Very rare</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>Flushing</td>
<td>--</td>
</tr>
<tr>
<td>Hypotension</td>
<td>Common</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Orthostatic hypotension</td>
<td>Uncommon</td>
<td>--</td>
</tr>
<tr>
<td>Phlebitis, thrombophlebitis</td>
<td>Uncommon</td>
<td>--</td>
</tr>
<tr>
<td>Vasculitis</td>
<td>--</td>
<td>Very rare</td>
</tr>
<tr>
<td>Disorder</td>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>Gastrointestinal disorders</td>
</tr>
<tr>
<td>-------------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>Cough</td>
<td>Uncommon</td>
<td>Abdominal discomfort, abdominal pain upper</td>
</tr>
<tr>
<td>Dyspnoea</td>
<td>Uncommon</td>
<td>Breath odour</td>
</tr>
<tr>
<td>Respiratory distress, pulmonary oedema, pneumonitis</td>
<td>--</td>
<td>Change of bowel habit</td>
</tr>
<tr>
<td>Rhinitis</td>
<td>--</td>
<td>Constipation</td>
</tr>
<tr>
<td>Throat irritation</td>
<td>Uncommon</td>
<td>Decreased appetite</td>
</tr>
<tr>
<td>Blairstasis</td>
<td>--</td>
<td>Diarrhoea</td>
</tr>
<tr>
<td>Breathing distress</td>
<td>Uncommon</td>
<td>Dry mouth</td>
</tr>
<tr>
<td>Pulmonary oedema</td>
<td>--</td>
<td>Dyspepsia</td>
</tr>
<tr>
<td>Rheumatism</td>
<td>--</td>
<td>Gastritis</td>
</tr>
<tr>
<td>Pruritus</td>
<td>--</td>
<td>Gingival hyperplasia</td>
</tr>
<tr>
<td>Acne</td>
<td>--</td>
<td>Hepatic enzyme elevation, including increase of serum bilirubin</td>
</tr>
<tr>
<td>Alopecia</td>
<td>--</td>
<td>Hepatitis</td>
</tr>
<tr>
<td>Angioedema</td>
<td>--</td>
<td>Intrahepatic cholestasis, jaundice</td>
</tr>
<tr>
<td>Cutaneous lupus erythematosus-like reactions, reactivation of cutaneous lupus erythematosus</td>
<td>--</td>
<td>Nausea</td>
</tr>
<tr>
<td>Erythema multiforme</td>
<td>--</td>
<td>Pancreatitis</td>
</tr>
<tr>
<td>Exanthema</td>
<td>--</td>
<td>Pneumonitis</td>
</tr>
<tr>
<td>Hyperhidrosis</td>
<td>Uncommon</td>
<td>Pruritus</td>
</tr>
<tr>
<td>Photosensitivity reaction*</td>
<td>--</td>
<td>Rash</td>
</tr>
<tr>
<td>Purpura</td>
<td>--</td>
<td>Rash</td>
</tr>
<tr>
<td>Rash</td>
<td>--</td>
<td>Skin discoloration</td>
</tr>
<tr>
<td>Urticaria and other forms of rash</td>
<td>--</td>
<td>Urticaria and other forms of rash</td>
</tr>
<tr>
<td>Vascular necrosis and toxic epidermal necrolysis</td>
<td>--</td>
<td>Vasculitis necrotising and toxic epidermal necrolysis</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Back pain</td>
<td>Uncommon</td>
<td>--</td>
</tr>
<tr>
<td>Joint swelling</td>
<td>Uncommon</td>
<td>--</td>
</tr>
<tr>
<td>Muscle spasm</td>
<td>Uncommon</td>
<td>--</td>
</tr>
<tr>
<td>Muscular weakness</td>
<td>Uncommon</td>
<td>--</td>
</tr>
<tr>
<td>Myalgia</td>
<td>Uncommon</td>
<td>--</td>
</tr>
<tr>
<td>Pain in extremity</td>
<td>Uncommon</td>
<td>--</td>
</tr>
</tbody>
</table>

Note: Medicinal product no longer authorised.
### Renal and urinary disorders

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Frequency 1</th>
<th>Frequency 2</th>
<th>Frequency 3</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elevation of serum creatinine</td>
<td>Uncommon</td>
<td>--</td>
<td>Not known</td>
<td>--</td>
</tr>
<tr>
<td>Micturition disorder</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Nocturia</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Pollakiuria</td>
<td>Common</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Renal dysfunction</td>
<td>--</td>
<td>--</td>
<td>Not known</td>
<td>--</td>
</tr>
<tr>
<td>Renal failure acute</td>
<td>Uncommon</td>
<td>--</td>
<td>Not known</td>
<td>--</td>
</tr>
<tr>
<td>Renal failure and impairment</td>
<td>--</td>
<td>--</td>
<td>Not known</td>
<td>Rare</td>
</tr>
</tbody>
</table>

### Reproductive system and breast disorders

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Frequency 1</th>
<th>Frequency 2</th>
<th>Frequency 3</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Impotence</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>Common</td>
</tr>
<tr>
<td>Gynaecomastia</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
</tbody>
</table>

### General disorders and administration site conditions

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Frequency 1</th>
<th>Frequency 2</th>
<th>Frequency 3</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abasia, gait disturbance</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Asthenia</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>Not known</td>
</tr>
<tr>
<td>Discomfort, malaise</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Fatigue</td>
<td>Common</td>
<td>Common</td>
<td>Uncommon</td>
<td>--</td>
</tr>
<tr>
<td>Non cardiac chest pain</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Oedema</td>
<td>Common</td>
<td>Common</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Pain</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Not known</td>
</tr>
</tbody>
</table>

### Investigations

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Frequency 1</th>
<th>Frequency 2</th>
<th>Frequency 3</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lipids increased</td>
<td>--</td>
<td>--</td>
<td>Very common</td>
<td></td>
</tr>
<tr>
<td>Blood urea nitrogen increased</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Blood uric acid increased</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Glycosuria</td>
<td>--</td>
<td>--</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td>Serum potassium decreased</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Serum potassium increased</td>
<td>--</td>
<td>--</td>
<td>Not known</td>
<td>--</td>
</tr>
<tr>
<td>Weight increase</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Weight decrease</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
</tr>
</tbody>
</table>

* See section 4.4 Photosensitivity

### 4.9 Overdose

**Symptoms**

There is no experience of overdose with Imprida HCT. The major symptom of overdose with valsartan is possibly pronounced hypotension with dizziness. Overdose with amlodipine may result in excessive peripheral vasodilation and, possibly, reflex tachycardia. Marked and potentially prolonged systemic hypotension, including shock with fatal outcome, have been reported with amlodipine.

**Treatment**

**Amlodipine/Valsartan/Hydrochlorothiazide**

Clinically significant hypotension due to Imprida HCT overdose calls for active cardiovascular support, including frequent monitoring of cardiac and respiratory function, elevation of extremities, and attention to circulating fluid volume and urine output. A vasoconstrictor may be helpful in restoring vascular tone and blood pressure, provided that there is no contraindication to its use. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade.

**Amlodipine**

If ingestion is recent, induction of vomiting or gastric lavage may be considered. Administration of activated charcoal to healthy volunteers immediately or up to two hours after ingestion of amlodipine has been shown to significantly decrease amlodipine absorption. Amlodipine is unlikely to be removed by haemodialysis.
**Valsartan**
Valsartan is unlikely to be removed by haemodialysis.

**Hydrochlorothiazide**
Overdose with hydrochlorothiazide is associated with electrolyte depletion (hypokalaemia, hypochloraemia) and hypovolaemia resulting from excessive diuresis. The most common signs and symptoms of overdose are nausea and somnolence. Hypokalaemia may result in muscle spasms and or accentuate arrhythmia associated with the concomitant use of digitalis glycosides or certain anti-arrhythmic medicinal products. The degree to which hydrochlorothiazide is removed by haemodialysis has not been established.

### 5. PHARMACOLOGICAL PROPERTIES

#### 5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Angiotensin II antagonists, plain (valsartan), combinations with dihydropyridine derivatives (amlodipine) and thiazide diuretics (hydrochlorothiazide), ATC code: C09DX01 valsartan, amlodipine and hydrochlorothiazide.

Imprida HCT combines three antihypertensive compounds with complementary mechanisms to control blood pressure in patients with essential hypertension: amlodipine belongs to the calcium antagonist class and valsartan to the angiotensin II antagonist class of medicines and hydrochlorothiazide belongs to the thiazide diuretics class of medicines. The combination of these substances has an additive antihypertensive effect.

*Amlodipine/Valsartan/Hydrochlorothiazide*

Imprida HCT was studied in a double-blind, active controlled study in hypertensive patients. A total of 2,271 patients with moderate to severe hypertension (mean baseline systolic/diastolic blood pressure was 170/107 mmHg) received treatments of amlodipine/valsartan/hydrochlorothiazide 10 mg/320 mg/25 mg, valsartan/hydrochlorothiazide 320 mg/25 mg, amlodipine/valsartan 10 mg/320 mg, or hydrochlorothiazide/amlodipine 25 mg/10 mg. At study initiation patients were assigned lower doses of their treatment combination and were titrated to their full treatment dose by week 2.

At week 8, the mean reductions in systolic/diastolic blood pressure were 39.7/24.7 mmHg with Imprida HCT, 32.0/19.7 mmHg with valsartan/hydrochlorothiazide, 33.5/21.5 mmHg with amlodipine/valsartan, and 31.5/19.5 mmHg with amlodipine/hydrochlorothiazide. The triple combination therapy was statistically superior to each of the three dual combination treatments in reduction of diastolic and systolic blood pressures. The reductions in systolic/diastolic blood pressure with Imprida HCT were 7.6/5.0 mmHg greater than with valsartan/hydrochlorothiazide, 6.2/3.3 mmHg greater than with amlodipine/valsartan, and 8.2/5.3 mmHg greater than with amlodipine/hydrochlorothiazide. The full blood pressure lowering effect was achieved 2 weeks after being on their maximal dose of Imprida HCT. Statistically greater proportions of patients achieved blood pressure control (<140/90 mmHg) with Imprida HCT (71%) compared to each of the three dual combination therapies (45-54%) (p<0.0001).

In a subgroup of 283 patients focusing on ambulatory blood pressure monitoring, clinically and statistically superior reductions in 24-hour systolic and diastolic blood pressures were observed with the triple combination compared to valsartan/hydrochlorothiazide, valsartan/amlodipine, and hydrochlorothiazide/amlodipine.
Amlodipine
The amlodipine component of Imprida HCT inhibits the transmembrane entry of calcium ions into cardiac and vascular smooth muscle. The mechanism of the antihypertensive action of amlodipine is due to a direct relaxant effect on vascular smooth muscle, causing reductions in peripheral vascular resistance and in blood pressure. Experimental data suggest that amlodipine binds to both dihydropyridine and non-dihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels.

Following administration of therapeutic doses to patients with hypertension, amlodipine produces vasodilation, resulting in a reduction of supine and standing blood pressures. These decreases in blood pressure are not accompanied by a significant change in heart rate or plasma catecholamine levels with chronic dosing.

Plasma concentrations correlate with effect in both young and elderly patients.

In hypertensive patients with normal renal function, therapeutic doses of amlodipine resulted in a decrease in renal vascular resistance and increases in glomerular filtration rate and effective renal plasma flow, without change in filtration fraction or proteinuria.

Valsartan
Valsartan is an orally active, potent and specific angiotensin II receptor antagonist. It acts selectively on the receptor subtype AT₁, which is responsible for the known actions of angiotensin II.

Administration of valsartan to patients with hypertension results in a drop in blood pressure without affecting pulse rate.

In most patients, after administration of a single oral dose, onset of antihypertensive activity occurs within 2 hours, and the peak drop in blood pressure is achieved within 4-6 hours. The antihypertensive effect persists over 24 hours after administration. During repeated administration, the maximum reduction in blood pressure with any dose is generally attained within 2-4 weeks.

Hydrochlorothiazide
The site of action of thiazide diuretics is primarily in the renal distal convoluted tubule. It has been shown that there is a high-affinity receptor in the renal cortex as the primary binding site for the thiazide diuretic action and inhibition of NaCl transport in the distal convoluted tubule. The mode of action of thiazides is through inhibition of the Na⁺Cl⁻ symporter perhaps by competing for the Cl⁻ site, thereby affecting electrolyte reabsorption mechanisms: directly increasing sodium and chloride excretion to an approximately equal extent, and indirectly, by this diuretic action, reducing plasma volume, with consequent increases in plasma renin activity, aldosterone secretion and urinary potassium loss, and a decrease in serum potassium.

The European Medicines Agency has waived the obligation to submit the results of studies with Imprida HCT in all subsets of the paediatric population in essential hypertension. See section 4.2 for information on paediatric use.

5.2 Pharmacokinetic properties

Linearity
Amlodipine, valsartan and hydrochlorothiazide exhibit linear pharmacokinetics.

Amlodipine/valsartan/hydrochlorothiazide
Following oral administration of Imprida HCT in normal healthy adults, peak plasma concentrations of amlodipine, valsartan and hydrochlorothiazide are reached in 6-8 hours, 3 hours, and 2 hours, respectively. The rate and extent of absorption of amlodipine, valsartan and hydrochlorothiazide from Imprida HCT are the same as when administered as individual dosage forms.
**Amlodipine**

**Absorption:** After oral administration of therapeutic doses of amlodipine alone, peak plasma concentrations of amlodipine are reached in 6-12 hours. Absolute bioavailability has been calculated as between 64% and 80%. Amlodipine bioavailability is unaffected by food ingestion.

**Distribution:** Volume of distribution is approximately 21 l/kg. *In vitro* studies with amlodipine have shown that approximately 97.5% of circulating drug is bound to plasma proteins.

**Biotransformation:** Amlodipine is extensively (approximately 90%) metabolised in the liver to inactive metabolites.

**Elimination:** Amlodipine elimination from plasma is biphasic, with a terminal elimination half-life of approximately 30 to 50 hours. Steady-state plasma levels are reached after continuous administration for 7-8 days. Ten per cent of original amlodipine and 60% of amlodipine metabolites are excreted in urine.

**Valsartan**

**Absorption:** Following oral administration of valsartan alone, peak plasma concentrations of valsartan are reached in 2-4 hours. Mean absolute bioavailability is 23%. Food decreases exposure (as measured by AUC) to valsartan by about 40% and peak plasma concentration (C_{max}) by about 50%, although from about 8 h post dosing plasma valsartan concentrations are similar for the fed and fasted groups. This reduction in AUC is not, however, accompanied by a clinically significant reduction in the therapeutic effect, and valsartan can therefore be given either with or without food.

**Distribution:** The steady-state volume of distribution of valsartan after intravenous administration is about 17 litres, indicating that valsartan does not distribute into tissues extensively. Valsartan is highly bound to serum proteins (94-97%), mainly serum albumin.

**Biotransformation:** Valsartan is not transformed to a high extent as only about 20% of dose is recovered as metabolites. A hydroxy metabolite has been identified in plasma at low concentrations (less than 10% of the valsartan AUC). This metabolite is pharmacologically inactive.

**Elimination:** Valsartan is primarily eliminated in faeces (about 83% of dose) and urine (about 13% of dose), mainly as unchanged drug. Following intravenous administration, plasma clearance of valsartan is about 2 l/h and its renal clearance is 0.62 l/h (about 30% of total clearance). The half-life of valsartan is 6 hours.

**Hydrochlorothiazide**

**Absorption:** The absorption of hydrochlorothiazide, after an oral dose, is rapid (T_{max} about 2 hours). The increase in mean AUC is linear and dose proportional in the therapeutic range.

The effect of food on hydrochlorothiazide absorption, if any, has little clinical significance. Absolute bioavailability of hydrochlorothiazide is 70% after oral administration.

**Distribution:** The apparent volume of distribution is 4-8 l/kg. Circulating hydrochlorothiazide is bound to serum proteins (40-70%), mainly serum albumin. Hydrochlorothiazide also accumulates in erythrocytes at approximately 3 times the level in plasma.

**Biotransformation:** Hydrochlorothiazide is eliminated predominantly as unchanged compound.

**Elimination:** Hydrochlorothiazide is eliminated from plasma with a half-life averaging 6 to 15 hours in the terminal elimination phase. There is no change in the kinetics of hydrochlorothiazide on repeated dosing, and accumulation is minimal when dosed once daily. More than 95% of the absorbed dose is being excreted as unchanged compound in the urine. The renal clearance is composed of passive filtration and active secretion into the renal tubule.
Special populations

**Paediatric patients (age below 18 years)**
No pharmacokinetic data are available in the paediatric population.

**Elderly (age 65 years or over)**
Time to peak plasma amlodipine concentrations is similar in young and elderly patients. In elderly patients, amlodipine clearance tends to decline, causing increases in the area under the curve (AUC) and elimination half-life. Mean systemic AUC of valsartan is higher by 70% in the elderly than in the young, therefore caution is required when increasing the dosage.

Systemic exposure to valsartan is slightly elevated in the elderly as compared to the young, but this has not been shown to have any clinical significance.

Limited data suggest that the systemic clearance of hydrochlorothiazide is reduced in both healthy and hypertensive elderly subjects compared to young healthy volunteers.

Since the three components are equally well tolerated in younger and elderly patients, normal dose regimens are recommended (see section 4.2).

**Renal impairment**
The pharmacokinetics of amlodipine are not significantly influenced by renal impairment. As expected for a compound where renal clearance accounts for only 30% of total plasma clearance, no correlation was seen between renal function and systemic exposure to valsartan.

Patients with mild to moderate renal impairment may therefore receive the usual initial dose (see sections 4.2 and 4.4).

In the presence of renal impairment, mean peak plasma levels and AUC values of hydrochlorothiazide are increased and the urinary excretion rate is reduced. In patients with mild to moderate renal impairment, a 3-fold increase in hydrochlorothiazide AUC has been observed. In patients with severe renal impairment an 8-fold increase in AUC has been observed. Imprida HCT is contraindicated in patients with severe renal impairment, anuria or undergoing dialysis (see section 4.3).

**Hepatic impairment**
Patients with hepatic insufficiency have decreased clearance of amlodipine with resulting increase of approximately 40–60% in AUC. On average, in patients with mild to moderate chronic liver disease, exposure (measured by AUC values) to valsartan is twice that found in healthy volunteers (matched by age, sex and weight). Due to the valsartan component, Imprida HCT is contraindicated in patients with hepatic impairment (see sections 4.2 and 4.3).

5.3 Preclinical safety data

**Amlodipine/Valsartan/Hydrochlorothiazide**
In a variety of preclinical safety studies conducted in several animal species with amlodipine, valsartan, hydrochlorothiazide, valsartan/hydrochlorothiazide, amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide (Imprida HCT), there was no evidence of systemic or target organ toxicity that would adversely affect the development of Imprida HCT for clinical use in humans.

Preclinical safety studies of up to 13 weeks in duration were conducted with amlodipine/valsartan/hydrochlorothiazide in rats. The combination resulted in expected reduction of red blood cell mass (erythrocytes, haemoglobin, haematocrit, and reticulocytes), increase in serum urea, increase in serum creatinine, increase in serum potassium, juxtaglomerular (JG) hyperplasia in the kidney and focal erosions in the glandular stomach in rats. All these changes were reversible after a 4-week recovery period and were considered to be exaggerated pharmacological effects.
The amlodipine/valsartan/hydrochlorothiazide combination was not tested for genotoxicity or carcinogenicity as there was no evidence of any interaction between these substances, which have been on the market for a long time. However, amlodipine, valsartan and hydrochlorothiazide have been tested individually for genotoxicity and carcinogenicity with negative results.

**Amlodipine**

Reproductive toxicology

Reproductive studies in rats and mice have shown delayed date of delivery, prolonged duration of labour and decreased pup survival at dosages approximately 50 times greater than the maximum recommended dosage for humans based on mg/kg.

**Impairment of fertility**

There was no effect on the fertility of rats treated with amlodipine (males for 64 days and females 14 days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human dose of 10 mg on a mg/m² basis). In another rat study in which male rats were treated with amlodipine besilate for 30 days at a dose comparable with the human dose based on mg/kg, decreased plasma follicle-stimulating hormone and testosterone were found as well as decreases in sperm density and in the number of mature spermatids and Sertoli cells.

**Carcinogenesis, mutagenesis**

Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity. The highest dose (for mice, similar to, and for rats twice* the maximum recommended clinical dose of 10 mg on a mg/m² basis) was close to the maximum tolerated dose for mice but not for rats.

Mutagenicity studies revealed no drug related effects at either the gene or chromosome levels.

* Based on patient weight of 50 kg

**Valsartan**

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential.

In rats, maternally toxic doses (600 mg/kg/day) during the last days of gestation and lactation led to lower survival, lower weight gain and delayed development (pinna detachment and ear-canal opening) in the offspring (see section 4.6). These doses in rats (600 mg/kg/day) are approximately 18 times the maximum recommended human dose on a mg/m² basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).

In non-clinical safety studies, high doses of valsartan (200 to 600 mg/kg body weight) caused in rats a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit) and evidence of changes in renal haemodynamics (slightly raised plasma urea, and renal tubular hyperplasia and basophilia in males). These doses in rats (200 and 600 mg/kg/day) are approximately 6 and 18 times the maximum recommended human dose on a mg/m² basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).

In marmosets at similar doses, the changes were similar though more severe, particularly in the kidney where the changes developed to a nephropathy which included raised urea and creatinine.

Hypertrophy of the renal juxtaglomerular cells was also seen in both species. All changes were considered to be caused by the pharmacological action of valsartan which produces prolonged hypotension, particularly in marmosets. For therapeutic doses of valsartan in humans, the hypertrophy of the renal juxtaglomerular cells does not seem to have any relevance.
6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core
Cellulose microcrystalline
Crospovidone
Silica, colloidal anhydrous
Magnesium stearate

Coating
Hypromellose
Macrogol 4000
Talc
Titanium dioxide (E171)
Iron oxide, yellow (E172)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

2 years

6.4 Special precautions for storage

Do not store above 30°C.

Store in the original package in order to protect from moisture.

6.5 Nature and contents of container

PVC/PVDC blisters. One blister contains 7, 10 or 14 film-coated tablets.
Pack sizes: 14, 28, 30, 56, 90, 98 or 280 film-coated tablets.
Multipacks of 280 tablets, comprising 20 cartons, each containing 14 tablets.

PVC/PVDC perforated unit dose blisters for hospital use:
Pack sizes: 56, 98 or 280 film-coated tablets
Multipacks of 280 tablets, comprising 4 cartons, each containing 70 tablets.

Not all pack sizes or strengths may be marketed.

6.6 Special precautions for disposal and other handling

No special requirements.

7. MARKETING AUTHORISATION HOLDER

Novartis Europharm Limited
Wimblehurst Road
Horsham
West Sussex, RH12 5AB
United Kingdom
8. MARKETING AUTHORISATION NUMBER(S)
EU/1/09/570/025-036

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
15.10.2009

10. DATE OF REVISION OF THE TEXT

Detailed information on this product is available on the website of the European Medicines Agency http://www.ema.europa.eu

Medicinal product no longer authorised
1. **NAME OF THE MEDICINAL PRODUCT**
Imprida HCT 10 mg/160 mg/25 mg film-coated tablets

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**
Each film-coated tablet contains 10 mg of amlodipine (as amlodipine besylate), 160 mg of valsartan, and 25 mg of hydrochlorothiazide.

For a full list of excipients, see section 6.1.

3. **PHARMACEUTICAL FORM**
Film-coated tablet (tablet)

Brown-yellow, ovaloid, biconvex tablets with bevelled edge, debossed “NVR” on one side and “VHL” on the other side.

4. **CLINICAL PARTICULARS**
4.1 Therapeutic indications
Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.

4.2 Posology and method of administration

**Posology**
The recommended dose of Imprida HCT is one tablet per day, to be taken preferably in the morning.

Before switching to Imprida HCT patients should be controlled on stable doses of the monocomponents taken at the same time. The dose of Imprida HCT should be based on the doses of the individual components of the combination at the time of switching.

The maximum recommended dose of Imprida HCT is 10 mg/320 mg/25 mg.

**Special populations**

**Renal impairment**
No adjustment of the initial dose is required for patients with mild to moderate renal impairment (see sections 4.4 and 5.2). Due to the hydrochlorothiazide component, Imprida HCT is contraindicated for use in patients with anuria (see section 4.3) and in patients with severe renal impairment (glomerular filtration rate (GFR) <30 ml/min/1.73 m²) (see sections 4.3, 4.4 and 5.2).

**Hepatic impairment**
Due to the valsartan component, Imprida HCT is contraindicated in patients with severe hepatic impairment (see section 4.3). In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan and therefore Imprida HCT is not suitable in this group of patients (see sections 4.3, 4.4 and 5.2).
Heart failure and coronary artery disease
There is limited experience with the use of Imprida HCT, particularly at the maximum dose, in
patients with heart failure and coronary artery disease. Caution is advised in patients with heart failure
and coronary artery disease, particularly at the maximum dose of Imprida HCT, 10 mg/320 mg/25 mg.

Elderly (age 65 years or over)
Caution, including more frequent monitoring of blood pressure, is recommended in elderly patients,
particularly at the maximum dose of Imprida HCT, 10 mg/320 mg/25 mg, since available data in this
patient population are limited.

Paediatric population
There is no relevant use of Imprida HCT in the paediatric population (patients below age 18 years) for
the indication of essential hypertension.

Method of administration
Imprida HCT can be taken with or without food. The tablets should be swallowed whole with some
water, at the same time of the day and preferably in the morning.

4.3 Contraindications
– Hypersensitivity to the active substances, to other sulphonamide derivatives, to dihydropyridine
derivatives, or to any of the excipients.
– Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
– Hepatic impairment, biliary cirrhosis or cholestasis.
– Severe renal impairment (GFR <30 ml/min/1.73 m²), anuria and patients undergoing dialysis.
– Refractory hypokalaemia, hyponatraemia, hypercalcaemia, and symptomatic hyperuricaemia.

4.4 Special warnings and precautions for use
Sodium- and/or volume-depleted patients
Excessive hypotension, including orthostatic hypotension, was seen in 1.7% of patients treated with
the maximum dose of Imprida HCT (10 mg/320 mg/25 mg) compared to 1.8% of
valsartan/hydrochlorothiazide (320 mg/25 mg) patients, 0.4% of amlodipine/valsartan (10 mg/320 mg)
patients, and 0.2% of hydrochlorothiazide/amlodipine (25 mg/10 mg) patients in a controlled trial in
patients with moderate to severe uncomplicated hypertension.

In sodium-depleted and/or volume-depleted patients, such as those receiving high doses of diuretics,
symptomatic hypotension may occur after initiation of treatment with Imprida HCT. Imprida HCT
should be used only after correction of any pre-existing sodium and/or volume depletion.

If excessive hypotension occurs with Imprida HCT, the patient should be placed in the supine position
and, if necessary, given an intravenous infusion of normal saline. Treatment can be continued once
blood pressure has been stabilised.

Serum electrolyte changes
Amlodipine/valsartan/hydrochlorothiazide
In the controlled trial of Imprida HCT, the counteracting effects of valsartan 320 mg and
hydrochlorothiazide 25 mg on serum potassium approximately balanced each other in many patients.
In other patients, one or the other effect may be dominant. Periodic determinations of serum
electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals.

Periodic determination of serum electrolytes and potassium in particular should be performed at
appropriate intervals to detect possible electrolyte imbalance, especially in patients with other risk
factors such as impaired renal function, treatment with other medicinal products or history of prior
electrolyte imbalances.
**Valsartan**
Concomitant use with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other medicinal products that may increase potassium levels (heparin, etc.) is not recommended. Monitoring of potassium should be undertaken as appropriate.

**Hydrochlorothiazide**
Treatment with Imprida HCT should only start after correction of hypokalaemia and any coexisting hypomagnesaemia. Thiazide diuretics can precipitate new onset hypokalaemia or exacerbate pre-existing hypokalaemia. Thiazide diuretics should be administered with caution in patients with conditions involving enhanced potassium loss, for example salt-losing nephropathies and prerenal (cardiogenic) impairment of kidney function. If hypokalaemia develops during hydrochlorothiazide therapy, Imprida HCT should be discontinued until stable correction of the potassium balance.

Thiazide diuretics can precipitate new onset hyponatraemia and hypochloroaemic alkalosis or exacerbate pre-existing hyponatraemia. Hyponatraemia, accompanied by neurological symptoms (nausea, progressive disorientation, apathy) has been observed. Treatment with hydrochlorothiazide should only be started after correction of pre-existing hyponatraemia. In case severe or rapid hyponatraemia develops during Imprida HCT therapy, the treatment should be discontinued until normalisation of natraemia.

All patients receiving thiazide diuretics should be periodically monitored for imbalances in electrolytes, particularly potassium, sodium and magnesium.

**Renal impairment**
Thiazide diuretics may precipitate azotaemia in patients with chronic kidney disease. When Imprida HCT is used in patients with renal impairment periodic monitoring of serum electrolytes (including potassium), creatinine and uric acid serum levels is recommended. Imprida HCT is contraindicated in patients with severe renal impairment, anuria or undergoing dialysis (see section 4.3).

No dosage adjustment of Imprida HCT is required for patients with mild to moderate renal impairment (GFR ≥30 ml/min/1.73 m²).

**Renal artery stenosis**
No data are available on the use of Imprida HCT in patients with unilateral or bilateral renal artery stenosis or stenosis to a solitary kidney.

**Kidney transplantation**
To date there is no experience of the safe use of Imprida HCT in patients who have had a recent kidney transplantation.

**Hepatic impairment**
Valsartan is mostly eliminated unchanged via the bile, whereas amlodipine is extensively metabolised by the liver. In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan, and therefore, Imprida HCT is not suitable in this group of patients (see sections 4.2, 4.3 and 5.2).

**Heart failure and coronary artery disease**
As a consequence of the inhibition of the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients with severe heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotaemia and (rarely) with acute renal failure and/or death. Similar outcomes have been reported with valsartan.
In a long-term, placebo-controlled study (PRAISE-2) of amlodipine in patients with NYHA (New York Heart Association Classification) III and IV heart failure of non-ischaemic aetiology, amlodipine was associated with increased reports of pulmonary oedema despite no significant difference in the incidence of worsening heart failure as compared to placebo.

Caution is advised in patients with heart failure and coronary artery disease, particularly at the maximum dose of Imprida HCT, 10 mg/320 mg/25 mg, since available data in these patient populations is limited.

Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy
As with all other vasodilators, special caution is indicated in patients with aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.

Pregnancy
Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).

Primary hyperaldosteronism
Patients with primary hyperaldosteronism should not be treated with the angiotensin II antagonist valsartan as their renin-angiotensin system is not activated. Therefore, Imprida HCT is not recommended in this population.

Systemic lupus erythematosus
Thiazide diuretics, including hydrochlorothiazide, have been reported to exacerbate or activate systemic lupus erythematosus.

Other metabolic disturbances
Thiazide diuretics, including hydrochlorothiazide, may alter glucose tolerance and raise serum levels of cholesterol, triglycerides and uric acid. In diabetic patients dosage adjustments of insulin or oral hypoglycaemic agents may be required.

Due to the hydrochlorothiazide component, Imprida HCT is contraindicated in symptomatic hyperuricaemia. Hydrochlorothiazide may raise the serum uric acid level due to reduced clearance of uric acid and may cause or exacerbate hyperuricaemia as well as precipitate gout in susceptible patients.

Thiazides reduce urinary calcium excretion and may cause intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Imprida HCT is contraindicated in patients with hypercalcaemia and should only be used after correction of any pre-existing hypercalcaemia. Imprida HCT should be discontinued if hypercalcaemia develops during treatment. Serum levels of calcium should be periodically monitored during treatment with thiazides. Marked hypercalcaemia may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function.

Photosensitivity
Cases of photosensitivity reactions have been reported with thiazide diuretics (see section 4.8). If photosensitivity reaction occurs during treatment with Imprida HCT, it is recommended to stop the treatment. If a readministration of the diuretic is deemed necessary, it is recommended to protect exposed areas to the sun or to artificial UVA.
Acute angle-closure glaucoma
Hydrochlorothiazide, a sulphonamide, has been associated with an idiosyncratic reaction resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to a week of treatment initiation. Untreated acute-angle closure glaucoma can lead to permanent vision loss.

The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatment may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle closure glaucoma may include a history of sulphonamide or penicillin allergy.

General
Caution should be exercised in patients who have shown prior hypersensitivity to other angiotensin II receptor antagonists. Hypersensitivity reactions to hydrochlorothiazide are more likely in patients with allergy and asthma.

Elderly (age 65 years or over)
Caution, including more frequent monitoring of blood pressure, is recommended in elderly patients, particularly at the maximum dose of Imprida HCT, 10 mg/320 mg/25 mg, since available data in this patient population are limited.

4.5 Interaction with other medicinal products and other forms of interaction

No formal interaction studies with other medicinal products were performed with Imprida HCT. Thus, only information on interactions with other medicinal products that are known for the individual active substances is provided in this section.

However, it is important to take into account that Imprida HCT may increase the hypotensive effect of other antihypertensive agents.
### Concomitant use not recommended

<table>
<thead>
<tr>
<th>Imprida HCT individual component</th>
<th>Known interactions with the following agents</th>
<th>Effect of the interaction with other medicinal products</th>
</tr>
</thead>
<tbody>
<tr>
<td>Valsartan and HCT</td>
<td>Lithium</td>
<td>Reversible increases in serum lithium concentrations and toxicity have been reported during concurrent use of ACE inhibitors and thiazides such as hydrochlorothiazide. Despite the lack of experience with concomitant use of valsartan and lithium, this combination is not recommended. If the combination proves necessary, careful monitoring of serum lithium levels is recommended (see section 4.4).</td>
</tr>
<tr>
<td></td>
<td>Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may increase potassium levels</td>
<td>If a medicinal product that affects potassium levels is considered necessary in combination with valsartan, frequent monitoring of potassium plasma levels is advised.</td>
</tr>
<tr>
<td>Amlodipine</td>
<td>Grapefruit or grapefruit juice</td>
<td>Administration of amlodipine with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients, resulting in increased blood pressure lowering effects.</td>
</tr>
</tbody>
</table>

### Caution required with concomitant use

<table>
<thead>
<tr>
<th>Imprida HCT individual component</th>
<th>Known interactions with the following agents</th>
<th>Effect of the interaction with other medicinal products</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amlodipine</td>
<td>CYP3A4 inhibitors (i.e. ketoconazole, itraconazole, ritonavir)</td>
<td>Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors, azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem) may give rise to significant increase in amlodipine exposure. The clinical translation of these pharmacokinetic variations may be more pronounced in the elderly. Clinical monitoring and dose adjustment may thus be required.</td>
</tr>
<tr>
<td></td>
<td>CYP3A4 inducers (anticonvulsant agents [e.g. carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone], rifampicin, Hypericum perforatum [St. John’s wort])</td>
<td>There is no data available regarding the effect of CYP3A4 inducers on amlodipine. The concomitant use of CYP3A4 inducers (e.g. rifampicin, Hypericum perforatum) may give a lower plasma concentration of amlodipine. Amlodipine should be used with caution together with CYP3A4 inducers.</td>
</tr>
<tr>
<td>Drug</td>
<td>Interaction</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>---------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Simvastatin</strong></td>
<td>Co-administration of multiple doses of 10 mg amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. It is recommended to limit the dose of simvastatin to 20 mg daily in patients on amlodipine.</td>
<td></td>
</tr>
<tr>
<td><strong>Dantrolene (infusion)</strong></td>
<td>In animals, lethal ventricular fibrillation and cardiovascular collapse are observed in association with hyperkalaemia after administration of verapamil and intravenous dantrolene. Due to risk of hyperkalaemia, it is recommended that the co-administration of calcium channel blockers such as amlodipine be avoided in patients susceptible to malignant hyperthermia and in the management of malignant hyperthermia.</td>
<td></td>
</tr>
<tr>
<td><strong>Valsartan and HCT</strong></td>
<td>Non-steroidal anti-inflammatory medicines (NSAIDs), including selective cyclooxygenase-2 inhibitors (COX-2 inhibitors), acetylsalicylic acid (&gt;3 g/day), and non-selective NSAIDs NSAIDS can attenuate the antihypertensive effect of both angiotensin II antagonists and hydrochlorothiazide when administered simultaneously. Furthermore, concomitant use of Imprida HCT and NSAIDs may lead to worsening of renal function and an increase in serum potassium. Therefore, monitoring of renal function at the beginning of the treatment is recommended, as well as adequate hydration of the patient.</td>
<td></td>
</tr>
<tr>
<td><strong>Valsartan</strong></td>
<td>Inhibitors of the uptake transporter (rifampicin, ciclosporin) or efflux transporter (ritonavir) The results of an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1 and of the hepatic efflux transporter MRP2. Co-administration of inhibitors of the uptake transporter (rifampicin, ciclosporin) or efflux transporter (ritonavir) may increase the systemic exposure to valsartan.</td>
<td></td>
</tr>
<tr>
<td><strong>HCT</strong></td>
<td>Alcohol, barbiturates or narcotics Concomitant administration of thiazide diuretics with substances that also have a blood pressure lowering effect (e.g. by reducing sympathetic central nervous system activity or direct vasodilatation) may potentiate orthostatic hypotension.</td>
<td></td>
</tr>
<tr>
<td><strong>Amantadine</strong></td>
<td>Thiazides, including hydrochlorothiazide, may increase the risk of adverse reactions caused by amantadine.</td>
<td></td>
</tr>
<tr>
<td><strong>Anticholinergic agents and other medicinal products affecting gastric motility</strong></td>
<td>The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents (e.g. atropine, biperiden), apparently due to a decrease in gastrointestinal motility and the stomach emptying rate. Conversely, it is anticipated that prokinetic substances such as cisapride may decrease the bioavailability of thiazide-type diuretics.</td>
<td></td>
</tr>
<tr>
<td><strong>Antidiabetic agents (e.g. insulin and oral antidiabetic agents)</strong></td>
<td>Thiazides may alter glucose tolerance. Dose adjustment of the antidiabetic medicinal product may be necessary.</td>
<td></td>
</tr>
<tr>
<td>– <strong>Metformin</strong></td>
<td>Metformin should be used with caution because of the risk of lactic acidosis induced by possible functional renal failure linked to hydrochlorothiazide.</td>
<td></td>
</tr>
<tr>
<td><strong>Beta blockers and diazoxide</strong></td>
<td>Concomitant use of thiazide diuretics, including hydrochlorothiazide, with beta blockers may increase the risk of hyperglycaemia. Thiazide diuretics, including hydrochlorothiazide, may enhance the hyperglycaemic effect of diazoxide.</td>
<td></td>
</tr>
<tr>
<td><strong>Ciclosporin</strong></td>
<td>Concomitant treatment with ciclosporin may increase the risk of hyperuricaemia and gout-type complications.</td>
<td></td>
</tr>
<tr>
<td><strong>Cytotoxic agents</strong></td>
<td>Thiazides, including hydrochlorothiazide, may reduce the renal excretion of cytotoxic agents (e.g. cyclophosphamide, methotrexate) and potentiate their myelosuppressive effects.</td>
<td></td>
</tr>
<tr>
<td><strong>Digitalis glycosides</strong></td>
<td>Thiazide-induced hypokalaemia or hypomagnesaemia may occur as undesirable effects, favouring the onset of digitalis-induced cardiac arrhythmias.</td>
<td></td>
</tr>
<tr>
<td><strong>Iodine contrast agents</strong></td>
<td>In case of diuretic-induced dehydration, there is an increased risk of acute renal failure, especially with high doses of iodine products. Patients should be re-hydrated before the administration.</td>
<td></td>
</tr>
<tr>
<td><strong>Ion exchange resins</strong></td>
<td>Absorption of thiazide diuretics, including hydrochlorothiazide, is decreased by cholestyramine or colestipol. This could result in sub-therapeutic effects of thiazide diuretics. However, staggering the dosage of hydrochlorothiazide and resin such that hydrochlorothiazide is administered at least 4 hours before or 4-6 hours after the administration of resins would potentially minimise the interaction.</td>
<td></td>
</tr>
<tr>
<td><strong>Medicinal products affecting serum potassium level</strong></td>
<td>The hypokalaemic effect of hydrochlorothiazide may be increased by concomitant administration of kaliuretic diuretics, corticosteroids, laxatives, adrenocorticotropic hormone (ACTH), amphotericin, carbenoxolone, penicillin G and salicylic acid derivatives or antiarrhythmics. If these medicinal products are to be prescribed with the amlodipine /valsartan /hydrochlorothiazide combination, monitoring of potassium plasma levels is advised.</td>
<td></td>
</tr>
<tr>
<td><strong>Medicinal products affecting serum sodium level</strong></td>
<td>The hyponatraemic effect of diuretics may be intensified by concomitant administration of medicinal products such as antidepressants, antipsychotics, antiepileptics, etc. Caution is indicated in long-term administration of these medicinal products.</td>
<td></td>
</tr>
<tr>
<td><strong>Medicinal products that could induce torsades de pointes</strong></td>
<td>Due to the risk of hypokalaemia, hydrochlorothiazide should be administered with caution when associated with medicinal products that could induce torsades de pointes, in particular Class Ia and Class III antiarrhythmics and some antipsychotics.</td>
<td></td>
</tr>
<tr>
<td><strong>Medicinal products used in the treatment of gout (probenecid, sulfinpyrazone and allopurinol)</strong></td>
<td>Dose adjustment of uricosuric medicinal products may be necessary as hydrochlorothiazide may raise the level of serum uric acid. Increase of dose of probenecid or sulfinpyrazone may be necessary. Co-administration of thiazide diuretics, including hydrochlorothiazide, may increase the incidence of hypersensitivity reactions to allopurinol.</td>
<td></td>
</tr>
<tr>
<td><strong>Methyldopa</strong></td>
<td>There have been isolated reports of haemolytic anaemia occurring with concomitant use of hydrochlorothiazide and methyldopa.</td>
<td></td>
</tr>
<tr>
<td><strong>Non-depolarising skeletal muscle relaxants (e.g. tubocurarine)</strong></td>
<td>Thiazides, including hydrochlorothiazide, potentiate the action of curare derivatives.</td>
<td></td>
</tr>
</tbody>
</table>
**Other anti-hypertensive drugs**

Thiazides potentiate the antihypertensive action of other antihypertensive drugs (e.g. guanethidine, methyldopa, beta-blockers, vasodilators, calcium channel blockers, ACE inhibitors, ARBs and Direct Renin Inhibitors [DRIs]).

**Pressor amines (e.g. noradrenaline, adrenaline)**

Hydrochlorothiazide may reduce the response to pressor amines such as noradrenaline. The clinical significance of this effect is uncertain and not sufficient to preclude their use.

**Vitamin D and calcium salts**

Administration of thiazide diuretics, including hydrochlorothiazide, with vitamin D or with calcium salts may potentiate the rise in serum calcium. Concomitant use of thiazide type diuretics may lead to hypercalcaemia in patients pre-disposed for hypercalcaemia (e.g. hyperparathyroidism, malignancy or vitamin-D-mediated conditions) by increasing tubular calcium reabsorption.

**No interaction**

<table>
<thead>
<tr>
<th>Imprida HCT individual component</th>
<th>Known interactions with the following agents</th>
<th>Effect of the interaction with other medicinal products</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Valsartan</strong></td>
<td><em>Others</em> (cimetidine, warfarin, furosemide, digoxin, atenolol, indometacin, hydrochlorothiazide, amlodipine, glibenclamide)</td>
<td>In monotherapy with valsartan, no interactions of clinical significance have been found with the following substances: cimetidine, warfarin, furosemide, digoxin, atenolol, indometacin, hydrochlorothiazide, amlodipine, glibenclamide. Some of these substances could interact with the hydrochlorothiazide component of Imprida HCT (see interactions related to HCT).</td>
</tr>
<tr>
<td><strong>Amlodipine</strong></td>
<td><em>Others</em></td>
<td>In clinical interaction studies, amlodipine did not affect the pharmacokinetics of atorvastatin, digoxin, warfarin or ciclosporin.</td>
</tr>
</tbody>
</table>

4.6 **Fertility, pregnancy and lactation**

**Pregnancy Amlodipine**

The safety of amlodipine in human pregnancy has not been established. In animal studies, reproductive toxicity was observed at high doses (see section 5.3). Use in pregnancy is only recommended when there is no safer alternative and when the disease itself carries greater risk for the mother and foetus.
Valsartan

The use of Angiotensin II Receptor Antagonists (AIIRAs) is not recommended during the first trimester of pregnancy (see section 4.4). The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 and 4.4).

Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and if appropriate, alternative therapy should be started.

Exposure to AIIRAs therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3).

Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.

Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3 and 4.4).

Hydrochlorothiazide

There is limited experience with hydrochlorothiazide during pregnancy, especially during the first trimester. Animal studies are insufficient.

Hydrochlorothiazide crosses the placenta. Based on the pharmacological mechanism of action of hydrochlorothiazide, its use during the second and third trimester may compromise foeto-placental perfusion and may cause foetal and neonatal effects like icterus, disturbance of electrolyte balance and thrombocytopenia.

Amlodipine/valsartan/hydrochlorothiazide

There is no experience on the use of Imprida HCT in pregnant women. Based on the existing data with the components, the use of Imprida HCT is not recommended during first trimester and contraindicated during the second and third trimester of pregnancy (see sections 4.3 and 4.4).

Breast-feeding

No information is available regarding the use of valsartan and/or amlodipine during breast-feeding. Hydrochlorothiazide is excreted in human milk in small amounts. Thiazides in high doses causing intense diuresis can inhibit milk production. The use of Imprida HCT during breast-feeding is not recommended. If Imprida HCT is used during breast-feeding, doses should be kept as low as possible. Alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.

Fertility

There are no clinical studies on fertility with Imprida HCT.

Valsartan

Valsartan had no adverse effects on the reproductive performance of male or female rats at oral doses up to 200 mg/kg/day. This dose is 6 times the maximum recommended human dose on a mg/m² basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).
**Amlodipine**

Reversible biochemical changes in the head of spermatozoa have been reported in some patients treated by calcium channel blockers. Clinical data are insufficient regarding the potential effect of amlodipine on fertility. In one rat study, adverse effects were found on male fertility (see section 5.3).

### 4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. When driving vehicles or using machines it should be taken into account that occasionally dizziness or weariness may occur.

### 4.8 Undesirable effects

The safety profile of Imprida HCT presented below is based on clinical studies performed with Imprida HCT and the known safety profile of the individual components amlodipine, valsartan and hydrochlorothiazide.

**Information on Imprida HCT**

The safety of Imprida HCT has been evaluated at its maximum dose of 10 mg/320 mg/25 mg in one controlled short-term (8 weeks) clinical study with 2,271 patients, 582 of whom received valsartan in combination with amlodipine and hydrochlorothiazide. Adverse reactions were generally mild and transient in nature and only infrequently required discontinuation of therapy. In this active controlled clinical trial, the most common reasons for discontinuation of therapy with Imprida HCT were dizziness and hypotension (0.7%).

In the 8-week controlled clinical study, no significant new or unexpected adverse reactions were observed with triple therapy treatment compared to the known effects of the monotherapy or dual therapy components.

In the 8-week controlled clinical study, changes in laboratory parameters observed with the combination of Imprida HCT were minor and consistent with the pharmacological mechanism of action of the monotherapy agents. The presence of valsartan in the triple combination attenuated the hypokalaemic effect of hydrochlorothiazide.

The following adverse reactions, listed by MedDRA System Organ Class and frequency, concern Imprida HCT (amlodipine/valsartan/HCT) and amlodipine, valsartan and HCT individually. Very common: ≥1/10; common: ≥1/100 to <1/10; uncommon: ≥1/1,000 to <1/100; rare: ≥1/10,000 to <1/1,000; very rare: <1/10,000; not known (cannot be estimated from the available data).

<table>
<thead>
<tr>
<th>MedDRA System Organ Class</th>
<th>Adverse reactions</th>
<th>Frequency</th>
<th>Imprida HCT</th>
<th>Amlodipine</th>
<th>Valsartan</th>
<th>HCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>Agranulocytosis, bone marrow depression</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Very rare</td>
</tr>
<tr>
<td></td>
<td>Decrease in haemoglobin and in haematocrit</td>
<td>--</td>
<td>--</td>
<td>Not known</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Haemolytic anaemia</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Very rare</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Leukopenia</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>Very rare</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Neutropenia</td>
<td>--</td>
<td>--</td>
<td>Not known</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thrombocytopenia, sometimes with purpura</td>
<td>--</td>
<td>Very rare</td>
<td>Not known</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aplastic anaemia</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Not known</td>
<td></td>
</tr>
</tbody>
</table>

MedDRA: not generated
<table>
<thead>
<tr>
<th>Immune system disorders</th>
<th>Hypersensitivity</th>
<th>--</th>
<th>Very rare</th>
<th>Not known</th>
<th>Very rare</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metabolism and nutrition disorders</td>
<td>Anorexia</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Hypercalcaemia</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td>Hyperglycaemia</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td>Hyperlipidaemia</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Hyperuricaemia</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>Common</td>
</tr>
<tr>
<td></td>
<td>Hypochloremic alkalosis</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Very rare</td>
</tr>
<tr>
<td></td>
<td>Hypokalaemia</td>
<td>Common</td>
<td>--</td>
<td>--</td>
<td>Very common</td>
</tr>
<tr>
<td></td>
<td>Hypomagnesaemia</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Common</td>
</tr>
<tr>
<td></td>
<td>Hyponatraemia</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>Common</td>
</tr>
<tr>
<td></td>
<td>Worsening of diabetic metabolic state</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Rare</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td>Depression</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td>Insomnia/sleep disturbances</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td>Mood swings</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Coordination abnormal</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Dizziness</td>
<td>Common</td>
<td>Common</td>
<td>--</td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td>Dizziness postural, dizziness exertional</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Dysgeusia</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Extrapyramidal syndrome</td>
<td>--</td>
<td>Not known</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Headache</td>
<td>Common</td>
<td>Common</td>
<td>--</td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td>Hypertonia</td>
<td>Very rare</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lethargy</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Paraesthesia</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td>Peripheral neuropathy, neuropathy</td>
<td>Uncommon</td>
<td>Very rare</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Somnolence</td>
<td>Uncommon</td>
<td>Common</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Syncope</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Tremor</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Eye disorders</td>
<td>Acute angle-closure glaucoma</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Not known</td>
</tr>
<tr>
<td></td>
<td>Visual impairment</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>Rare</td>
</tr>
<tr>
<td>Ear and labyrinth disorders</td>
<td>Tinnitus</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Vertigo</td>
<td>Uncommon</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td>Palpitations</td>
<td>--</td>
<td>Common</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Tachycardia</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Arrhythmias (including bradycardia, ventricular tachycardia, and atrial fibrillation)</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td>Myocardial infarction</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>Flushing</td>
<td>--</td>
<td>Common</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Hypotension</td>
<td>Common</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Orthostatic hypotension</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>Common</td>
</tr>
<tr>
<td></td>
<td>Phlebitis, thrombophlebitis</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Vasculitis</td>
<td>--</td>
<td>Very rare</td>
<td>Not known</td>
<td>--</td>
</tr>
<tr>
<td>Symptoms and Conditions</td>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>Gastrointestinal disorders</td>
<td>Hepatobiliary disorders</td>
<td>Skin and subcutaneous tissue disorders</td>
<td>Musculoskeletal and connective tissue disorders</td>
</tr>
<tr>
<td>------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
<td>---------------------------</td>
<td>------------------------</td>
<td>----------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Cough</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>Common</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyspnoea</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>Very rare</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory distress, pulmonary oedema, pneumonitis</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Very rare</td>
<td></td>
</tr>
<tr>
<td>Rhinitis</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Throat irritation</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Abdominal discomfort, abdominal pain upper</td>
<td>Uncommon</td>
<td>Common</td>
<td>Uncommon</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td>Breath odour</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Change of bowel habit</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Constipation</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>--</td>
<td>--</td>
<td>Common</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td>Dry mouth</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>Common</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Gastritis</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Gingival hyperplasia</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>Uncommon</td>
<td>Common</td>
<td>--</td>
<td>Common</td>
<td></td>
</tr>
<tr>
<td>Pancreatitis</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>Very rare</td>
<td></td>
</tr>
<tr>
<td>Vomiting</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>Common</td>
<td></td>
</tr>
<tr>
<td>Hepatic enzyme elevation, including increase of serum bilirubin</td>
<td>--</td>
<td>Very rare</td>
<td>Not known</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Hepatitis</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Intrahepatic cholestasis, jaundice</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td>Alopecia</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Angioedema</td>
<td>--</td>
<td>Very rare</td>
<td>Not known</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Cutaneous lupus erythematosus-like reactions, reactivation of cutaneous lupus erythematosus</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Very rare</td>
<td></td>
</tr>
<tr>
<td>Erythema multiforme</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>Not known</td>
<td></td>
</tr>
<tr>
<td>Exanthema</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Hyperhidrosis</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Photosensitivity reaction*</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td>Puritus</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>Not known</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Purpura</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td>Rash</td>
<td>--</td>
<td>Uncommon</td>
<td>Not known</td>
<td>Common</td>
<td></td>
</tr>
<tr>
<td>Skin discoloration</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Urticaria and other forms of rash</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>Common</td>
<td></td>
</tr>
<tr>
<td>Vasculitis necrotising and toxic epidermal necrolysis</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Very rare</td>
<td></td>
</tr>
<tr>
<td>Arthralgia</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Back pain</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Joint swelling</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Muscle spasm</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>Not known</td>
<td></td>
</tr>
<tr>
<td>Muscular weakness</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Myalgia</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>Not known</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Pain in extremity</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Renal and urinary disorders</td>
<td>Elevation of serum creatinine</td>
<td>Uncommon</td>
<td>--</td>
<td>Not known</td>
<td>--</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-----------------------------</td>
<td>----------</td>
<td>----</td>
<td>-----------</td>
<td>----</td>
</tr>
<tr>
<td>Micturition disorder</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Nocturia</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Pollakiuria</td>
<td>Common</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Renal dysfunction</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Renal failure acute</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Renal failure and impairment</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Not known</td>
<td>Rare</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reproductive system and breast disorders</th>
<th>Impotence</th>
<th>Uncommon</th>
<th>Uncommon</th>
<th>--</th>
<th>Common</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Gynaecomastia</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>General disorders and administration site conditions</th>
<th>Abasia, gait disturbance</th>
<th>Uncommon</th>
<th>--</th>
<th>--</th>
<th>--</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Asthenia</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>Not known</td>
</tr>
<tr>
<td></td>
<td>Discomfort, malaise</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Fatigue</td>
<td>Common</td>
<td>Common</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Non cardiac chest pain</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Oedema</td>
<td>Common</td>
<td>Common</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Pain</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Pyrexia</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Not known</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Investigations</th>
<th>Lipids increased</th>
<th>Very common</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Blood urea nitrogen increased</td>
<td>Uncommon</td>
</tr>
<tr>
<td></td>
<td>Blood uric acid increased</td>
<td>Uncommon</td>
</tr>
<tr>
<td></td>
<td>Glycosuria</td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td>Serum potassium decreased</td>
<td>Uncommon</td>
</tr>
<tr>
<td></td>
<td>Serum potassium increased</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Weight increase</td>
<td>Uncommon</td>
</tr>
<tr>
<td></td>
<td>Weight decrease</td>
<td>Uncommon</td>
</tr>
</tbody>
</table>

* See section 4.4 Photosensitivity

### 4.9 Overdose

**Symptoms**

There is no experience of overdose with Imprida HCT. The major symptom of overdose with valsartan is possibly pronounced hypotension with dizziness. Overdose with amlodipine may result in excessive peripheral vasodilation and, possibly, reflex tachycardia. Marked and potentially prolonged systemic hypotension, including shock with fatal outcome, have been reported with amlodipine.

**Treatment**

**Amlodipine/Valsartan/Hydrochlorothiazide**

Clinically significant hypotension due to Imprida HCT overdose calls for active cardiovascular support, including frequent monitoring of cardiac and respiratory function, elevation of extremities, and attention to circulating fluid volume and urine output. A vasoconstrictor may be helpful in restoring vascular tone and blood pressure, provided that there is no contraindication to its use. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade.

**Amlodipine**

If ingestion is recent, induction of vomiting or gastric lavage may be considered. Administration of activated charcoal to healthy volunteers immediately or up to two hours after ingestion of amlodipine has been shown to significantly decrease amlodipine absorption. Amlodipine is unlikely to be removed by haemodialysis.
**Valsartan**

Valsartan is unlikely to be removed by haemodialysis.

**Hydrochlorothiazide**

Overdose with hydrochlorothiazide is associated with electrolyte depletion (hypokalaemia, hypochloraemia) and hypovolaemia resulting from excessive diuresis. The most common signs and symptoms of overdose are nausea and somnolence. Hypokalaemia may result in muscle spasms and accentuate arrhythmia associated with the concomitant use of digitalis glycosides or certain anti-arrhythmic medicinal products. The degree to which hydrochlorothiazide is removed by haemodialysis has not been established.

5. **PHARMACOLOGICAL PROPERTIES**

5.1 **Pharmacodynamic properties**

Pharmacotherapeutic group: Angiotensin II antagonists, plain (valsartan), combinations with dihydropyridine derivatives (amlodipine) and thiazide diuretics (hydrochlorothiazide), ATC code: C09DX01 valsartan, amlodipine and hydrochlorothiazide.

Imprida HCT combines three antihypertensive compounds with complementary mechanisms to control blood pressure in patients with essential hypertension: amlodipine belongs to the calcium antagonist class and valsartan to the angiotensin II antagonist class of medicines and hydrochlorothiazide belongs to the thiazide diuretics class of medicines. The combination of these substances has an additive antihypertensive effect.

**Amlodipine/Valsartan/Hydrochlorothiazide**

Imprida HCT was studied in a double-blind, active controlled study in hypertensive patients. A total of 2,271 patients with moderate to severe hypertension (mean baseline systolic/diastolic blood pressure was 170/107 mmHg) received treatments of amlodipine/valsartan/hydrochlorothiazide 10 mg/320 mg/25 mg, valsartan/hydrochlorothiazide 320 mg/25 mg, amlodipine/valsartan 10 mg/320 mg, or hydrochlorothiazide/amlodipine 25 mg/10 mg. At study initiation patients were assigned lower doses of their treatment combination and were titrated to their full treatment dose by week 2.

At week 8, the mean reductions in systolic/diastolic blood pressure were 39.7/24.7 mmHg with Imprida HCT, 32.0/19.7 mmHg with valsartan/hydrochlorothiazide, 33.5/21.5 mmHg with amlodipine/valsartan, and 31.5/19.5 mmHg with amlodipine/hydrochlorothiazide. The triple combination therapy was statistically superior to each of the three dual combination treatments in reduction of diastolic and systolic blood pressures. The reductions in systolic/diastolic blood pressure with Imprida HCT were 7.6/5.0 mmHg greater than with valsartan/hydrochlorothiazide, 6.2/3.3 mmHg greater than with amlodipine/valsartan, and 8.2/5.3 mmHg greater than with amlodipine/hydrochlorothiazide. The full blood pressure lowering effect was achieved 2 weeks after being on their maximal dose of Imprida HCT. Statistically greater proportions of patients achieved blood pressure control (<140/90 mmHg) with Imprida HCT (71%) compared to each of the three dual combination therapies (45-54%) (p<0.0001).

In a subgroup of 283 patients focusing on ambulatory blood pressure monitoring, clinically and statistically superior reductions in 24-hour systolic and diastolic blood pressures were observed with the triple combination compared to valsartan/hydrochlorothiazide, valsartan/amlodipine, and hydrochlorothiazide/amlodipine.
**Amlodipine**
The amlodipine component of Imprida HCT inhibits the transmembrane entry of calcium ions into cardiac and vascular smooth muscle. The mechanism of the antihypertensive action of amlodipine is due to a direct relaxant effect on vascular smooth muscle, causing reductions in peripheral vascular resistance and in blood pressure. Experimental data suggest that amlodipine binds to both dihydropyridine and non-dihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels.

Following administration of therapeutic doses to patients with hypertension, amlodipine produces vasodilation, resulting in a reduction of supine and standing blood pressures. These decreases in blood pressure are not accompanied by a significant change in heart rate or plasma catecholamine levels with chronic dosing.

Plasma concentrations correlate with effect in both young and elderly patients.

In hypertensive patients with normal renal function, therapeutic doses of amlodipine resulted in a decrease in renal vascular resistance and increases in glomerular filtration rate and effective renal plasma flow, without change in filtration fraction or proteinuria.

**Valsartan**
Valsartan is an orally active, potent and specific angiotensin II receptor antagonist. It acts selectively on the receptor subtype AT$_1$, which is responsible for the known actions of angiotensin II.

Administration of valsartan to patients with hypertension results in a drop in blood pressure without affecting pulse rate.

In most patients, after administration of a single oral dose, onset of antihypertensive activity occurs within 2 hours, and the peak drop in blood pressure is achieved within 4-6 hours. The antihypertensive effect persists over 24 hours after administration. During repeated administration, the maximum reduction in blood pressure with any dose is generally attained within 2-4 weeks.

**Hydrochlorothiazide**
The site of action of thiazide diuretics is primarily in the renal distal convoluted tubule. It has been shown that there is a high-affinity receptor in the renal cortex as the primary binding site for the thiazide diuretic action and inhibition of NaCl transport in the distal convoluted tubule. The mode of action of thiazides is through inhibition of the Na$^+$Cl$^-$ symporter perhaps by competing for the Cl$^-$ site, thereby affecting electrolyte reabsorption mechanisms: directly increasing sodium and chloride excretion to an approximately equal extent, and indirectly, by this diuretic action, reducing plasma volume, with consequent increases in plasma renin activity, aldosterone secretion and urinary potassium loss, and a decrease in serum potassium.

The European Medicines Agency has waived the obligation to submit the results of studies with Imprida HCT in all subsets of the paediatric population in essential hypertension. See section 4.2 for information on paediatric use.

5.2 Pharmacokinetic properties

**Linearity**
Amlodipine, valsartan and hydrochlorothiazide exhibit linear pharmacokinetics.

**Amlodipine/valsartan/hydrochlorothiazide**
Following oral administration of Imprida HCT in normal healthy adults, peak plasma concentrations of amlodipine, valsartan and hydrochlorothiazide are reached in 6-8 hours, 3 hours, and 2 hours, respectively. The rate and extent of absorption of amlodipine, valsartan and hydrochlorothiazide from Imprida HCT are the same as when administered as individual dosage forms.
**Amlodipine**

**Absorption:** After oral administration of therapeutic doses of amlodipine alone, peak plasma concentrations of amlodipine are reached in 6-12 hours. Absolute bioavailability has been calculated as between 64% and 80%. Amlodipine bioavailability is unaffected by food ingestion.

**Distribution:** Volume of distribution is approximately 21 l/kg. *In vitro* studies with amlodipine have shown that approximately 97.5% of circulating drug is bound to plasma proteins.

**Biotransformation:** Amlodipine is extensively (approximately 90%) metabolised in the liver to inactive metabolites.

**Elimination:** Amlodipine elimination from plasma is biphasic, with a terminal elimination half-life of approximately 30 to 50 hours. Steady-state plasma levels are reached after continuous administration for 7-8 days. Ten per cent of original amlodipine and 60% of amlodipine metabolites are excreted in urine.

**Valsartan**

**Absorption:** Following oral administration of valsartan alone, peak plasma concentrations of valsartan are reached in 2-4 hours. Mean absolute bioavailability is 23%. Food decreases exposure (as measured by AUC) to valsartan by about 40% and peak plasma concentration ($C_{max}$) by about 50%, although from about 8 h post dosing plasma valsartan concentrations are similar for the fed and fasted groups. This reduction in AUC is not, however, accompanied by a clinically significant reduction in the therapeutic effect, and valsartan can therefore be given either with or without food.

**Distribution:** The steady-state volume of distribution of valsartan after intravenous administration is about 17 litres, indicating that valsartan does not distribute into tissues extensively. Valsartan is highly bound to serum proteins (94-97%), mainly serum albumin.

**Biotransformation:** Valsartan is not transformed to a high extent as only about 20% of dose is recovered as metabolites. A hydroxy metabolite has been identified in plasma at low concentrations (less than 10% of the valsartan AUC). This metabolite is pharmacologically inactive.

**Elimination:** Valsartan is primarily eliminated in faeces (about 83% of dose) and urine (about 13% of dose), mainly as unchanged drug. Following intravenous administration, plasma clearance of valsartan is about 2 l/h and its renal clearance is 0.62 l/h (about 30% of total clearance). The half-life of valsartan is 6 hours.

**Hydrochlorothiazide**

**Absorption:** The absorption of hydrochlorothiazide, after an oral dose, is rapid ($T_{max}$ about 2 hours). The increase in mean AUC is linear and dose proportional in the therapeutic range.

The effect of food on hydrochlorothiazide absorption, if any, has little clinical significance. Absolute bioavailability of hydrochlorothiazide is 70% after oral administration.

**Distribution:** The apparent volume of distribution is 4-8 l/kg. Circulating hydrochlorothiazide is bound to serum proteins (40-70%), mainly serum albumin. Hydrochlorothiazide also accumulates in erythrocytes at approximately 3 times the level in plasma.

**Biotransformation:** Hydrochlorothiazide is eliminated predominantly as unchanged compound.

**Elimination:** Hydrochlorothiazide is eliminated from plasma with a half-life averaging 6 to 15 hours in the terminal elimination phase. There is no change in the kinetics of hydrochlorothiazide on repeated dosing, and accumulation is minimal when dosed once daily. More than 95% of the absorbed dose is being excreted as unchanged compound in the urine. The renal clearance is composed of passive filtration and active secretion into the renal tubule.
Special populations

**Paediatric patients (age below 18 years)**

No pharmacokinetic data are available in the paediatric population.

**Elderly (age 65 years or over)**

Time to peak plasma amlodipine concentrations is similar in young and elderly patients. In elderly patients, amlodipine clearance tends to decline, causing increases in the area under the curve (AUC) and elimination half-life. Mean systemic AUC of valsartan is higher by 70% in the elderly than in the young, therefore caution is required when increasing the dosage.

Systemic exposure to valsartan is slightly elevated in the elderly as compared to the young, but this has not been shown to have any clinical significance.

Limited data suggest that the systemic clearance of hydrochlorothiazide is reduced in both healthy and hypertensive elderly subjects compared to young healthy volunteers.

Since the three components are equally well tolerated in younger and elderly patients, normal dose regimens are recommended (see section 4.2).

**Renal impairment**

The pharmacokinetics of amlodipine are not significantly influenced by renal impairment. As expected for a compound where renal clearance accounts for only 30% of total plasma clearance, no correlation was seen between renal function and systemic exposure to valsartan.

Patients with mild to moderate renal impairment may therefore receive the usual initial dose (see sections 4.2 and 4.4).

In the presence of renal impairment, mean peak plasma levels and AUC values of hydrochlorothiazide are increased and the urinary excretion rate is reduced. In patients with mild to moderate renal impairment, a 3-fold increase in hydrochlorothiazide AUC has been observed. In patients with severe renal impairment an 8-fold increase in AUC has been observed. Imprida HCT is contraindicated in patients with severe renal impairment, anuria or undergoing dialysis (see section 4.3).

**Hepatic impairment**

Patients with hepatic insufficiency have decreased clearance of amlodipine with resulting increase of approximately 40–60% in AUC. On average, in patients with mild to moderate chronic liver disease, exposure (measured by AUC values) to valsartan is twice that found in healthy volunteers (matched by age, sex and weight). Due to the valsartan component, Imprida HCT is contraindicated in patients with hepatic impairment (see sections 4.2 and 4.3).

### 5.3 Preclinical safety data

**Amlodipine/Valsartan/Hydrochlorothiazide**

In a variety of preclinical safety studies conducted in several animal species with amlodipine, valsartan, hydrochlorothiazide, valsartan/hydrochlorothiazide, amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide (Imprida HCT), there was no evidence of systemic or target organ toxicity that would adversely affect the development of Imprida HCT for clinical use in humans.

Preclinical safety studies of up to 13 weeks in duration were conducted with amlodipine/valsartan/hydrochlorothiazide in rats. The combination resulted in expected reduction of red blood cell mass (erythrocytes, haemoglobin, haematocrit, and reticulocytes), increase in serum urea, increase in serum creatinine, increase in serum potassium, juxtaglomerular (JG) hyperplasia in the kidney and focal erosions in the glandular stomach in rats. All these changes were reversible after a 4-week recovery period and were considered to be exaggerated pharmacological effects.
The amlodipine/valsartan/hydrochlorothiazide combination was not tested for genotoxicity or carcinogenicity as there was no evidence of any interaction between these substances, which have been on the market for a long time. However, amlodipine, valsartan and hydrochlorothiazide have been tested individually for genotoxicity and carcinogenicity with negative results.

**Amlodipine**

*Reproductive toxicology*

Reproductive studies in rats and mice have shown delayed date of delivery, prolonged duration of labour and decreased pup survival at dosages approximately 50 times greater than the maximum recommended dosage for humans based on mg/kg.

*Impairment of fertility*

There was no effect on the fertility of rats treated with amlodipine (males for 64 days and females 14 days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human dose of 10 mg on a mg/m² basis). In another rat study in which male rats were treated with amlodipine besilate for 30 days at a dose comparable with the human dose based on mg/kg, decreased plasma follicle-stimulating hormone and testosterone were found as well as decreases in sperm density and in the number of mature spermatids and Sertoli cells.

*Carcinogenesis, mutagenesis*

Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity. The highest dose (for mice, similar to, and for rats twice* the maximum recommended clinical dose of 10 mg on a mg/m² basis) was close to the maximum tolerated dose for mice but not for rats.

Mutagenicity studies revealed no drug related effects at either the gene or chromosome levels.

* Based on patient weight of 50 kg

**Valsartan**

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential.

In rats, maternally toxic doses (600 mg/kg/day) during the last days of gestation and lactation led to lower survival, lower weight gain and delayed development (pinna detachment and ear-canal opening) in the offspring (see section 4.6). These doses in rats (600 mg/kg/day) are approximately 18 times the maximum recommended human dose on a mg/m² basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).

In non-clinical safety studies, high doses of valsartan (200 to 600 mg/kg body weight) caused in rats a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit) and evidence of changes in renal haemodynamics (slightly raised plasma urea, and renal tubular hyperplasia and basophilia in males). These doses in rats (200 and 600 mg/kg/day) are approximately 6 and 18 times the maximum recommended human dose on a mg/m² basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).

In marmosets at similar doses, the changes were similar though more severe, particularly in the kidney where the changes developed to a nephropathy which included raised urea and creatinine.

Hypertrophy of the renal juxtaglomerular cells was also seen in both species. All changes were considered to be caused by the pharmacological action of valsartan which produces prolonged hypotension, particularly in marmosets. For therapeutic doses of valsartan in humans, the hypertrophy of the renal juxtaglomerular cells does not seem to have any relevance.
6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core
Cellulose microcrystalline
Crospovidone
Silica, colloidal anhydrous
Magnesium stearate

Coating
Hypromellose
Macrogol 4000
Talc
Iron oxide, yellow (E172)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

2 years

6.4 Special precautions for storage

Do not store above 30°C.

Store in the original package in order to protect from moisture.

6.5 Nature and contents of container

PVC/PVDC blisters. One blister contains 7, 10 or 14 film-coated tablets.
Pack sizes: 14, 28, 30, 56, 90, 98 or 280 film-coated tablets.
Multipacks of 280 tablets, comprising 20 cartons, each containing 14 tablets.

PVC/PVDC perforated unit dose blisters for hospital use:
Pack sizes: 56, 98 or 280 film-coated tablets
Multipacks of 280 tablets, comprising 4 cartons, each containing 70 tablets.

Not all pack sizes or strengths may be marketed.

6.6 Special precautions for disposal and other handling

No special requirements.

7. MARKETING AUTHORISATION HOLDER

Novartis Europharm Limited
Wimblehurst Road
Horsham
West Sussex, RH12 5AB
United Kingdom
8. MARKETING AUTHORISATION NUMBER(S)

EU/1/09/570/037-048

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

15.10.2009

10. DATE OF REVISION OF THE TEXT

Detailed information on this product is available on the website of the European Medicines Agency http://www.ema.europa.eu

Medicinal product no longer authorised
1. NAME OF THE MEDICINAL PRODUCT

Imprida HCT 10 mg/320 mg/25 mg film-coated tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film-coated tablet contains 10 mg of amlodipine (as amlodipine besylate), 320 mg of valsartan and 25 mg of hydrochlorothiazide.

For a full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Film-coated tablet (tablet)

Brown-yellow, ovaloid, biconvex tablets with bevelled edge, debossed “NVR” on one side and “VFL” on the other side.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.

4.2 Posology and method of administration

**Posology**
The recommended dose of Imprida HCT is one tablet per day, to be taken preferably in the morning.

Before switching to Imprida HCT patients should be controlled on stable doses of the monocomponents taken at the same time. The dose of Imprida HCT should be based on the doses of the individual components of the combination at the time of switching.

The maximum recommended dose of Imprida HCT is 10 mg/320 mg/25 mg.

**Special populations**

**Renal impairment**

No adjustment of the initial dose is required for patients with mild to moderate renal impairment (see sections 4.4 and 5.2). Due to the hydrochlorothiazide component, Imprida HCT is contraindicated for use in patients with anuria (see section 4.3) and in patients with severe renal impairment (glomerular filtration rate (GFR) <30 ml/min/1.73 m$^2$) (see sections 4.3, 4.4 and 5.2).

**Hepatic impairment**

Due to the valsartan component, Imprida HCT is contraindicated in patients with severe hepatic impairment (see section 4.3). In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan and therefore Imprida HCT is not suitable in this group of patients (see sections 4.3, 4.4 and 5.2).
Heart failure and coronary artery disease
There is limited experience with the use of Imprida HCT, particularly at the maximum dose, in patients with heart failure and coronary artery disease. Caution is advised in patients with heart failure and coronary artery disease, particularly at the maximum dose of Imprida HCT, 10 mg/320 mg/25 mg.

Elderly (age 65 years or over)
Caution, including more frequent monitoring of blood pressure, is recommended in elderly patients, particularly at the maximum dose of Imprida HCT, 10 mg/320 mg/25 mg, since available data in this patient population are limited.

Paediatric population
There is no relevant use of Imprida HCT in the paediatric population (patients below age 18 years) for the indication of essential hypertension.

Method of administration
Imprida HCT can be taken with or without food. The tablets should be swallowed whole with some water, at the same time of the day and preferably in the morning.

4.3 Contraindications
– Hypersensitivity to the active substances, to other sulphonamide derivatives, to dihydropyridine derivatives, or to any of the excipients.
– Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
– Hepatic impairment, biliary cirrhosis or cholestasis.
– Severe renal impairment (GFR <30 ml/min/1.73 m²), anuria and patients undergoing dialysis.
– Refractory hypokalaemia, hyponatraemia, hypercalcaemia, and symptomatic hyperuricaemia.

4.4 Special warnings and precautions for use
Sodium- and/or volume-depleted patients
Excessive hypotension, including orthostatic hypotension, was seen in 1.7% of patients treated with the maximum dose of Imprida HCT (10 mg/320 mg/25 mg) compared to 1.8% of valsartan/hydrochlorothiazide (320 mg/25 mg) patients, 0.4% of amlodipine/valsartan (10 mg/320 mg) patients, and 0.2% of hydrochlorothiazide/amlodipine (25 mg/10 mg) patients in a controlled trial in patients with moderate to severe uncomplicated hypertension.

In sodium-depleted and/or volume-depleted patients, such as those receiving high doses of diuretics, symptomatic hypotension may occur after initiation of treatment with Imprida HCT. Imprida HCT should be used only after correction of any pre-existing sodium and/or volume depletion.

If excessive hypotension occurs with Imprida HCT, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline. Treatment can be continued once blood pressure has been stabilised.

Serum electrolyte changes
Amlodipine/valsartan/hydrochlorothiazide
In the controlled trial of Imprida HCT, the counteracting effects of valsartan 320 mg and hydrochlorothiazide 25 mg on serum potassium approximately balanced each other in many patients. In other patients, one or the other effect may be dominant. Periodic determinations of serum electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals.

Periodic determination of serum electrolytes and potassium in particular should be performed at appropriate intervals to detect possible electrolyte imbalance, especially in patients with other risk factors such as impaired renal function, treatment with other medicinal products or history of prior electrolyte imbalances.
**Valsartan**
Concomitant use with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other medicinal products that may increase potassium levels (heparin, etc.) is not recommended. Monitoring of potassium should be undertaken as appropriate.

**Hydrochlorothiazide**
Treatment with Imprida HCT should only start after correction of hypokalaemia and any coexisting hypomagnesaemia. Thiazide diuretics can precipitate new onset hypokalaemia or exacerbate pre-existing hypokalaemia. Thiazide diuretics should be administered with caution in patients with conditions involving enhanced potassium loss, for example salt-losing nephropathies and prerenal (cardiogenic) impairment of kidney function. If hypokalaemia develops during hydrochlorothiazide therapy, Imprida HCT should be discontinued until stable correction of the potassium balance.

Thiazide diuretics can precipitate new onset hyponatraemia and hypochloremic alkalosis or exacerbate pre-existing hyponatraemia. Hyponatraemia, accompanied by neurological symptoms (nausea, progressive disorientation, apathy) has been observed. Treatment with hydrochlorothiazide should only be started after correction of pre-existing hyponatraemia. In case severe or rapid hyponatraemia develops during Imprida HCT therapy, the treatment should be discontinued until normalisation of nataemia.

All patients receiving thiazide diuretics should be periodically monitored for imbalances in electrolytes, particularly potassium, sodium and magnesium.

**Renal impairment**
Thiazide diuretics may precipitate azotaemia in patients with chronic kidney disease. When Imprida HCT is used in patients with renal impairment periodic monitoring of serum electrolytes (including potassium), creatinine and uric acid serum levels is recommended. Imprida HCT is contraindicated in patients with severe renal impairment, anuria or undergoing dialysis (see section 4.3).

No dosage adjustment of Imprida HCT is required for patients with mild to moderate renal impairment (GFR ≥30 ml/min/1.73 m²).

**Renal artery stenosis**
No data are available on the use of Imprida HCT in patients with unilateral or bilateral renal artery stenosis or stenosis to a solitary kidney.

**Kidney transplantation**
To date there is no experience of the safe use of Imprida HCT in patients who have had a recent kidney transplantation.

**Hepatic impairment**
Valsartan is mostly eliminated unchanged via the bile, whereas amlodipine is extensively metabolised by the liver. In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan, and therefore, Imprida HCT is not suitable in this group of patients (see sections 4.2, 4.3 and 5.2).

**Heart failure and coronary artery disease**
As a consequence of the inhibition of the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients with severe heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotaemia and (rarely) with acute renal failure and/or death. Similar outcomes have been reported with valsartan.
In a long-term, placebo-controlled study (PRAISE-2) of amlodipine in patients with NYHA (New York Heart Association Classification) III and IV heart failure of non-ischaemic aetiology, amlodipine was associated with increased reports of pulmonary oedema despite no significant difference in the incidence of worsening heart failure as compared to placebo.

Caution is advised in patients with heart failure and coronary artery disease, particularly at the maximum dose of Imprida HCT, 10 mg/320 mg/25 mg, since available data in these patient populations is limited.

Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy
As with all other vasodilators, special caution is indicated in patients with aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.

Pregnancy
Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).

Primary hyperaldosteronism
Patients with primary hyperaldosteronism should not be treated with the angiotensin II antagonist valsartan as their renin-angiotensin system is not activated. Therefore, Imprida HCT is not recommended in this population.

Systemic lupus erythematosus
Thiazide diuretics, including hydrochlorothiazide, have been reported to exacerbate or activate systemic lupus erythematosus.

Other metabolic disturbances
Thiazide diuretics, including hydrochlorothiazide, may alter glucose tolerance and raise serum levels of cholesterol, triglycerides and uric acid. In diabetic patients dosage adjustments of insulin or oral hypoglycaemic agents may be required.

Due to the hydrochlorothiazide component, Imprida HCT is contraindicated in symptomatic hyperuricaemia. Hydrochlorothiazide may raise the serum uric acid level due to reduced clearance of uric acid and may cause or exacerbate hyperuricaemia as well as precipitate gout in susceptible patients.

Thiazides reduce urinary calcium excretion and may cause intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Imprida HCT is contraindicated in patients with hypercalcaemia and should only be used after correction of any pre-existing hypercalcaemia. Imprida HCT should be discontinued if hypercalcaemia develops during treatment. Serum levels of calcium should be periodically monitored during treatment with thiazides. Marked hypercalcaemia may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function.

Photosensitivity
Cases of photosensitivity reactions have been reported with thiazide diuretics (see section 4.8). If photosensitivity reaction occurs during treatment with Imprida HCT, it is recommended to stop the treatment. If a readministration of the diuretic is deemed necessary, it is recommended to protect exposed areas to the sun or to artificial UVA.
Acute angle-closure glaucoma

Hydrochlorothiazide, a sulphonamide, has been associated with an idiosyncratic reaction resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to a week of treatment initiation. Untreated acute-angle closure glaucoma can lead to permanent vision loss.

The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatment may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle closure glaucoma may include a history of sulphonamide or penicillin allergy.

General
Caution should be exercised in patients who have shown prior hypersensitivity to other angiotensin II receptor antagonists. Hypersensitivity reactions to hydrochlorothiazide are more likely in patients with allergy and asthma.

Elderly (age 65 years or over)
Caution, including more frequent monitoring of blood pressure, is recommended in elderly patients, particularly at the maximum dose of Imprida HCT, 10 mg/320 mg/25 mg, since available data in this patient population are limited.

4.5 Interaction with other medicinal products and other forms of interaction

No formal interaction studies with other medicinal products were performed with Imprida HCT. Thus, only information on interactions with other medicinal products that are known for the individual active substances is provided in this section.

However, it is important to take into account that Imprida HCT may increase the hypotensive effect of other antihypertensive agents.
### Concomitant use not recommended

<table>
<thead>
<tr>
<th>Imprida HCT individual component</th>
<th>Known interactions with the following agents</th>
<th>Effect of the interaction with other medicinal products</th>
</tr>
</thead>
<tbody>
<tr>
<td>Valsartan and HCT</td>
<td>Lithium</td>
<td>Reversible increases in serum lithium concentrations and toxicity have been reported during concurrent use of ACE inhibitors and thiazides such as hydrochlorothiazide. Despite the lack of experience with concomitant use of valsartan and lithium, this combination is not recommended. If the combination proves necessary, careful monitoring of serum lithium levels is recommended (see section 4.4).</td>
</tr>
<tr>
<td>Valsartan</td>
<td>Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may increase potassium levels</td>
<td>If a medicinal product that affects potassium levels is considered necessary in combination with valsartan, frequent monitoring of potassium plasma levels is advised.</td>
</tr>
<tr>
<td>Amlodipine</td>
<td>Grapefruit or grapefruit juice</td>
<td>Administration of amlodipine with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients, resulting in increased blood pressure lowering effects.</td>
</tr>
</tbody>
</table>

### Caution required with concomitant use

<table>
<thead>
<tr>
<th>Imprida HCT individual component</th>
<th>Known interactions with the following agents</th>
<th>Effect of the interaction with other medicinal products</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amlodipine</td>
<td><em>CYP3A4 inhibitors</em> (i.e. ketoconazole, itraconazole, ritonavir)</td>
<td>Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors,azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem) may give rise to significant increase in amlodipine exposure. The clinical translation of these pharmacokinetic variations may be more pronounced in the elderly. Clinical monitoring and dose adjustment may thus be required.</td>
</tr>
<tr>
<td>Amlodipine</td>
<td><em>CYP3A4 inducers</em> (anticonvulsant agents [e.g. carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone], rifampicin, Hypericum perforatum [St. John’s wort])</td>
<td>There is no data available regarding the effect of CYP3A4 inducers on amlodipine. The concomitant use of CYP3A4 inducers (e.g. rifampicin, Hypericum perforatum) may give a lower plasma concentration of amlodipine. Amlodipine should be used with caution together with CYP3A4 inducers.</td>
</tr>
</tbody>
</table>
### Simvastatin

Co-administration of multiple doses of 10 mg amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. It is recommended to limit the dose of simvastatin to 20 mg daily in patients on amlodipine.

### Dantrolene (infusion)

In animals, lethal ventricular fibrillation and cardiovascular collapse are observed in association with hyperkalaemia after administration of verapamil and intravenous dantrolene. Due to risk of hyperkalaemia, it is recommended that the co-administration of calcium channel blockers such as amlodipine be avoided in patients susceptible to malignant hyperthermia and in the management of malignant hyperthermia.

### Valsartan and HCT

- **Non-steroidal anti-inflammatory medicines (NSAIDs), including selective cyclooxygenase-2 inhibitors (COX-2 inhibitors), acetylsalicylic acid (>3 g/day), and non-selective NSAIDs**
  - NSAIDS can attenuate the antihypertensive effect of both angiotensin II antagonists and hydrochlorothiazide when administered simultaneously. Furthermore, concomitant use of Imprida HCT and NSAIDs may lead to worsening of renal function and an increase in serum potassium. Therefore, monitoring of renal function at the beginning of the treatment is recommended, as well as adequate hydration of the patient.

- **Inhibitors of the uptake transporter (rifampicin, ciclosporin) or efflux transporter (ritonavir)**
  - The results of an *in vitro* study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1 and of the hepatic efflux transporter MRP2. Co-administration of inhibitors of the uptake transporter (rifampicin, ciclosporin) or efflux transporter (ritonavir) may increase the systemic exposure to valsartan.

### Valsartan

- **Inhibitors of the uptake transporter (rifampicin, ciclosporin) or efflux transporter (ritonavir)**

### HCT

- **Alcohol, barbiturates or narcotics**
  - Concomitant administration of thiazide diuretics with substances that also have a blood pressure lowering effect (e.g. by reducing sympathetic central nervous system activity or direct vasodilatation) may potentiate orthostatic hypotension.

- **Amantadine**
  - Thiazides, including hydrochlorothiazide, may increase the risk of adverse reactions caused by amantadine.

- **Anticholinergic agents and other medicinal products affecting gastric motility**
  - The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents (e.g. atropine, biperiden), apparently due to a decrease in gastrointestinal motility and the stomach emptying rate. Conversely, it is anticipated that prokinetic substances such as cisapride may decrease the bioavailability of thiazide-type diuretics.

- **Antidiabetic agents (e.g. insulin and oral antidiabetic agents)**
  - **Metformin**
    - Metformin should be used with caution because of the risk of lactic acidosis induced by possible functional renal failure linked to hydrochlorothiazide.

- **Beta blockers and diazoxide**
  - Concomitant use of thiazide diuretics, including hydrochlorothiazide, with beta blockers may increase the risk of hyperglycaemia. Thiazide diuretics, including hydrochlorothiazide, may enhance the hyperglycaemic effect of diazoxide.
<table>
<thead>
<tr>
<th><strong>Ciclosporin</strong></th>
<th>Concomitant treatment with ciclosporin may increase the risk of hyperuricaemia and gout-type complications.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cytotoxic agents</strong></td>
<td>Thiazides, including hydrochlorothiazide, may reduce the renal excretion of cytotoxic agents (e.g. cyclophosphamide, methotrexate) and potentiate their myelosuppressive effects.</td>
</tr>
<tr>
<td><strong>Digitalis glycosides</strong></td>
<td>Thiazide-induced hypokalaemia or hypomagnesaemia may occur as undesirable effects, favouring the onset of digitalis-induced cardiac arrhythmias.</td>
</tr>
<tr>
<td><strong>Iodine contrasting agents</strong></td>
<td>In case of diuretic-induced dehydration, there is an increased risk of acute renal failure, especially with high doses of iodine products. Patients should be re-hydrated before the administration.</td>
</tr>
<tr>
<td><strong>Ion exchange resins</strong></td>
<td>Absorption of thiazide diuretics, including hydrochlorothiazide, is decreased by cholestyramine or colestipol. This could result in sub-therapeutic effects of thiazide diuretics. However, staggering the dosage of hydrochlorothiazide and resin such that hydrochlorothiazide is administered at least 4 hours before or 4-6 hours after the administration of resins would potentially minimise the interaction.</td>
</tr>
<tr>
<td><strong>Medicinal products affecting serum potassium level</strong></td>
<td>The hypokalaemic effect of hydrochlorothiazide may be increased by concomitant administration of kaliuretic diuretics, corticosteroids, laxatives, adrenocorticotropic hormone (ACTH), amphotericin, carbenoxolone, penicillin G and salicylic acid derivatives or antiarrhythmics. If these medicinal products are to be prescribed with the amlodipine /valsartan /hydrochlorothiazide combination, monitoring of potassium plasma levels is advised.</td>
</tr>
<tr>
<td><strong>Medicinal products affecting serum sodium level</strong></td>
<td>The hyponatraemic effect of diuretics may be intensified by concomitant administration of medicinal products such as antidepressants, antipsychotics, antiepileptics, etc. Caution is indicated in long-term administration of these medicinal products.</td>
</tr>
<tr>
<td><strong>Medicinal products that could induce torsades de pointes</strong></td>
<td>Due to the risk of hypokalaemia, hydrochlorothiazide should be administered with caution when associated with medicinal products that could induce torsades de pointes, in particular Class Ia and Class III antiarrhythmics and some antipsychotics.</td>
</tr>
<tr>
<td><strong>Medicinal products used in the treatment of gout (probenecid, sulfinpyrazone and allopurinol)</strong></td>
<td>Dose adjustment of uricosuric medicinal products may be necessary as hydrochlorothiazide may raise the level of serum uric acid. Increase of dose of probenecid or sulfinpyrazone may be necessary. Co-administration of thiazide diuretics, including hydrochlorothiazide, may increase the incidence of hypersensitivity reactions to allopurinol.</td>
</tr>
<tr>
<td><strong>Methyldopa</strong></td>
<td>There have been isolated reports of haemolytic anaemia occurring with concomitant use of hydrochlorothiazide and methyldopa.</td>
</tr>
<tr>
<td><strong>Non-depolarising skeletal muscle relaxants (e.g. tubocurarine)</strong></td>
<td>Thiazides, including hydrochlorothiazide, potentiate the action of curare derivatives.</td>
</tr>
</tbody>
</table>
Other anti-hypertensive drugs

Thiazides potentiate the antihypertensive action of other antihypertensive drugs (e.g. guanethidine, methyldopa, beta-blockers, vasodilators, calcium channel blockers, ACE inhibitors, ARBs and Direct Renin Inhibitors [DRIs]).

Pressor amines (e.g. noradrenaline, adrenaline)

Hydrochlorothiazide may reduce the response to pressor amines such as noradrenaline. The clinical significance of this effect is uncertain and not sufficient to preclude their use.

Vitamin D and calcium salts

Administration of thiazide diuretics, including hydrochlorothiazide, with vitamin D or with calcium salts may potentiate the rise in serum calcium. Concomitant use of thiazide type diuretics may lead to hypercalcaemia in patients pre-disposed for hypercalcaemia (e.g. hyperparathyroidism, malignancy or vitamin-D-mediated conditions) by increasing tubular calcium reabsorption.

No interaction

Imprida HCT individual component

Known interactions with the following agents

Effect of the interaction with other medicinal products

Valsartan

 Others
 (cimetidine, warfarin, furosemide, digoxin, atenolol, indometacin, hydrochlorothiazide, amlodipine, glibenclamide)

In monotherapy with valsartan, no interactions of clinical significance have been found with the following substances: cimetidine, warfarin, furosemide, digoxin, atenolol, indometacin, hydrochlorothiazide, amlodipine, glibenclamide. Some of these substances could interact with the hydrochlorothiazide component of Imprida HCT (see interactions related to HCT).

Amlodipine

 Others

In clinical interaction studies, amlodipine did not affect the pharmacokinetics of atorvastatin, digoxin, warfarin or ciclosporin.

4.6 Fertility, pregnancy and lactation

Pregnancy

Amlodipine

The safety of amlodipine in human pregnancy has not been established. In animal studies, reproductive toxicity was observed at high doses (see section 5.3). Use in pregnancy is only recommended when there is no safer alternative and when the disease itself carries greater risk for the mother and foetus.
Valsartan

The use of Angiotensin II Receptor Antagonists (AIIRAs) is not recommended during the first trimester of pregnancy (see section 4.4). The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 and 4.4).

Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and if appropriate, alternative therapy should be started.

Exposure to AIIRAs therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3).

Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.

Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3 and 4.4).

Hydrochlorothiazide

There is limited experience with hydrochlorothiazide during pregnancy, especially during the first trimester. Animal studies are insufficient.

Hydrochlorothiazide crosses the placenta. Based on the pharmacological mechanism of action of hydrochlorothiazide, its use during the second and third trimester may compromise foeto-placental perfusion and may cause foetal and neonatal effects like icterus, disturbance of electrolyte balance and thrombocytopenia.

Amlodipine/valsartan/hydrochlorothiazide

There is no experience on the use of Imprida HCT in pregnant women. Based on the existing data with the components, the use of Imprida HCT is not recommended during first trimester and contraindicated during the second and third trimester of pregnancy (see sections 4.3 and 4.4).

Breast-feeding

No information is available regarding the use of valsartan and/or amlodipine during breast-feeding. Hydrochlorothiazide is excreted in human milk in small amounts. Thiazides in high doses causing intense diuresis can inhibit milk production. The use of Imprida HCT during breast-feeding is not recommended. If Imprida HCT is used during breast-feeding, doses should be kept as low as possible. Alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.

Fertility

There are no clinical studies on fertility with Imprida HCT.

Valsartan

Valsartan had no adverse effects on the reproductive performance of male or female rats at oral doses up to 200 mg/kg/day. This dose is 6 times the maximum recommended human dose on a mg/m² basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).
**Amlodipine**

Reversible biochemical changes in the head of spermatozoa have been reported in some patients treated by calcium channel blockers. Clinical data are insufficient regarding the potential effect of amlodipine on fertility. In one rat study, adverse effects were found on male fertility (see section 5.3).

### 4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. When driving vehicles or using machines it should be taken into account that occasionally dizziness or weariness may occur.

### 4.8 Undesirable effects

The safety profile of Imprida HCT presented below is based on clinical studies performed with Imprida HCT and the known safety profile of the individual components amlodipine, valsartan and hydrochlorothiazide.

**Information on Imprida HCT**

The safety of Imprida HCT has been evaluated at its maximum dose of 10 mg/320 mg/25 mg in one controlled short-term (8 weeks) clinical study with 2,271 patients, 582 of whom received valsartan in combination with amlodipine and hydrochlorothiazide. Adverse reactions were generally mild and transient in nature and only infrequently required discontinuation of therapy. In this active controlled clinical trial, the most common reasons for discontinuation of therapy with Imprida HCT were dizziness and hypotension (0.7%).

In the 8-week controlled clinical study, no significant new or unexpected adverse reactions were observed with triple therapy treatment compared to the known effects of the monotherapy or dual therapy components.

In the 8-week controlled clinical study, changes in laboratory parameters observed with the combination of Imprida HCT were minor and consistent with the pharmacological mechanism of action of the monotherapy agents. The presence of valsartan in the triple combination attenuated the hypokalaemic effect of hydrochlorothiazide.

The following adverse reactions, listed by MedDRA System Organ Class and frequency, concern Imprida HCT (amlodipine/valsartan/HCT) and amlodipine, valsartan and HCT individually. Very common: ≥1/10; common: ≥1/100 to <1/10; uncommon: ≥1/1,000 to <1/100; rare: ≥1/10,000 to <1/1,000; very rare: <1/10,000, not known (cannot be estimated from the available data).

<table>
<thead>
<tr>
<th>MedDRA System Organ Class</th>
<th>Adverse reactions</th>
<th>Frequency</th>
<th>Imprida HCT</th>
<th>Amlodipine</th>
<th>Valsartan</th>
<th>HCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>Agranulocytosis, bone marrow depression</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Very rare</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Decrease in haemoglobin and in haematocrit</td>
<td>--</td>
<td>--</td>
<td>Not known</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Haemolytic anaemia</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Very rare</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Leukopenia</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>Very rare</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Neutropenia</td>
<td>--</td>
<td>--</td>
<td>Not known</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thrombocytopenia, sometimes with purpura</td>
<td>--</td>
<td>Very rare</td>
<td>Not known</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aplastic anaemia</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Not known</td>
<td></td>
</tr>
<tr>
<td>Disorder Category</td>
<td>Disorder</td>
<td>Incidence</td>
<td>Probability</td>
<td>Commonality</td>
<td>Incidence</td>
<td>Probability</td>
</tr>
<tr>
<td>-----------------------------------------</td>
<td>---------------------------</td>
<td>-----------------</td>
<td>-------------</td>
<td>-------------</td>
<td>-----------------</td>
<td>-------------</td>
</tr>
<tr>
<td><strong>Immune system disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hypersensitivity</td>
<td>--</td>
<td>Very rare</td>
<td>Not known</td>
<td>Very rare</td>
<td></td>
</tr>
<tr>
<td><strong>Metabolism and nutrition disorders</strong></td>
<td>Anorexia</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td>Hypercalcaemia</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>Rare</td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td>Hyperglycaemia</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>Rare</td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td>Hyperlipidaemia</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Hyperuricaemia</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>Common</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Hypochloroaemic alkalosis</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Rare</td>
<td>Very rare</td>
</tr>
<tr>
<td></td>
<td>Hypokalaemia</td>
<td>Common</td>
<td>--</td>
<td>--</td>
<td>Very rare</td>
<td>Common</td>
</tr>
<tr>
<td></td>
<td>Hypomagnesaemia</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Common</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Hyponatraemia</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>Common</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Worsening of diabetic</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Rare</td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td>metabolic state</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Psychiatric disorders</strong></td>
<td>Depression</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Insomnia/sleep disturbances</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>Rare</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mood swings</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nervous system disorders</strong></td>
<td>Coordination abnormal</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Dizziness</td>
<td>Common</td>
<td>Common</td>
<td>--</td>
<td>Rare</td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td>Dizziness postural, dizziness exertional</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Dyseusia</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Extrapyramidal syndrome</td>
<td>--</td>
<td>Not known</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Headache</td>
<td>Common</td>
<td>Common</td>
<td>--</td>
<td>Rare</td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td>Hypertonia</td>
<td>Very rare</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Lethargy</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Paraesthesia</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>Rare</td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td>Peripheral neuropathy, neuropathy</td>
<td>Uncommon</td>
<td>Very rare</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Somnolence</td>
<td>Uncommon</td>
<td>Common</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Syncope</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Tremor</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td><strong>Eye disorders</strong></td>
<td>Acute angle-closure glaucoma</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Not known</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Visual impairment</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td><strong>Ear and labyrinth disorders</strong></td>
<td>Tinnitus</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Vertigo</td>
<td>Uncommon</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td><strong>Cardiac disorders</strong></td>
<td>Palpitations</td>
<td>--</td>
<td>Common</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Tachycardia</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Arrhythmias (including bradycardia, ventricular tachycardia, and atrial fibrillation)</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Myocardial infarction</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td><strong>Vascular disorders</strong></td>
<td>Flushing</td>
<td>--</td>
<td>Common</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Hypotension</td>
<td>Common</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>Common</td>
</tr>
<tr>
<td></td>
<td>Orthostatic hypotension</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>Common</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Phlebitis, thrombophlebitis</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Vasculitis</td>
<td>--</td>
<td>Very rare</td>
<td>Not known</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Disorder</td>
<td>Uncommon</td>
<td>Very rare</td>
<td>Uncommon</td>
<td>Rare</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------------------------------------------------------------</td>
<td>----------</td>
<td>-----------</td>
<td>----------</td>
<td>------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cough</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyspnoea</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory distress, pulmonary oedema, pneumonitis</td>
<td></td>
<td></td>
<td></td>
<td>Very rare</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rhinitis</td>
<td></td>
<td>Uncommon</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Throat irritation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Uncommon</td>
<td>Common</td>
<td>Uncommon</td>
<td>Rare</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdominal discomfort, abdominal pain upper</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breath odour</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change of bowel habit</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Constipation</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Rare</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Common</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>Rare</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dry mouth</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>--</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>Common</td>
<td>Uncommon</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastritis</td>
<td>--</td>
<td>Very rare</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gingival hyperplasia</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>--</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>Uncommon</td>
<td>Common</td>
<td></td>
<td>Common</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancreatitis</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>Very rare</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vomiting</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>--</td>
<td>Common</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatic enzyme elevation, including increase of serum bilirubin</td>
<td>--</td>
<td>Very rare</td>
<td>Not known</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intrahepatic cholestasis, jaundice</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>Rare</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>Uncommon</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alopecia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Angioedema</td>
<td></td>
<td>Very rare</td>
<td>Not known</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cutaneous lupus erythematosus-like reactions, reactivation of cutaneous lupus erythematosus</td>
<td></td>
<td></td>
<td></td>
<td>Very rare</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythema multiforme</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>Not known</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exanthema</td>
<td>--</td>
<td>Uncommon</td>
<td>--</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperhidrosis</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Photosensitivity reaction*</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Rare</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pruritus</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>Not known</td>
<td>--</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purpura</td>
<td>--</td>
<td>Uncommon</td>
<td></td>
<td>Rare</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rash</td>
<td>--</td>
<td>Uncommon</td>
<td>Not known</td>
<td>Common</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin discoloration</td>
<td>--</td>
<td>Uncommon</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urticaria and other forms of rash</td>
<td>--</td>
<td>Very rare</td>
<td>--</td>
<td>Common</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vasculitis necrotising and toxic epidermal necrolysis</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>Very rare</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td>Uncommon</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthralgia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Back pain</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joint swelling</td>
<td>Uncommon</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Muscle spasm</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td></td>
<td>Not known</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Muscular weakness</td>
<td>Uncommon</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myalgia</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>Not known</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain in extremity</td>
<td>Uncommon</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Medicinal product no longer authorised*
## Renal and Urinary Disorders

<table>
<thead>
<tr>
<th>Condition</th>
<th>Frequency</th>
<th>Not Known</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elevation of serum creatinine</td>
<td>Uncommon</td>
<td>Not known</td>
<td>Common</td>
</tr>
<tr>
<td>Micturition disorder</td>
<td>Uncommon</td>
<td>Common</td>
<td>Rare</td>
</tr>
<tr>
<td>Nocturia</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Pollakiuria</td>
<td>Common Uncommon</td>
<td>Common</td>
<td>Common</td>
</tr>
<tr>
<td>Renal dysfunction</td>
<td>-- -- Not known</td>
<td>-- --</td>
<td>--</td>
</tr>
<tr>
<td>Renal failure acute</td>
<td>Uncommon --</td>
<td>-- --</td>
<td>--</td>
</tr>
<tr>
<td>Renal failure and impairment</td>
<td>-- -- Not known</td>
<td>Common</td>
<td>Rare</td>
</tr>
</tbody>
</table>

## Reproductive System and Breast Disorders

<table>
<thead>
<tr>
<th>Condition</th>
<th>Frequency</th>
<th>Not Known</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Impotence</td>
<td>Uncommon</td>
<td>Common</td>
<td>Rare</td>
</tr>
<tr>
<td>Gynaecomastia</td>
<td>Uncommon</td>
<td>Common</td>
<td>Rare</td>
</tr>
</tbody>
</table>

## General Disorders and Administration Site Conditions

<table>
<thead>
<tr>
<th>Condition</th>
<th>Frequency</th>
<th>Not Known</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abasia, gait disturbance</td>
<td>Uncommon</td>
<td>Common</td>
<td>Rare</td>
</tr>
<tr>
<td>Asthenia</td>
<td>Uncommon</td>
<td>Common</td>
<td>Common</td>
</tr>
<tr>
<td>Discomfort, malaise</td>
<td>Uncommon</td>
<td>Common</td>
<td>Common</td>
</tr>
<tr>
<td>Fatigue</td>
<td>Common Uncommon</td>
<td>Common</td>
<td>Common</td>
</tr>
<tr>
<td>Non cardiac chest pain</td>
<td>Uncommon</td>
<td>Common</td>
<td>Common</td>
</tr>
<tr>
<td>Oedema</td>
<td>Common Uncommon</td>
<td>Common</td>
<td>Common</td>
</tr>
<tr>
<td>Pain</td>
<td>Common Uncommon</td>
<td>Common</td>
<td>Common</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>Common Uncommon</td>
<td>Common</td>
<td>Common</td>
</tr>
<tr>
<td>Weight increase</td>
<td>Uncommon</td>
<td>Uncommon</td>
<td>Common</td>
</tr>
<tr>
<td>Weight decrease</td>
<td>Common Uncommon</td>
<td>Common</td>
<td>Common</td>
</tr>
</tbody>
</table>

## Investigations

<table>
<thead>
<tr>
<th>Condition</th>
<th>Frequency</th>
<th>Not Known</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lipids increased</td>
<td>Very common</td>
<td>Common</td>
<td>Common</td>
</tr>
<tr>
<td>Blood urea nitrogen increased</td>
<td>Uncommon</td>
<td>Common</td>
<td>Common</td>
</tr>
<tr>
<td>Blood uric acid increased</td>
<td>Uncommon</td>
<td>Common</td>
<td>Common</td>
</tr>
<tr>
<td>Glycosuria</td>
<td>Rare</td>
<td>Common</td>
<td>Common</td>
</tr>
<tr>
<td>Serum potassium decreased</td>
<td>Uncommon</td>
<td>Common</td>
<td>Common</td>
</tr>
<tr>
<td>Serum potassium increased</td>
<td>Common Uncommon</td>
<td>Common</td>
<td>Common</td>
</tr>
<tr>
<td>Weight increase</td>
<td>Common Uncommon</td>
<td>Common</td>
<td>Common</td>
</tr>
<tr>
<td>Weight decrease</td>
<td>Common Uncommon</td>
<td>Common</td>
<td>Common</td>
</tr>
</tbody>
</table>

* See section 4.4 Photosensitivity

### 4.9 Overdose

#### Symptoms

There is no experience of overdose with Imprida HCT. The major symptom of overdose with valsartan is possibly pronounced hypotension with dizziness. Overdose with amlodipine may result in excessive peripheral vasodilation and, possibly, reflex tachycardia. Marked and potentially prolonged systemic hypotension, including shock with fatal outcome, have been reported with amlodipine.

#### Treatment

**Amlodipine/Valsartan/Hydrochlorothiazide**

Clinically significant hypotension due to Imprida HCT overdose calls for active cardiovascular support, including frequent monitoring of cardiac and respiratory function, elevation of extremities, and attention to circulating fluid volume and urine output. A vasoconstrictor may be helpful in restoring vascular tone and blood pressure, provided that there is no contraindication to its use. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade.

**Amlodipine**

If ingestion is recent, induction of vomiting or gastric lavage may be considered. Administration of activated charcoal to healthy volunteers immediately or up to two hours after ingestion of amlodipine has been shown to significantly decrease amlodipine absorption. Amlodipine is unlikely to be removed by haemodialysis.
Valsartan
Valsartan is unlikely to be removed by haemodialysis.

Hydrochlorothiazide
Overdose with hydrochlorothiazide is associated with electrolyte depletion (hypokalaemia, hypochloraemia) and hypovolaemia resulting from excessive diuresis. The most common signs and symptoms of overdose are nausea and somnolence. Hypokalaemia may result in muscle spasms and or accentuate arrhythmia associated with the concomitant use of digitalis glycosides or certain anti-arrhythmic medicinal products. The degree to which hydrochlorothiazide is removed by haemodialysis has not been established.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Angiotensin II antagonists, plain (valsartan), combinations with dihydropyridine derivatives (amlodipine) and thiazide diuretics (hydrochlorothiazide), ATC code: C09DX01 valsartan, amlodipine and hydrochlorothiazide.

Imprida HCT combines three antihypertensive compounds with complementary mechanisms to control blood pressure in patients with essential hypertension: amlodipine belongs to the calcium antagonist class and valsartan to the angiotensin II antagonist class of medicines and hydrochlorothiazide belongs to the thiazide diuretics class of medicines. The combination of these substances has an additive antihypertensive effect.

Amlodipine/Valsartan/Hydrochlorothiazide
Imprida HCT was studied in a double-blind, active controlled study in hypertensive patients. A total of 2,271 patients with moderate to severe hypertension (mean baseline systolic/diastolic blood pressure was 170/107 mmHg) received treatments of amlodipine/valsartan/hydrochlorothiazide 10 mg/320 mg/25 mg, valsartan/hydrochlorothiazide 320 mg/25 mg, amlodipine/valsartan 10 mg/320 mg, or hydrochlorothiazide/amlodipine 25 mg/10 mg. At study initiation patients were assigned lower doses of their treatment combination and were titrated to their full treatment dose by week 2.

At week 8, the mean reductions in systolic/diastolic blood pressure were 39.7/24.7 mmHg with Imprida HCT, 32.0/19.7 mmHg with valsartan/hydrochlorothiazide, 33.5/21.5 mmHg with amlodipine/valsartan, and 31.5/19.5 mmHg with amlodipine/hydrochlorothiazide. The triple combination therapy was statistically superior to each of the three dual combination treatments in reduction of diastolic and systolic blood pressures. The reductions in systolic/diastolic blood pressure with Imprida HCT were 7.6/5.0 mmHg greater than with valsartan/hydrochlorothiazide, 6.2/3.3 mmHg greater than with amlodipine/valsartan, and 8.2/5.3 mmHg greater than with amlodipine/hydrochlorothiazide. The full blood pressure lowering effect was achieved 2 weeks after being on their maximal dose of Imprida HCT. Statistically greater proportions of patients achieved blood pressure control (<140/90 mmHg) with Imprida HCT (71%) compared to each of the three dual combination therapies (45-54%) (p<0.0001).

In a subgroup of 283 patients focusing on ambulatory blood pressure monitoring, clinically and statistically superior reductions in 24-hour systolic and diastolic blood pressures were observed with the triple combination compared to valsartan/hydrochlorothiazide, valsartan/amlodipine, and hydrochlorothiazide/amlodipine.
**Amlodipine**

The amlodipine component of Imprida HCT inhibits the transmembrane entry of calcium ions into cardiac and vascular smooth muscle. The mechanism of the antihypertensive action of amlodipine is due to a direct relaxant effect on vascular smooth muscle, causing reductions in peripheral vascular resistance and in blood pressure. Experimental data suggest that amlodipine binds to both dihydropyridine and non-dihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels.

Following administration of therapeutic doses to patients with hypertension, amlodipine produces vasodilation, resulting in a reduction of supine and standing blood pressures. These decreases in blood pressure are not accompanied by a significant change in heart rate or plasma catecholamine levels with chronic dosing.

Plasma concentrations correlate with effect in both young and elderly patients.

In hypertensive patients with normal renal function, therapeutic doses of amlodipine resulted in a decrease in renal vascular resistance and increases in glomerular filtration rate and effective renal plasma flow, without change in filtration fraction or proteinuria.

**Valsartan**

Valsartan is an orally active, potent and specific angiotensin II receptor antagonist. It acts selectively on the receptor subtype AT₁, which is responsible for the known actions of angiotensin II.

Administration of valsartan to patients with hypertension results in a drop in blood pressure without affecting pulse rate.

In most patients, after administration of a single oral dose, onset of antihypertensive activity occurs within 2 hours, and the peak drop in blood pressure is achieved within 4-6 hours. The antihypertensive effect persists over 24 hours after administration. During repeated administration, the maximum reduction in blood pressure with any dose is generally attained within 2-4 weeks.

**Hydrochlorothiazide**

The site of action of thiazide diuretics is primarily in the renal distal convoluted tubule. It has been shown that there is a high-affinity receptor in the renal cortex as the primary binding site for the thiazide diuretic action and inhibition of NaCl transport in the distal convoluted tubule. The mode of action of thiazides is through inhibition of the Na⁺Cl⁻ symporter perhaps by competing for the Cl⁻ site, thereby affecting electrolyte reabsorption mechanisms: directly increasing sodium and chloride excretion to an approximately equal extent, and indirectly, by this diuretic action, reducing plasma volume, with consequent increases in plasma renin activity, aldosterone secretion and urinary potassium loss, and a decrease in serum potassium.

The European Medicines Agency has waived the obligation to submit the results of studies with Imprida HCT in all subsets of the paediatric population in essential hypertension. See section 4.2 for information on paediatric use.

### 5.2 Pharmacokinetic properties

**Linearity**

Amlodipine, valsartan and hydrochlorothiazide exhibit linear pharmacokinetics.

**Amlodipine/valsartan/hydrochlorothiazide**

Following oral administration of Imprida HCT in normal healthy adults, peak plasma concentrations of amlodipine, valsartan and hydrochlorothiazide are reached in 6-8 hours, 3 hours, and 2 hours, respectively. The rate and extent of absorption of amlodipine, valsartan and hydrochlorothiazide from Imprida HCT are the same as when administered as individual dosage forms.
Amlodipine

Absorption: After oral administration of therapeutic doses of amlodipine alone, peak plasma concentrations of amlodipine are reached in 6-12 hours. Absolute bioavailability has been calculated as between 64% and 80%. Amlodipine bioavailability is unaffected by food ingestion.

Distribution: Volume of distribution is approximately 21 l/kg. In vitro studies with amlodipine have shown that approximately 97.5% of circulating drug is bound to plasma proteins.

Biotransformation: Amlodipine is extensively (approximately 90%) metabolised in the liver to inactive metabolites.

Elimination: Amlodipine elimination from plasma is biphasic, with a terminal elimination half-life of approximately 30 to 50 hours. Steady-state plasma levels are reached after continuous administration for 7-8 days. Ten per cent of original amlodipine and 60% of amlodipine metabolites are excreted in urine.

Valsartan

Absorption: Following oral administration of valsartan alone, peak plasma concentrations of valsartan are reached in 2-4 hours. Mean absolute bioavailability is 23%. Food decreases exposure (as measured by AUC) to valsartan by about 40% and peak plasma concentration (Cmax) by about 50%, although from about 8 h post dosing plasma valsartan concentrations are similar for the fed and fasted groups. This reduction in AUC is not, however, accompanied by a clinically significant reduction in the therapeutic effect, and valsartan can therefore be given either with or without food.

Distribution: The steady-state volume of distribution of valsartan after intravenous administration is about 17 litres, indicating that valsartan does not distribute into tissues extensively. Valsartan is highly bound to serum proteins (94-97%), mainly serum albumin.

Biotransformation: Valsartan is not transformed to a high extent as only about 20% of dose is recovered as metabolites. A hydroxy metabolite has been identified in plasma at low concentrations (less than 10% of the valsartan AUC). This metabolite is pharmacologically inactive.

Elimination: Valsartan is primarily eliminated in faeces (about 83% of dose) and urine (about 13% of dose), mainly as unchanged drug. Following intravenous administration, plasma clearance of valsartan is about 2 l/h and its renal clearance is 0.62 l/h (about 30% of total clearance). The half-life of valsartan is 6 hours.

Hydrochlorothiazide

Absorption: The absorption of hydrochlorothiazide, after an oral dose, is rapid (Tmax about 2 hours). The increase in mean AUC is linear and dose proportional in the therapeutic range.

The effect of food on hydrochlorothiazide absorption, if any, has little clinical significance. Absolute bioavailability of hydrochlorothiazide is 70% after oral administration.

Distribution: The apparent volume of distribution is 4-8 l/kg. Circulating hydrochlorothiazide is bound to serum proteins (40-70%), mainly serum albumin. Hydrochlorothiazide also accumulates in erythrocytes at approximately 3 times the level in plasma.

Biotransformation: Hydrochlorothiazide is eliminated predominantly as unchanged compound.

Elimination: Hydrochlorothiazide is eliminated from plasma with a half-life averaging 6 to 15 hours in the terminal elimination phase. There is no change in the kinetics of hydrochlorothiazide on repeated dosing, and accumulation is minimal when dosed once daily. More than 95% of the absorbed dose is being excreted as unchanged compound in the urine. The renal clearance is composed of passive filtration and active secretion into the renal tubule.
Special populations

Pediatric patients (age below 18 years)
No pharmacokinetic data are available in the pediatric population.

Elderly (age 65 years or over)
Time to peak plasma amlodipine concentrations is similar in young and elderly patients. In elderly patients, amlodipine clearance tends to decline, causing increases in the area under the curve (AUC) and elimination half-life. Mean systemic AUC of valsartan is higher by 70% in the elderly than in the young, therefore caution is required when increasing the dosage.

Systemic exposure to valsartan is slightly elevated in the elderly as compared to the young, but this has not been shown to have any clinical significance.

Limited data suggest that the systemic clearance of hydrochlorothiazide is reduced in both healthy and hypertensive elderly subjects compared to young healthy volunteers.

Since the three components are equally well tolerated in younger and elderly patients, normal dose regimens are recommended (see section 4.2).

Renal impairment
The pharmacokinetics of amlodipine are not significantly influenced by renal impairment. As expected for a compound where renal clearance accounts for only 30% of total plasma clearance, no correlation was seen between renal function and systemic exposure to valsartan.

Patients with mild to moderate renal impairment may therefore receive the usual initial dose (see sections 4.2 and 4.4).

In the presence of renal impairment, mean peak plasma levels and AUC values of hydrochlorothiazide are increased and the urinary excretion rate is reduced. In patients with mild to moderate renal impairment, a 3-fold increase in hydrochlorothiazide AUC has been observed. In patients with severe renal impairment an 8-fold increase in AUC has been observed. Imprida HCT is contraindicated in patients with severe renal impairment, anuria or undergoing dialysis (see section 4.3).

Hepatic impairment
Patients with hepatic insufficiency have decreased clearance of amlodipine with resulting increase of approximately 40–60% in AUC. On average, in patients with mild to moderate chronic liver disease, exposure (measured by AUC values) to valsartan is twice that found in healthy volunteers (matched by age, sex and weight). Due to the valsartan component, Imprida HCT is contraindicated in patients with hepatic impairment (see sections 4.2 and 4.3).

5.3 Preclinical safety data
Amlodipine/Valsartan/Hydrochlorothiazide
In a variety of preclinical safety studies conducted in several animal species with amlodipine, valsartan, hydrochlorothiazide, valsartan/hydrochlorothiazide, amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide (Imprida HCT), there was no evidence of systemic or target organ toxicity that would adversely affect the development of Imprida HCT for clinical use in humans.

Preclinical safety studies of up to 13 weeks in duration were conducted with amlodipine/valsartan/hydrochlorothiazide in rats. The combination resulted in expected reduction of red blood cell mass (erythrocytes, haemoglobin, haematocrit, and reticulocytes), increase in serum urea, increase in serum creatinine, increase in serum potassium, juxtaglomerular (JG) hyperplasia in the kidney and focal erosions in the glandular stomach in rats. All these changes were reversible after a 4-week recovery period and were considered to be exaggerated pharmacological effects.
The amlodipine/valsartan/hydrochlorothiazide combination was not tested for genotoxicity or carcinogenicity as there was no evidence of any interaction between these substances, which have been on the market for a long time. However, amlodipine, valsartan and hydrochlorothiazide have been tested individually for genotoxicity and carcinogenicity with negative results.

**Amlodipine**

**Reproductive toxicology**

Reproductive studies in rats and mice have shown delayed date of delivery, prolonged duration of labour and decreased pup survival at dosages approximately 50 times greater than the maximum recommended dosage for humans based on mg/kg.

**Impairment of fertility**

There was no effect on the fertility of rats treated with amlodipine (males for 64 days and females 14 days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human dose of 10 mg on a mg/m² basis). In another rat study in which male rats were treated with amlodipine besilate for 30 days at a dose comparable with the human dose based on mg/kg, decreased plasma follicle-stimulating hormone and testosterone were found as well as decreases in sperm density and in the number of mature spermatids and Sertoli cells.

**Carcinogenesis, mutagenesis**

Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity. The highest dose (for mice, similar to, and for rats twice* the maximum recommended clinical dose of 10 mg on a mg/m² basis) was close to the maximum tolerated dose for mice but not for rats.

Mutagenicity studies revealed no drug related effects at either the gene or chromosome levels.

* Based on patient weight of 50 kg

**Valsartan**

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential.

In rats, maternally toxic doses (600 mg/kg/day) during the last days of gestation and lactation led to lower survival, lower weight gain and delayed development (pinna detachment and ear-canal opening) in the offspring (see section 4.6). These doses in rats (600 mg/kg/day) are approximately 18 times the maximum recommended human dose on a mg/m² basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).

In non-clinical safety studies, high doses of valsartan (200 to 600 mg/kg body weight) caused in rats a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit) and evidence of changes in renal haemodynamics (slightly raised plasma urea, and renal tubular hyperplasia and basophilia in males). These doses in rats (200 and 600 mg/kg/day) are approximately 6 and 18 times the maximum recommended human dose on a mg/m² basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).

In marmosets at similar doses, the changes were similar though more severe, particularly in the kidney where the changes developed to a nephropathy which included raised urea and creatinine.

Hypertrophy of the renal juxtaglomerular cells was also seen in both species. All changes were considered to be caused by the pharmacological action of valsartan which produces prolonged hypotension, particularly in marmosets. For therapeutic doses of valsartan in humans, the hypertrophy of the renal juxtaglomerular cells does not seem to have any relevance.
6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core
Cellulose microcrystalline
Crospovidone
Silica, colloidal anhydrous
Magnesium stearate

Coating
Hypromellose
Macrogol 4000
Talc
Iron oxide, yellow (E172)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

2 years

6.4 Special precautions for storage

Do not store above 30°C.

Store in the original package in order to protect from moisture.

6.5 Nature and contents of container

PVC/PVDC blisters. One blister contains 7, 10 or 14 film-coated tablets.
Pack sizes: 14, 28, 30, 56, 90, 98 or 280 film-coated tablets.
Multipacks of 280 tablets, comprising 20 cartons, each containing 14 tablets.

PVC/PVDC perforated unit dose blisters for hospital use:
Pack sizes: 56, 98 or 280 film-coated tablets
Multipacks of 280 tablets, comprising 4 cartons, each containing 70 tablets.

Not all pack sizes or strengths may be marketed.

6.6 Special precautions for disposal and other handling

No special requirements.

7. MARKETING AUTHORISATION HOLDER

Novartis Europharm Limited
Wimblehurst Road
Horsham
West Sussex, RH12 5AB
United Kingdom
8. MARKETING AUTHORISATION NUMBER(S)

EU/1/09/570/049-060

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

15.10.2009

10. DATE OF REVISION OF THE TEXT

Detailed information on this product is available on the website of the European Medicines Agency http://www.ema.europa.eu

Medicinal product no longer authorised
ANNEX II

A. MANUFACTURING AUTHORIZATION HOLDER RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OF THE MARKETING AUTHORIZATION
A. MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer responsible for batch release

Novartis Pharma GmbH
Roonstrasse 25
D-90429 Nürnberg
Germany

B. CONDITIONS OF THE MARKETING AUTHORISATION

- CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE MARKETING AUTHORISATION HOLDER

Medicinal product subject to medical prescription.

- CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

Not applicable.

- OTHER CONDITIONS

Pharmacovigilance system
The MAH must ensure that the system of pharmacovigilance, presented in Module 1.8.1. of the Marketing Authorisation, is in place and functioning before and whilst the product is on the market.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON OF UNIT PACK

1. NAME OF THE MEDICINAL PRODUCT

Imprida HCT 5 mg/160 mg/12.5 mg film-coated tablets
amlodipine/valsartan/hydrochlorothiazide

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 5 mg amlodipine (as amlodipine besylate), 160 mg valsartan and 12.5 mg hydrochlorothiazide.

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

14 film-coated tablets
28 film-coated tablets
30 film-coated tablets
56 film-coated tablets
56 x 1 film-coated tablet (unit dose)
90 film-coated tablets
98 film-coated tablets
98 x 1 film-coated tablet (unit dose)
280 film-coated tablets
280 x 1 film-coated tablet (unit dose)

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use
Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP
9. SPECIAL STORAGE CONDITIONS

Do not store above 30°C.
Store in the original package in order to protect from moisture.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Novartis Europharm Limited
Wimblehurst Road
Horsham
West Sussex, RH12 5AB
United Kingdom

12. MARKETING AUTHORISATION NUMBER(S)

<table>
<thead>
<tr>
<th>Marketing Authorisation number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU/1/09/570/001</td>
<td>14 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/002</td>
<td>28 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/003</td>
<td>30 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/004</td>
<td>56 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/005</td>
<td>90 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/006</td>
<td>98 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/007</td>
<td>280 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/008</td>
<td>56 x 1 film-coated tablet (unit dose)</td>
</tr>
<tr>
<td>EU/1/09/570/009</td>
<td>98 x 1 film-coated tablet (unit dose)</td>
</tr>
<tr>
<td>EU/1/09/570/010</td>
<td>280 x 1 film-coated tablet (unit dose)</td>
</tr>
</tbody>
</table>

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Imprida HCT 5 mg/160 mg/12.5 mg
**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX)**

1. **NAME OF THE MEDICINAL PRODUCT**

   Imprida HCT 5 mg/160 mg/12.5 mg film-coated tablets
   amlodipine/valsartan/hydrochlorothiazide

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**

   Each tablet contains 5 mg amlodipine (as amlodipine besylate), 160 mg valsartan and 12.5 mg hydrochlorothiazide.

3. **LIST OF EXCIPIENTS**

4. **PHARMACEUTICAL FORM AND CONTENTS**

   14 film-coated tablets
   Component of a multipack comprising 20 cartons, each containing 14 tablets.
   70 film-coated tablets
   Component of a multipack comprising 4 cartons, each containing 70 tablets.

5. **METHOD AND ROUTE(S) OF ADMINISTRATION**

   Oral use
   Read the package leaflet before use.

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN**

   Keep out of the reach and sight of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. **EXPIRY DATE**

   EXP

9. **SPECIAL STORAGE CONDITIONS**

   Do not store above 30°C.
   Store in the original package in order to protect from moisture.
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Novartis Europharm Limited
Wimblehurst Road
Horsham
West Sussex, RH12 5AB
United Kingdom

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/09/570/012 280 film-coated tablets (multipack, 20 cartons of 14 tablets)
EU/1/09/570/011 280 film-coated tablets (multipack, 4 cartons of 70 tablets) (unit dose)

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Imprida HCT 5 mg/160 mg/12.5 mg
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON OF MULTIPACK (WITH BLUE BOX)

1. NAME OF THE MEDICINAL PRODUCT

Imprida HCT 5 mg/160 mg/12.5 mg film-coated tablets
amlodipine/valsartan/hydrochlorothiazide

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 5 mg amlodipine (as amlodipine besylate), 160 mg valsartan and 12.5 mg hydrochlorothiazide.

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

280 film-coated tablets
Multipack comprising 20 cartons each containing 14 tablets.
Multipack comprising 4 cartons, each containing 70 tablets.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use
Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Do not store above 30°C.
Store in the original package in order to protect from moisture.
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Novartis Europharm Limited
Wimblehurst Road
Horsham
West Sussex, RH12 5AB
United Kingdom

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/09/570/012 280 film-coated tablets (multipack, 20 cartons of 14 tablets)
EU/1/09/570/011 280 film-coated tablets (multipack, 4 cartons of 70 tablets) (unit dose)

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Imprida HCT 5 mg/160 mg/12.5 mg
### MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

#### BLISTERS

1. **NAME OF THE MEDICINAL PRODUCT**

   Imprida HCT 5 mg/160 mg/12.5 mg film-coated tablets
   amlodipine/valsartan/hydrochlorothiazide

2. **NAME OF THE MARKETING AUTHORIZATION HOLDER**

   Novartis Europharm Limited

3. **EXPIRY DATE**

   EXP

4. **BATCH NUMBER**

   Lot

5. **OTHER**

   Medicinal product no longer authorised
**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**CARTON OF UNIT PACK**

1. **NAME OF THE MEDICINAL PRODUCT**

   Imprida HCT 10 mg/160 mg/12.5 mg film-coated tablets
   amlodipine/valsartan/hydrochlorothiazide

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**

   Each tablet contains 10 mg amlodipine (as amlodipine besylate), 160 mg valsartan and 12.5 mg hydrochlorothiazide.

3. **LIST OF EXCIPIENTS**

4. **PHARMACEUTICAL FORM AND CONTENTS**

   - 14 film-coated tablets
   - 28 film-coated tablets
   - 30 film-coated tablets
   - 56 film-coated tablets
   - 56 x 1 film-coated tablet (unit dose)
   - 90 film-coated tablets
   - 98 film-coated tablets
   - 98 x 1 film-coated tablet (unit dose)
   - 280 film-coated tablets
   - 280 x 1 film-coated tablet (unit dose)

5. **METHOD AND ROUTE(S) OF ADMINISTRATION**

   Oral use
   Read the package leaflet before use.

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN**

   Keep out of the reach and sight of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. **EXPIRY DATE**

   EXP
9. **SPECIAL STORAGE CONDITIONS**

Do not store above 30°C.
Store in the original package in order to protect from moisture.

10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited
Wimblehurst Road
Horsham
West Sussex, RH12 5AB
United Kingdom

12. **MARKETING AUTHORISATION NUMBER(S)**

<table>
<thead>
<tr>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU/1/09/570/013</td>
<td>14 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/014</td>
<td>28 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/015</td>
<td>30 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/016</td>
<td>56 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/017</td>
<td>90 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/018</td>
<td>98 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/019</td>
<td>280 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/020</td>
<td>56 x 1 film-coated tablet (unit dose)</td>
</tr>
<tr>
<td>EU/1/09/570/021</td>
<td>98 x 1 film-coated tablet (unit dose)</td>
</tr>
<tr>
<td>EU/1/09/570/022</td>
<td>280 x 1 film-coated tablet (unit dose)</td>
</tr>
</tbody>
</table>

13. **BATCH NUMBER**

Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

Medicinal product subject to medical prescription.

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Imprida HCT 10 mg/160 mg/12.5 mg
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX)

1. **NAME OF THE MEDICINAL PRODUCT**

Imprida HCT 10 mg/160 mg/12.5 mg film-coated tablets
amlodipine/valsartan/hydrochlorothiazide

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**

Each tablet contains 10 mg amlodipine (as amlodipine besylate), 160 mg valsartan and 12.5 mg hydrochlorothiazide.

3. **LIST OF EXCIPIENTS**

4. **PHARMACEUTICAL FORM AND CONTENTS**

14 film-coated tablets
Component of a multipack comprising 20 cartons, each containing 14 tablets.
70 film-coated tablets
Component of a multipack comprising 4 cartons, each containing 70 tablets.

5. **METHOD AND ROUTE(S) OF ADMINISTRATION**

Oral use
Read the package leaflet before use.

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN**

Keep out of the reach and sight of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. **EXPIRY DATE**

EXP

9. **SPECIAL STORAGE CONDITIONS**

Do not store above 30°C.
Store in the original package in order to protect from moisture.
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Novartis Europharm Limited
Wimblehurst Road
Horsham
West Sussex, RH12 5AB
United Kingdom

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/09/570/024 280 film-coated tablets (multipack, 20 cartons of 14 tablets)
EU/1/09/570/023 280 film-coated tablets (multipack, 4 cartons of 70 tablets) (unit dose)

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Imprida HCT 10 mg/160 mg/12.5 mg

Medicinal product no longer authorised
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON OF MULTIPACK (WITH BLUE BOX)

1. NAME OF THE MEDICINAL PRODUCT

Imprida HCT 10 mg/160 mg/12.5 mg film-coated tablets
amlodipine/valsartan/hydrochlorothiazide

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 10 mg amlodipine (as amlodipine besylate), 160 mg valsartan and 12.5 mg hydrochlorothiazide.

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

280 film-coated tablets
Multipack comprising 20 cartons each containing 14 tablets,
Multipack comprising 4 cartons, each containing 70 tablets.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use
Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Do not store above 30°C.
Store in the original package in order to protect from moisture.
10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited
Wimblehurst Road
Horsham
West Sussex, RH12 5AB
United Kingdom

12. **MARKETING AUTHORISATION NUMBER(S)**

EU/1/09/570/024 280 film-coated tablets (multipack, 20 cartons of 14 tablets)
EU/1/09/570/023 280 film-coated tablets (multipack, 4 cartons of 70 tablets) (unit dose)

13. **BATCH NUMBER**

Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

Medicinal product subject to medical prescription.

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Imprida HCT 10 mg/160 mg/12.5 mg
### MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

#### BLISTERS

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. NAME OF THE MEDICINAL PRODUCT</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Imprida HCT 10 mg/160 mg/12.5 mg film-coated tablets amlodipine/valsartan/hydrochlorothiazide</td>
</tr>
<tr>
<td><strong>2. NAME OF THE MARKETING AUTHORITY HELD</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Novartis Europharm Limited</td>
</tr>
<tr>
<td><strong>3. EXPIRY DATE</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>EXP</td>
</tr>
<tr>
<td><strong>4. BATCH NUMBER</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lot</td>
</tr>
<tr>
<td><strong>5. OTHER</strong></td>
<td>Medicinal product no longer authorised</td>
</tr>
</tbody>
</table>
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
CARTON OF UNIT PACK

1. NAME OF THE MEDICINAL PRODUCT

Imprida HCT 5 mg/160 mg/25 mg film-coated tablets
amlodipine/valsartan/hydrochlorothiaziade

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 5 mg amlodipine (as amlodipine besylate), 160 mg valsartan and 25 mg hydrochlorothiazide.

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

14 film-coated tablets
28 film-coated tablets
30 film-coated tablets
56 film-coated tablets
56 x 1 film-coated tablet (unit dose)
90 film-coated tablets
98 film-coated tablets
98 x 1 film-coated tablet (unit dose)
280 film-coated tablets
280 x 1 film-coated tablet (unit dose)

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use
Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP
9. SPECIAL STORAGE CONDITIONS

Do not store above 30°C.
Store in the original package in order to protect from moisture.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Novartis Europharm Limited
Wimblehurst Road
Horsham
West Sussex, RH12 5AB
United Kingdom

12. MARKETING AUTHORISATION NUMBER(S)

<table>
<thead>
<tr>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU/1/09/570/025</td>
<td>14 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/026</td>
<td>28 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/027</td>
<td>30 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/028</td>
<td>56 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/029</td>
<td>90 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/030</td>
<td>98 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/031</td>
<td>280 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/032</td>
<td>56 x 1 film-coated tablet (unit dose)</td>
</tr>
<tr>
<td>EU/1/09/570/033</td>
<td>98 x 1 film-coated tablet (unit dose)</td>
</tr>
<tr>
<td>EU/1/09/570/034</td>
<td>280 x 1 film-coated tablet (unit dose)</td>
</tr>
</tbody>
</table>

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Imprida HCT 5 mg/160 mg/25 mg
### PARTICULARS TO APPEAR ON THE OUTER PACKAGING

**INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX)**

<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imprida HCT 5 mg/160 mg/25 mg film-coated tablets amlodipine/valsartan/hydrochlorothiazide</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. STATEMENT OF ACTIVE SUBSTANCE(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Each tablet contains 5 mg amlodipine (as amlodipine besylate), 160 mg valsartan and 25 mg hydrochlorothiazide.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. LIST OF EXCIPIENTS</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>4. PHARMACEUTICAL FORM AND CONTENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>14 film-coated tablets Component of a multipack comprising 20 cartons, each containing 14 tablets.</td>
</tr>
<tr>
<td>70 film-coated tablets Component of a multipack comprising 4 cartons, each containing 70 tablets.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. METHOD AND ROUTE(S) OF ADMINISTRATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral use Read the package leaflet before use.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keep out of the reach and sight of children.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>7. OTHER SPECIAL WARNING(S), IF NECESSARY</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>8. EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>9. SPECIAL STORAGE CONDITIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do not store above 30°C. Store in the original package in order to protect from moisture.</td>
</tr>
</tbody>
</table>
10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited  
Wimbledon Road  
Horsham  
West Sussex, RH12 5AB  
United Kingdom

12. **MARKETING AUTHORISATION NUMBER(S)**

EU/1/09/570/036  280 film-coated tablets (multipack, 20 cartons of 14 tablets)  
EU/1/09/570/035  280 film-coated tablets (multipack, 4 cartons of 70 tablets) (unit dose)

13. **BATCH NUMBER**

Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

Medicinal product subject to medical prescription.

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Imprida HCT 5 mg/160 mg/25 mg

Medicinal product no longer authorised
### PARTICULARS TO APPEAR ON THE OUTER PACKAGING

**OUTER CARTON OF MULTIPACK (WITH BLUE BOX)**

<table>
<thead>
<tr>
<th>1. <strong>NAME OF THE MEDICINAL PRODUCT</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Imprida HCT 5 mg/160 mg/25 mg film-coated tablets</td>
</tr>
<tr>
<td>amlodipine/valsartan/hydrochlorothiazide</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. <strong>STATEMENT OF ACTIVE SUBSTANCE(S)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Each tablet contains 5 mg amlodipine (as amlodipine besylate), 160 mg valsartan and 25 mg hydrochlorothiazide.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. <strong>LIST OF EXCIPIENTS</strong></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>4. <strong>PHARMACEUTICAL FORM AND CONTENTS</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>280 film-coated tablets</td>
</tr>
<tr>
<td>Multipack comprising 20 cartons each containing 14 tablets.</td>
</tr>
<tr>
<td>Multipack comprising 4 cartons, each containing 70 tablets.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. <strong>METHOD AND ROUTE(S) OF ADMINISTRATION</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral use</td>
</tr>
<tr>
<td>Read the package leaflet before use.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. <strong>SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Keep out of the reach and sight of children.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>7. <strong>OTHER SPECIAL WARNING(S), IF NECESSARY</strong></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>8. <strong>EXPIRY DATE</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>9. <strong>SPECIAL STORAGE CONDITIONS</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Do not store above 30°C.</td>
</tr>
<tr>
<td>Store in the original package in order to protect from moisture.</td>
</tr>
</tbody>
</table>
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Novartis Europharm Limited
Wimblehurst Road
Horsham
West Sussex, RH12 5AB
United Kingdom

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/09/570/036 280 film-coated tablets (multipack, 20 cartons of 14 tablets)
EU/1/09/570/035 280 film-coated tablets (multipack, 4 cartons of 70 tablets) (unit dose)

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Imprida HCT 5 mg/160 mg/25 mg
1. **NAME OF THE MEDICINAL PRODUCT**

   Imprida HCT 5 mg/160 mg/25 mg film-coated tablets
   amlodipine/valsartan/hydrochlorothiazide

2. **NAME OF THE MARKETING AUTHORISATION HOLDER**

   Novartis Europharm Limited

3. **EXPIRY DATE**

   EXP

4. **BATCH NUMBER**

   Lot

5. **OTHER**

   Medicinal product no longer authorised
1. NAME OF THE MEDICINAL PRODUCT

Imprida HCT 10 mg/160 mg/25 mg film-coated tablets
amlodipine/valsartan/hydrochlorothiazide

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 10 mg amlodipine (as amlodipine besylate), 160 mg valsartan and 25 mg hydrochlorothiazide.

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

14 film-coated tablets
28 film-coated tablets
30 film-coated tablets
56 film-coated tablets
56 x 1 film-coated tablet (unit dose)
90 film-coated tablets
98 film-coated tablets
98 x 1 film-coated tablet (unit dose)
280 film-coated tablets
280 x 1 film-coated tablet (unit dose)

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use
Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP
9. SPECIAL STORAGE CONDITIONS

Do not store above 30°C.
Store in the original package in order to protect from moisture.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Novartis Europharm Limited
Wimblehurst Road
Horsham
West Sussex, RH12 5AB
United Kingdom

12. MARKETING AUTHORISATION NUMBER(S)

<table>
<thead>
<tr>
<th>Marketing Authorisation Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU/1/09/570/037</td>
<td>14 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/038</td>
<td>28 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/039</td>
<td>30 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/040</td>
<td>56 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/041</td>
<td>90 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/042</td>
<td>98 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/043</td>
<td>280 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/044</td>
<td>56 x 1 film-coated tablet (unit dose)</td>
</tr>
<tr>
<td>EU/1/09/570/045</td>
<td>98 x 1 film-coated tablet (unit dose)</td>
</tr>
<tr>
<td>EU/1/09/570/046</td>
<td>280 x 1 film-coated tablet (unit dose)</td>
</tr>
</tbody>
</table>

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Imprida HCT 10 mg/160 mg/25 mg
### PARTICULARS TO APPEAR ON THE OUTER PACKAGING

**INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX)**

### 1. NAME OF THE MEDICINAL PRODUCT

Imprida HCT 10 mg/160 mg/25 mg film-coated tablets
amlodipine/valsartan/hydrochlorothiazide

### 2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 10 mg amlodipine (as amlodipine besylate), 160 mg valsartan and 25 mg hydrochlorothiazide.

### 3. LIST OF EXCIPIENTS

### 4. PHARMACEUTICAL FORM AND CONTENTS

14 film-coated tablets
Component of a multipack comprising 20 cartons, each containing 14 tablets.
70 film-coated tablets
Component of a multipack comprising 4 cartons, each containing 70 tablets.

### 5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use
Read the package leaflet before use.

### 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

### 7. OTHER SPECIAL WARNING(S), IF NECESSARY

### 8. EXPIRY DATE

EXP

### 9. SPECIAL STORAGE CONDITIONS

Do not store above 30°C.
Store in the original package in order to protect from moisture.
10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited  
Wimblehurst Road  
Horsham  
West Sussex, RH12 5AB  
United Kingdom

12. **MARKETING AUTHORISATION NUMBER(S)**

EU/1/09/570/048  280 film-coated tablets (multipack, 20 cartons of 14 tablets)  
EU/1/09/570/047  280 film-coated tablets (multipack, 4 cartons of 70 tablets) (unit dose)

13. **BATCH NUMBER**

Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

Medicinal product subject to medical prescription.

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Imprida HCT 10 mg/160 mg/25 mg
## PARTICULARS TO APPEAR ON THE OUTER PACKAGING
### OUTER CARTON OF MULTIPACK (WITH BLUE BOX)

### 1. NAME OF THE MEDICINAL PRODUCT

Imprida HCT 10 mg/160 mg/25 mg film-coated tablets 
amlodipine/valsartan/hydrochlorothiazide

### 2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 10 mg amlodipine (as amlodipine besylate), 160 mg valsartan and 25 mg 
hydrochlorothiazide.

### 3. LIST OF EXCIPIENTS

### 4. PHARMACEUTICAL FORM AND CONTENTS

280 film-coated tablets
Multipack comprising 20 cartons each containing 14 tablets.
Multipack comprising 4 cartons, each containing 70 tablets.

### 5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use
Read the package leaflet before use.

### 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

### 7. OTHER SPECIAL WARNING(S), IF NECESSARY

### 8. EXPIRY DATE

EXP

### 9. SPECIAL STORAGE CONDITIONS

Do not store above 30°C.
Store in the original package in order to protect from moisture.
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Novartis Europharm Limited
Wimblehurst Road
Horsham
West Sussex, RH12 5AB
United Kingdom

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/09/570/048 280 film-coated tablets (multipack, 20 cartons of 14 tablets)
EU/1/09/570/047 280 film-coated tablets (multipack, 4 cartons of 70 tablets) (unit dose)

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Imprida HCT 10 mg/160 mg/25 mg
### MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

#### BLISTERS

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. NAME OF THE MEDICINAL PRODUCT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imprida HCT 10 mg/160 mg/25 mg film-coated tablets</td>
<td></td>
<td></td>
</tr>
<tr>
<td>amlodipine/valsartan/hydrochlorothiazide</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>2. NAME OF THE MARKETING AUTHORISATION HOLDER</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Novartis Europharm Limited</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>3. EXPIRY DATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EXP</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>4. BATCH NUMBER</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lot</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>5. OTHER</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medicinal product no longer authorised</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
CARTON OF UNIT PACK

1. NAME OF THE MEDICINAL PRODUCT

Imprida HCT 10 mg/320 mg/25 mg film-coated tablets
amlodipine/valsartan/hydrochlorothiazide

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 10 mg amlodipine (as amlodipine besylate), 320 mg valsartan and 25 mg hydrochlorothiazide.

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

14 film-coated tablets
28 film-coated tablets
30 film-coated tablets
56 film-coated tablets
56 x 1 film-coated tablet (unit dose)
90 film-coated tablets
98 film-coated tablets
98 x 1 film-coated tablet (unit dose)
280 film-coated tablets
280 x 1 film-coated tablet (unit dose)

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use
Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP
9. **SPECIAL STORAGE CONDITIONS**

Do not store above 30°C.
Store in the original package in order to protect from moisture.

10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited
Wimblehurst Road
Horsham
West Sussex, RH12 5AB
United Kingdom

12. **MARKETING AUTHORISATION NUMBER(S)**

<table>
<thead>
<tr>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU/1/09/570/049</td>
<td>14 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/050</td>
<td>28 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/051</td>
<td>30 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/052</td>
<td>56 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/053</td>
<td>90 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/054</td>
<td>98 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/055</td>
<td>280 film-coated tablets</td>
</tr>
<tr>
<td>EU/1/09/570/056</td>
<td>56 x 1 film-coated tablet (unit dose)</td>
</tr>
<tr>
<td>EU/1/09/570/057</td>
<td>98 x 1 film-coated tablet (unit dose)</td>
</tr>
<tr>
<td>EU/1/09/570/058</td>
<td>280 x 1 film-coated tablet (unit dose)</td>
</tr>
</tbody>
</table>

13. **BATCH NUMBER**

Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

Medicinal product subject to medical prescription.

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Imprida HCT 10 mg/320 mg/25 mg
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX)

1. **NAME OF THE MEDICINAL PRODUCT**

   Imprida HCT 10 mg/320 mg/25 mg film-coated tablets
   amlodipine/valsartan/hydrochlorothiazide

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**

   Each tablet contains 10 mg amlodipine (as amlodipine besylate), 320 mg valsartan and 25 mg hydrochlorothiazide.

3. **LIST OF EXCIPIENTS**

4. **PHARMACEUTICAL FORM AND CONTENTS**

   14 film-coated tablets
   Component of a multipack comprising 20 cartons, each containing 14 tablets.
   70 film-coated tablets
   Component of a multipack comprising 4 cartons, each containing 70 tablets.

5. **METHOD AND ROUTE(S) OF ADMINISTRATION**

   Oral use
   Read the package leaflet before use.

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN**

   Keep out of the reach and sight of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. **EXPIRY DATE**

   EXP

9. **SPECIAL STORAGE CONDITIONS**

   Do not store above 30°C.
   Store in the original package in order to protect from moisture.
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORIZATION HOLDER

Novartis Europharm Limited
Wimblehurst Road
Horsham
West Sussex, RH12 5AB
United Kingdom

12. MARKETING AUTHORIZATION NUMBER(S)

EU/1/09/570/060 280 film-coated tablets (multipack, 20 cartons of 14 tablets)
EU/1/09/570/059 280 film-coated tablets (multipack, 4 cartons of 70 tablets) (unit dose)

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Imprida HCT 10/mg/320 mg/25 mg
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON OF MULTIPACK (WITH BLUE BOX)

1. NAME OF THE MEDICINAL PRODUCT

Imprida HCT 10 mg/320 mg/25 mg film-coated tablets
amlodipine/valsartan/hydrochlorothiazide

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 10 mg amlodipine (as amlodipine besylate), 320 mg valsartan and 25 mg hydrochlorothiazide.

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

280 film-coated tablets
Multipack comprising 20 cartons each containing 14 tablets, each containing 70 tablets.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use
Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Do not store above 30°C.
Store in the original package in order to protect from moisture.
10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited
Wimblehurst Road
Horsham
West Sussex, RH12 5AB
United Kingdom

12. **MARKETING AUTHORISATION NUMBER(S)**

<table>
<thead>
<tr>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU/1/09/570/060</td>
<td>280 film-coated tablets (multipack, 20 cartons of 14 tablets)</td>
</tr>
<tr>
<td>EU/1/09/570/059</td>
<td>280 film-coated tablets (multipack, 4 cartons of 70 tablets)</td>
</tr>
</tbody>
</table>

13. **BATCH NUMBER**

Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

Medicinal product subject to medical prescription.

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Imprida HCT 10 mg/320 mg/25 mg
**MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS**

**BLISTERS**

<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT</th>
<th>Imprida HCT 10 mg/320 mg/25 mg film-coated tablets amlodipine/valsartan/hydrochlorothiazide</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. NAME OF THE MARKETING AUTHORISATION HOLDER</td>
<td>Novartis Europharm Limited</td>
</tr>
<tr>
<td>3. EXPIRY DATE</td>
<td>EXP</td>
</tr>
<tr>
<td>4. BATCH NUMBER</td>
<td>Lot</td>
</tr>
<tr>
<td>5. OTHER</td>
<td>Medicinal product no longer authorised</td>
</tr>
</tbody>
</table>
B. PACKAGE LEAFLET
Imprida HCT tablets contain three substances called amlodipine, valsartan and hydrochlorothiazide. All of these substances help to control high blood pressure.

- Amlodipine belongs to a group of substances called “calcium channel blockers”. Amlodipine stops calcium from moving into the blood vessel wall, which stops the blood vessels from tightening.
- Valsartan belongs to a group of substances called “angiotensin-II receptor antagonists”. Angiotensin II is produced by the body and makes the blood vessels tighten, thus increasing the blood pressure. Valsartan works by blocking the effect of angiotensin II.
- Hydrochlorothiazide belongs to a group of substances called “thiazide diuretics”. Hydrochlorothiazide increases urine output, which also lowers blood pressure. As a result of all three mechanisms, the blood vessels relax and blood pressure is lowered.

Imprida HCT is used to treat high blood pressure in adult patients who are already taking amlodipine, valsartan and hydrochlorothiazide and who may benefit from taking one tablet containing all three substances.

2. BEFORE YOU TAKE IMPRIDA HCT

Do not take Imprina HCT

- if you are more than 3 months pregnant. (It is also better to avoid Imprina HCT in early pregnancy – see Pregnancy section).
- if you are allergic (hypersensitive) to amlodipine, valsartan, hydrochlorothiazide, sulphonamide-derived medicines (medicines used to treat chest or urinary infections), or any of the other ingredients of Imprina HCT (see section 6, “What Imprina HCT contains”). If you think you may be allergic, do not take Imprina HCT and talk to your doctor.
- if you have liver disease, destruction of the small bile ducts within the liver (biliary cirrhosis) leading to the build up of bile in the liver (cholestasis).
- if you have severe kidney problems or if you are having dialysis.
- if you are unable to produce urine (anuria).
— if the level of potassium or sodium in your blood is too low despite treatment.
— if the level of calcium in your blood is too high despite treatment.
— if you have gout (uric acid crystals in the joints).

If any of the above applies to you, do not take Imprida HCT and talk to your doctor.

Take special care with Imprida HCT
— if you have a low level of potassium or magnesium in your blood (with or without symptoms such as muscle weakness, muscle spasms, abnormal heart rhythm).
— if you have a low level of sodium in your blood (with or without symptoms such as tiredness, confusion, muscle twitching, convulsions).
— if you have a high level of calcium in your blood (with or without symptoms such as nausea, vomiting, constipation, stomach pain, frequent urination, thirst, muscle weakness and twitching).
— if you are taking medicines or substances that increase the amount of potassium in your blood. These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines and heparin. It may be necessary to check the amount of potassium in your blood at regular intervals.
— if you have kidney problems, have had a kidney transplant or if you had been told that you have a narrowing of your kidney arteries.
— if you have liver problems.
— if you have or have had heart failure or coronary artery disease, particularly if you are taking the maximum dose of Imprida HCT (10 mg/320 mg/25 mg).
— if your doctor has told you that you have a narrowing of the valves in your heart (called “aortic or mitral stenosis”) or that the thickness of your heart muscle is abnormally increased (called “obstructive hypertrophic cardiomyopathy”).
— if you suffer from aldosteronism. This is a disease in which the adrenal glands make too much of the hormone aldosterone. If this applies to you, the use of Imprida HCT is not recommended.
— if you suffer from a disease called systemic lupus erythematosus (also called “lupus” or “SLE”).
— if you have diabetes (high level of sugar in your blood).
— if you have high levels of cholesterol or triglycerides in your blood.
— if you experience skin reactions such as rash after sun exposure.
— if you had an allergic reaction to other high blood pressure medicines or diuretics (a type of medicine also known as “water tablets”), especially if you suffer from asthma and allergies.
— if you have been sick (vomiting or diarrhoea).
— if you experience dizziness and/or fainting during treatment with Imprida HCT, tell your doctor as soon as possible.
— if you experience a decrease in vision or eye pain. These could be symptoms of an increase of pressure in your eye and can happen within hours to a week of taking Imprida HCT. This can lead to permanent vision impairment, if not treated.

If any of these apply to you, talk to your doctor.

You must tell your doctor if you think that you are (or might become) pregnant. Imprida HCT is not recommended in early pregnancy and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at this stage (see section “Pregnancy and breast-feeding”).

The use of Imprida HCT in children and adolescents under 18 years of age is not recommended.

Imprida HCT and older people (age 65 years and older)
Imprida HCT can be used by people aged 65 years and over at the same dose as for other adults and in the same way as they have already taken the three substances called amlodipine, valsartan and hydrochlorothiazide. Elderly patients, particularly those taking the maximum dose of Imprida HCT (10 mg/320 mg/25 mg), should have their blood pressure checked regularly.
Using other medicines

Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. Your doctor may need to change the dose or take other precautions. In some cases you may have to stop using one of the medicines. This is especially important if you are using any of the medicines listed below:

Do not take together with:
- lithium (a medicine used to treat some types of depression);
- medicines or substances that increase the amount of potassium in your blood. These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines and heparin.

Caution should be used with:
- alcohol, sleeping pills and anaesthetics (medicines allowing patients to undergo surgery and other procedures);
- amantadine (anti-Parkinson therapy, also used to treat or prevent certain illnesses caused by viruses);
- anticholinergic agents (medicines used to treat a variety of disorders such as gastrointestinal cramps, urinary bladder spasm, asthma, motion sickness, muscular spasm, Parkinson's disease and as an aid to anaesthesia);
- anticonvulsant medicines and mood-stabilising medicines used to treat epilepsy and bipolar disorder (e.g. carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone);
- cholestyramine, colestipol or other resins (substances used mainly to treat high levels of lipids in the blood);
- simvastatin (a medicine used to control high cholesterol levels);
- ciclosporin (a medicine used in transplantation to prevent organ rejection or for other conditions, e.g: rheumatoid arthritis or atopic dermatitis);
- cytotoxic medicines (used to treat cancer), such as methotrexate or cyclophosphamide;
- digoxin or other digitalis glycosides (medicines used to treat heart problems);
- verapamil, diltiazem (heart medicines);
- iodine contrast media (agents used for imaging examinations);
- medicines for the treatment of diabetes (oral agents such as metformin or insulins);
- medicines for the treatment of gout, such as allopurinol;
- medicines that may increase blood sugar levels (beta blockers, diazoxide);
- medicines that may induce, “torsades de pointes” (irregular heart beat), such as antiarrhythmics (medicines used to treat heart problems) and some antipsychotics;
- medicines that may reduce the amount of sodium in your blood, such as antidepressants, antipsychotics, antiepileptics;
- medicines that may reduce the amount of potassium in your blood, such as diuretics (water tablets), corticosteroids, laxatives, amphotericin or penicillin G;
- medicines to increase blood pressure such as adrenaline or noradrenaline;
- medicines used for HIV/AIDS (e.g. ritonavir, indinavir, nelfinavir);
- medicines used to treat fungal infections (e.g. ketoconazole, itraconazole);
- medicines used for oesophageal ulceration and inflammation (carbenoxolone);
- medicines used to relieve pain or inflammation, especially non-steroidal anti-inflammatory agents (NSAIDs), including selective cyclooxygenase-2 inhibitors (Cox-2 inhibitors);
- muscle relaxants (medicines to relax the muscles which are used during operations);
- nitroglycerin and other nitrates, or other substances called “vasodilators”;
- other medicines to treat high blood pressure, including methyldopa;
- rifampicin (used, for example, to treat tuberculosis);
- St. John’s wort;
- dantrolene (infusion for severe body temperature abnormalities);
- vitamin D and calcium salts.

Talk to your doctor before drinking alcohol. Alcohol may make your blood pressure fall too much and/or increase the possibility of dizziness or fainting.
Taking Imprida HCT with food and drink
You can take Imprida HCT with or without food. Grapefruit and grapefruit juice should not be consumed by people who are taking Imprida HCT. This is because grapefruit and grapefruit juice can lead to an increase in the blood levels of the active substance amlodipine, which can cause an unpredictable increase in the blood pressure lowering effect of Imprida HCT.

Pregnancy and breast-feeding
Pregnancy
You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking Imprida HCT before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Imprida HCT. Imprida HCT is not recommended in early pregnancy and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.

Breast-feeding
Tell your doctor if you are breast-feeding or about to start breast-feeding. Imprida HCT is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is a newborn, or was born prematurely.

Ask your doctor or pharmacist for advice before taking any medicine.

Driving and using machines
As with many other medicines used to treat high blood pressure, this medicine may make you feel dizzy. If you experience this symptom, do not drive or use tools or machines.

3. HOW TO TAKE IMPRIDA HCT
Always take this medicine exactly as your doctor has told you. You should check with your doctor if you are not sure. This will help you get the best results and lower the risk of side effects.

The usual dose of Imprida HCT is one tablet per day.
– It is best to take the tablet at the same time each day. Morning is the best time.
– Swallow the tablet whole with a glass of water.
– You can take Imprida HCT with or without food. Do not take Imprida HCT with grapefruit or grapefruit juice.

Depending on how you respond to the treatment, your doctor may suggest a higher or lower dose.

If you take more Imprida HCT than you should
If you have accidentally taken too many Imprida HCT tablets, talk to a doctor immediately. You may require medical attention.

If you forget to take Imprida HCT
If you forget to take a dose of this medicine, take it as soon as you remember and then take the next dose at its usual time. If it is almost time for your next dose you should simply take the next tablet at the usual time. Do not take a double dose (two tablets at once) to make up for a forgotten tablet.

If you stop taking Imprida HCT
Stopping your treatment with Imprida HCT may cause your disease to get worse. Do not stop taking your medicine unless your doctor tells you to.
Always take this medicine, even if you are feeling well
People who have high blood pressure often do not notice any signs of the problem. Many feel normal. It is very important that you take this medicine exactly as your doctor tells you to get the best results and reduce the risk of side effects. Keep your appointments with the doctor even if you are feeling well.

If you have any further questions on the use of this product ask your doctor or pharmacist.

4. POSSIBLE SIDE EFFECTS

Like all medicines, Imprida HCT can cause side effects, although not everybody gets them. These side effects may occur with certain frequencies, which are defined as follows:
very common: affects more than 1 user in 10
common: affects 1 to 10 users in 100
uncommon: affects 1 to 10 users in 1,000
rare: affects 1 to 10 users in 10,000
very rare: affects less than 1 user in 10,000
not known: frequency cannot be estimated from the available data

Some side effects can be serious and need immediate medical attention:
You should see your doctor immediately if you experience any of the following symptoms:
Common
• dizziness
• low blood pressure (feeling of faintness, light-headedness, sudden loss of consciousness)

Uncommon
• severely decreased urine output (decreased kidney function)

Rare
• spontaneous bleeding
• irregular heart beat
• liver disorder

Very rare
• allergic reaction with symptoms such as rash, itching
• angioedema: swelling of face or lips or tongue, difficulty of breathing
• crushing/tight chest pain that gets worse or that does not go away
• weakness, bruising, fever and frequent infections
• stiffness

Other possible side effects of Imprida HCT:
Common
• stomach discomfort after meal
• tiredness
• swelling
• low level of potassium in the blood
• headache
• frequent urination
Uncommon
- fast heart beat
- spinning sensation
- vision disorder
- stomach discomfort
- chest pain
- increase of urea nitrogen, creatinine and uric acid in the blood
- high level of calcium, fat or sodium in the blood
- decrease of potassium in the blood
- breath odour
- diarrhoea
- dry mouth
- nausea
- vomiting
- abdominal pain
- weight increase
- loss of appetite
- disturbed sense of taste
- back pain
- joint swelling
- muscle cramps/weakness/pain
- pain in extremity
- inability to either stand or walk in a normal manner
- weakness
- abnormal coordination
- dizziness on standing up or after exercising
- lack of energy
- sleep disturbances
- tingling or numbness
- neuropathy
- sleepiness
- sudden, temporary loss of consciousness
- low blood pressure on standing up
- impotence
- cough
- breathlessness
- throat irritation
- excessive sweating
- itching
- swelling, reddening and pain along a vein
- skin reddening
- trembling

Not known
- changes in blood tests for kidney function, increase of potassium in your blood, low level of red blood cells
Side effects reported with amlodipine or valsartan or hydrochlorothiazide alone, but not observed with Imprida HCT or observed in a higher frequency:

Amlodipine

Common
• palpitations
• abdominal pain
• nausea
• sleepiness
• hot flushes

Uncommon
• ringing noise in ears
• change of bowel habit
• pain
• weight decrease
• joint pain
• trembling
• mood swings
• urination disorders
• urination at night
• breast enlargement in men
• runny nose
• hair loss
• skin eruption
• purple skin patches
• rash
• skin discoloration

Very rare
• low level of white blood cells and blood platelets
• irregular heart beat
• heart attack
• inflammation of the stomach lining or of the pancreas, gingival overgrowth, abnormal liver function test
• liver disorder which can occur together with yellow skin and eyes, or dark-coloured urine
• allergic reaction including swelling deeper in the skin and difficulty breathing
• high level of sugar in the blood
• increased muscle stiffness
• skin reaction with skin reddening and peeling, blistering of lips, eyes or mouth
• itchy rash
• inflammation of blood vessels

Not known
• stiff limbs and trembling hands
Valsartan

Not known

- abnormal red blood cell test
- low level of a certain type of white blood cell and blood platelet
- increase of potassium in the blood
- increase of creatinine in the blood
- abnormal liver function test
- allergic reaction including swelling deeper in the skin and difficulty breathing
- muscle pain
- severely decreased urine output
- itching
- rash
- inflammation of blood vessels

Hydrochlorothiazide

Very common

- low level of potassium in the blood
- increase of lipids in the blood

Common

- high level of uric acid in the blood
- low level of magnesium in the blood
- low level of sodium in the blood
- dizziness, fainting on standing up
- reduced appetite
- nausea and vomiting
- itchy rash and other types of rash
- inability to achieve or maintain erection

Rare

- low level of blood platelets (sometimes with bleeding or bruising underneath the skin)
- sugar in the urine
- high level of sugar in the blood
- worsening of the diabetic metabolic state
- sad mood (depression)
- irregular heart beat
- abdominal discomfort
- constipation
- liver disorders which can occur together with yellow skin and eyes, or dark-coloured urine (haemolytic anaemia)
- increased sensitivity of skin to sun
- purple skin patches
- kidney disorders

Very rare

- fever, sore throat or mouth ulcers, more frequent infections (lack or low level of white blood cells)
- pale skin, tiredness, breathlessness, dark-coloured urine (haemolytic anaemia, abnormal breakdown of red blood cells either in the blood vessels or elsewhere in the body)
- confusion, tiredness, muscle twitching and spasm, rapid breathing (hypochloraemic alkalosis)
- severe upper stomach ache (inflammation of the pancreas)
- rash, itching, hives, difficulty breathing or swallowing, dizziness (hypersensitivity reactions)
- difficulty breathing with fever, coughing, wheezing, breathlessness (respiratory distress, pulmonary oedema, pneumonitis)
facial rash, joint pain, muscle disorder, fever (lupus erythematosus)
• inflammation of blood vessels with symptoms such as rash, purplish-red spots, fever (vasculitis)
• severe skin disease that causes rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever (toxic epidermal necrolysis)

Not known
• weakness, bruising and frequent infections (aplastic anaemia)
• decrease in vision or pain in your eyes due to high pressure (possible signs of acute angle-closure glaucoma)
• breathlessness
• severely decreased urine output (possible signs of renal disorder or renal failure)
• severe skin disease that causes rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever (erythema multiforme)
• muscle spasm
• fever (pyrexia)

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

5. HOW TO STORE IMPRIDA HCT

Keep out of the reach and sight of children.
Do not use Imprida HCT after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.
Do not store above 30°C.
Store in the original package in order to protect from moisture.
Do not use any Imprida HCT pack that is damaged or shows signs of tampering.

6. FURTHER INFORMATION

What Imprida HCT contains
– The active substances of Imprida HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide.
– Imprida HCT 5 mg/160 mg/12.5 mg film-coated tablets: Each film-coated tablet contains 5 mg amlodipine (as amlodipine besylate), 160 mg valsartan and 12.5 mg hydrochlorothiazide. The other ingredients are cellulose microcrystalline; crospovidone; silica, colloidal anhydrous; magnesium stearate; hypromellose, macrogol 4000, talc, titanium dioxide (E171).

What Imprida HCT looks like and contents of the pack
– Imprida HCT 5 mg/160 mg/12.5 mg film-coated tablets are white, oval tablets with “NVR” on one side and “VCL” on the other side.

Imprida HCT is available in packs containing 14, 28, 30, 56, 90, 98 or 280 film-coated tablets, in multipacks of 280 tablets (comprising 4 cartons, each containing 70 tablets, or 20 cartons, each containing 14 tablets), and in hospital packs containing 56, 98 or 280 tablets in single unit blisters. Not all pack sizes may be available in your country.
**Marketing Authorisation Holder**
Novartis Europharm Limited
Wimblehurst Road
Horsham
West Sussex, RH12 5AB
United Kingdom

**Manufacturer**
Novartis Pharma GmbH
Roonstraße 25
D-90429 Nuremberg
Germany

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

**België/Belgique/Belgien**
Novartis Pharma N.V.
Tél/Tel: +32 2 246 16 11

**България**
Novartis Pharma Services Inc.
Tel.: +359 2 976 98 28

**Česká republika**
Novartis s.r.o.
Tel: +420 225 775 111

**Danmark**
Novartis Healthcare A/S
Tlf: +45 39 16 84 00

**Deutschland**
Novartis Pharma GmbH
Tel: +49 911 273 0

**Ελλάδα**
Novartis (Hellas) A.E.B.E.
Τηλ.: +30 210 281 17 12

**España**
Lacer, S.A.
Tel: +34 93 446 53 00

**France**
Novartis Pharma S.A.S.
Tél: +33 1 55 47 66 00

**Ireland**
Novartis Ireland Limited
Tel: +353 1 260 12 55

**Luxembourg/Luxemburg**
Novartis Pharma N.V.
Tél/Tel: +32 2 246 16 11

**Magyarország**
Novartis Hungária Kft. Pharma
Tel.: +36 1 457 65 00

**Malta**
Novartis Pharma Services Inc.
Tel: +356 2298 3217

**Nederland**
Novartis Pharma B.V.
Tel: +31 26 37 82 111

**Norge**
Novartis Norge AS
Tlf: +47 23 05 20 00

**Österreich**
Novartis Pharma GmbH
Tel: +43 1 86 6570

**Polska**
Novartis Poland Sp. z o.o.
Tel.: +48 22 375 4888

**Portugal**
Novartis Farma - Produtos Farmacêuticos, S.A.
Tel: +351 21 000 8600

**Ромânia**
Novartis Pharma Services Romania SRL
Tel: +40 21 31299 01

**Slovenija**
Novartis Pharma Services Inc.
Tel: +386 1 300 75 50
This leaflet was last approved in

Detailed information on this medicine is available on the European Medicines Agency web site:
http://www.ema.europa.eu
1. WHAT IMPRIDA HCT IS AND WHAT IT IS USED FOR

Imprida HCT tablets contain three substances called amlodipine, valsartan and hydrochlorothiazide. All of these substances help to control high blood pressure.

- Amlodipine belongs to a group of substances called “calcium channel blockers”. Amlodipine stops calcium from moving into the blood vessel wall, which stops the blood vessels from tightening.
- Valsartan belongs to a group of substances called “angiotensin-II receptor antagonists”. Angiotensin II is produced by the body and makes the blood vessels tighten, thus increasing the blood pressure. Valsartan works by blocking the effect of angiotensin II.
- Hydrochlorothiazide belongs to a group of substances called “thiazide diuretics”. Hydrochlorothiazide increases urine output, which also lowers blood pressure.

As a result of all three mechanisms, the blood vessels relax and blood pressure is lowered.

Imprida HCT is used to treat high blood pressure in adult patients who are already taking amlodipine, valsartan and hydrochlorothiazide and who may benefit from taking one tablet containing all three substances.

2. BEFORE YOU TAKE IMPRIDA HCT

Do not take Imprida HCT
- if you are more than 3 months pregnant. (It is also better to avoid Imprida HCT in early pregnancy – see Pregnancy section).
- if you are allergic (hypersensitive) to amlodipine, valsartan, hydrochlorothiazide, sulphonamide-derived medicines (medicines used to treat chest or urinary infections), or any of the other ingredients of Imprida HCT (see section 6, “What Imprida HCT contains”).
- if you have liver disease, destruction of the small bile ducts within the liver (biliary cirrhosis) leading to the build up of bile in the liver (cholestasis).
- if you have severe kidney problems or if you are having dialysis.
- if you are unable to produce urine (anuria).
– if the level of potassium or sodium in your blood is too low despite treatment.
– if the level of calcium in your blood is too high despite treatment.
– if you have gout (uric acid crystals in the joints).

If any of the above applies to you, do not take Imprida HCT and talk to your doctor.

Take special care with Imprida HCT

– if you have a low level of potassium or magnesium in your blood (with or without symptoms such as muscle weakness, muscle spasms, abnormal heart rhythm).
– if you have a low level of sodium in your blood (with or without symptoms such as tiredness, confusion, muscle twitching, convulsions).
– if you have a high level of calcium in your blood (with or without symptoms such as nausea, vomiting, constipation, stomach pain, frequent urination, thirst, muscle weakness and twitching).
– if you are taking medicines or substances that increase the amount of potassium in your blood. These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines and heparin. It may be necessary to check the amount of potassium in your blood at regular intervals.
– if you have kidney problems, have had a kidney transplant or if you had been told that you have a narrowing of your kidney arteries.
– if you have liver problems.
– if you have or have had heart failure or coronary artery disease, particularly if you are taking the maximum dose of Imprida HCT (10 mg/320 mg/25 mg).
– if your doctor has told you that you have a narrowing of the valves in your heart (called “aortic or mitral stenosis”) or that the thickness of your heart muscle is abnormally increased (called “obstructive hypertrophic cardiomyopathy”).
– if you suffer from aldosteronism. This is a disease in which the adrenal glands make too much of the hormone aldosterone. If this applies to you, the use of Imprida HCT is not recommended.
– if you suffer from a disease called systemic lupus erythematosus (also called “lupus” or “SLE”).
– if you have diabetes (high level of sugar in your blood).
– if you have high levels of cholesterol or triglycerides in your blood.
– if you experience skin reactions such as rash after sun exposure.
– if you had an allergic reaction to other high blood pressure medicines or diuretics (a type of medicine also known as “water tablets”), especially if you suffer from asthma and allergies.
– if you have been sick (vomiting or diarrhoea).
– if you experience dizziness and/or fainting during treatment with Imprida HCT, tell your doctor as soon as possible.
– if you experience a decrease in vision or eye pain. These could be symptoms of an increase of pressure in your eye and can happen within hours to a week of taking Imprida HCT. This can lead to permanent vision impairment, if not treated.

If any of these apply to you, talk to your doctor.

You must tell your doctor if you think that you are (or might become) pregnant. Imprida HCT is not recommended in early pregnancy and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at this stage (see section “Pregnancy and breast-feeding”).

The use of Imprida HCT in children and adolescents under 18 years of age is not recommended.

Imprida HCT and older people (age 65 years and older)
Imprida HCT can be used by people aged 65 years and over at the same dose as for other adults and in the same way as they have already taken the three substances called amlodipine, valsartan and hydrochlorothiazide. Elderly patients, particularly those taking the maximum dose of Imprida HCT (10 mg/320 mg/25 mg), should have their blood pressure checked regularly.
Using other medicines

Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. Your doctor may need to change the dose or take other precautions. In some cases you may have to stop using one of the medicines. This is especially important if you are using any of the medicines listed below:

Do not take together with:

- lithium (a medicine used to treat some types of depression);
- medicines or substances that increase the amount of potassium in your blood. These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines and heparin.

Caution should be used with:

- alcohol, sleeping pills and anaesthetics (medicines allowing patients to undergo surgery and other procedures);
- amantadine (anti-Parkinson therapy, also used to treat or prevent certain illnesses caused by viruses);
- anticholinergic agents (medicines used to treat a variety of disorders such as gastrointestinal cramps, urinary bladder spasm, asthma, motion sickness, muscular spasm, Parkinson's disease and as an aid to anaesthesia);
- anticonvulsant medicines and mood-stabilising medicines used to treat epilepsy and bipolar disorder (e.g. carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone);
- cholestyramine, colestipol or other resins (substances used mainly to treat high levels of lipids in the blood);
- simvastatin (a medicine used to control high cholesterol levels);
- ciclosporin (a medicine used in transplantation to prevent organ rejection or for other conditions, e.g: rheumatoid arthritis or atopic dermatitis);
- cytotoxic medicines (used to treat cancer), such as methotrexate or cyclophosphamide;
- digoxin or other digitalis glycosides (medicines used to treat heart problems);
- verapamil, diltilzem (heart medicines);
- iodine contrast media (agents used for imaging examinations);
- medicines for the treatment of diabetes (oral agents such as metformin or insulins);
- medicines for the treatment of gout, such as allopurinol;
- medicines that may increase blood sugar levels (beta blockers, diazoxide);
- medicines that may induce, “torsades de pointes” (irregular heart beat), such as antiarrhythmics (medicines used to treat heart problems) and some antipsychotics;
- medicines that may reduce the amount of sodium in your blood, such as antidepressants, antipsychotics, antiepileptics;
- medicines that may reduce the amount of potassium in your blood, such as diuretics (water tablets), corticosteroids, laxatives, amphotericin or penicillin G;
- medicines to increase blood pressure such as adrenaline or noradrenaline;
- medicines used for HIV/AIDS (e.g. ritonavir, indinavir, nelfinavir);
- medicines used to treat fungal infections (e.g. ketoconazole, itraconazole);
- medicines used for oesophageal ulceration and inflammation (carbenoxolone);
- medicines used to relieve pain or inflammation, especially non-steroidal anti-inflammatory agents (NSAIDs), including selective cyclooxygenase-2 inhibitors (Cox-2 inhibitors);
- muscle relaxants (medicines to relax the muscles which are used during operations);
- nitroglycerin and other nitrates, or other substances called “vasodilators”;
- other medicines to treat high blood pressure, including methyldopa;
- rifampicin (used, for example, to treat tuberculosis);
- St. John’s wort;
- dantrolene (infusion for severe body temperature abnormalities);
- vitamin D and calcium salts.

Talk to your doctor before drinking alcohol. Alcohol may make your blood pressure fall too much and/or increase the possibility of dizziness or fainting.
Taking Imprida HCT with food and drink
You can take Imprida HCT with or without food. Grapefruit and grapefruit juice should not be consumed by people who are taking Imprida HCT. This is because grapefruit and grapefruit juice can lead to an increase in the blood levels of the active substance amlodipine, which can cause an unpredictable increase in the blood pressure lowering effect of Imprida HCT.

Pregnancy and breast-feeding

Pregnancy
You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking Imprida HCT before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Imprida HCT. Imprida HCT is not recommended in early pregnancy and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.

Breast-feeding
Tell your doctor if you are breast-feeding or about to start breast-feeding. Imprida HCT is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is a newborn, or was born prematurely.

Ask your doctor or pharmacist for advice before taking any medicine.

Driving and using machines
As with many other medicines used to treat high blood pressure, this medicine may make you feel dizzy. If you experience this symptom, do not drive or use tools or machines.

3. HOW TO TAKE IMPRIDA HCT

Always take this medicine exactly as your doctor has told you. You should check with your doctor if you are not sure. This will help you get the best results and lower the risk of side effects.

The usual dose of Imprida HCT is one tablet per day.
- It is best to take the tablet at the same time each day. Morning is the best time.
- Swallow the tablet whole with a glass of water.
- You can take Imprida HCT with or without food. Do not take Imprida HCT with grapefruit or grapefruit juice.

Depending on how you respond to the treatment, your doctor may suggest a higher or lower dose.

If you take more Imprida HCT than you should
If you have accidentally taken too many Imprida HCT tablets, talk to a doctor immediately. You may require medical attention.

If you forget to take Imprida HCT
If you forget to take a dose of this medicine, take it as soon as you remember and then take the next dose at its usual time. If it is almost time for your next dose you should simply take the next tablet at the usual time. Do not take a double dose (two tablets at once) to make up for a forgotten tablet.

If you stop taking Imprida HCT
Stopping your treatment with Imprida HCT may cause your disease to get worse. Do not stop taking your medicine unless your doctor tells you to.
Always take this medicine, even if you are feeling well
People who have high blood pressure often do not notice any signs of the problem. Many feel normal. It is very important that you take this medicine exactly as your doctor tells you to get the best results and reduce the risk of side effects. Keep your appointments with the doctor even if you are feeling well.

If you have any further questions on the use of this product ask your doctor or pharmacist.

4. POSSIBLE SIDE EFFECTS

Like all medicines, Imprida HCT can cause side effects, although not everybody gets them. These side effects may occur with certain frequencies, which are defined as follows:

- **very common**: affects more than 1 user in 10
- **common**: affects 1 to 10 users in 100
- **uncommon**: affects 1 to 10 users in 1,000
- **rare**: affects 1 to 10 users in 10,000
- **very rare**: affects less than 1 user in 10,000
- **not known**: frequency cannot be estimated from the available data

**Some side effects can be serious and need immediate medical attention:**

You should see your doctor immediately if you experience any of the following symptoms:

**Common**
- dizziness
- low blood pressure (feeling of faintness, light-headedness, sudden loss of consciousness)

**Uncommon**
- severely decreased urine output (decreased kidney function)

**Rare**
- spontaneous bleeding
- irregular heart beat
- liver disorder

**Very rare**
- allergic reaction with symptoms such as rash, itching
- angioedema: swelling of face or lips or tongue, difficulty of breathing
- crushing/tight chest pain that gets worse or that does not go away
- weakness, bruising, fever and frequent infections
- stiffness

**Other possible side effects of Imprida HCT:**

**Common**
- stomach discomfort after meal
- tiredness
- swelling
- low level of potassium in the blood
- headache
- frequent urination
Uncommon

- fast heart beat
- spinning sensation
- vision disorder
- stomach discomfort
- chest pain
- increase of urea nitrogen, creatinine and uric acid in the blood
- high level of calcium, fat or sodium in the blood
- decrease of potassium in the blood
- breath odour
- diarrhoea
- dry mouth
- nausea
- vomiting
- abdominal pain
- weight increase
- loss of appetite
- disturbed sense of taste
- back pain
- joint swelling
- muscle cramps/weakness/pain
- pain in extremity
- inability to either stand or walk in a normal manner
- weakness
- abnormal coordination
- dizziness on standing up or after exercising
- lack of energy
- sleep disturbances
- tingling or numbness
- neuropathy
- sleepiness
- sudden, temporary loss of consciousness
- low blood pressure on standing up
- impotence
- cough
- breathlessness
- throat irritation
- excessive sweating
- itching
- swelling, reddening and pain along a vein
- skin reddening
- trembling

Not known

- changes in blood tests for kidney function, increase of potassium in your blood, low level of red blood cells
Side effects reported with amlodipine or valsartan or hydrochlorothiazide alone, but not observed with Imprida HCT or observed in a higher frequency:

**Amlodipine**

*Common*
- palpitations
- abdominal pain
- nausea
- sleepiness
- hot flushes

*Uncommon*
- ringing noise in ears
- change of bowel habit
- pain
- weight decrease
- joint pain
- trembling
- mood swings
- urination disorders
- urination at night
- breast enlargement in men
- runny nose
- hair loss
- skin eruption
- purple skin patches
- rash
- skin discoloration

*Very rare*
- low level of white blood cells and blood platelets
- irregular heart beat
- heart attack
- inflammation of the stomach lining or of the pancreas, gingival overgrowth, abnormal liver function test
- liver disorder which can occur together with yellow skin and eyes, or dark-coloured urine
- allergic reaction including swelling deeper in the skin and difficulty breathing
- high level of sugar in the blood
- increased muscle stiffness
- skin reaction with skin reddening and peeling, blistering of lips, eyes or mouth
- itchy rash
- inflammation of blood vessels

*Not known*
- stiff limbs and trembling hands
Valsartan

*Not known*
- abnormal red blood cell test
- low level of a certain type of white blood cell and blood platelet
- increase of potassium in the blood
- increase of creatinine in the blood
- abnormal liver function test
- allergic reaction including swelling deeper in the skin and difficulty breathing
- muscle pain
- severely decreased urine output
- itching
- rash
- inflammation of blood vessels

Hydrochlorothiazide

*Very common*
- low level of potassium in the blood
- increase of lipids in the blood

*Common*
- high level of uric acid in the blood
- low level of magnesium in the blood
- low level of sodium in the blood
- dizziness, fainting on standing up
- reduced appetite
- nausea and vomiting
- itchy rash and other types of rash
- inability to achieve or maintain erection

*Rare*
- low level of blood platelets (sometimes with bleeding or bruising underneath the skin)
- sugar in the urine
- high level of sugar in the blood
- worsening of the diabetic metabolic state
- sad mood (depression)
- irregular heart beat
- abdominal discomfort
- constipation
- liver disorders which can occur together with yellow skin and eyes, or dark-coloured urine (haemolytic anaemia)
- increased sensitivity of skin to sun
- purple skin patches
- kidney disorders

*Very rare*
- fever, sore throat or mouth ulcers, more frequent infections (lack or low level of white blood cells)
- pale skin, tiredness, breathlessness, dark-coloured urine (haemolytic anaemia, abnormal breakdown of red blood cells either in the blood vessels or elsewhere in the body)
- confusion, tiredness, muscle twitching and spasm, rapid breathing (hypochloraemic alkalosis)
- severe upper stomach ache (inflammation of the pancreas)
- rash, itching, hives, difficulty breathing or swallowing, dizziness (hypersensitivity reactions)
- difficulty breathing with fever, coughing, wheezing, breathlessness (respiratory distress, pulmonary oedema, pneumonitis)
• facial rash, joint pain, muscle disorder, fever (lupus erythematosus)
• inflammation of blood vessels with symptoms such as rash, purplish-red spots, fever (vasculitis)
• severe skin disease that causes rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever (toxic epidermal necrolysis)

*Not known*
• weakness, bruising and frequent infections (aplastic anaemia)
• decrease in vision or pain in your eyes due to high pressure (possible signs of acute angle-closure glaucoma)
• breathlessness
• severely decreased urine output (possible signs of renal disorder or renal failure)
• severe skin disease that causes rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever (erythema multiforme)
• muscle spasm
• fever (pyrexia)

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

5. HOW TO STORE IMPRIDA HCT

Keep out of the reach and sight of children. Do not use Imprida HCT after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month. Do not store above 30°C. Store in the original package in order to protect from moisture. Do not use any Imprida HCT pack that is damaged or shows signs of tampering.

6. FURTHER INFORMATION

What Imprida HCT contains

– The active substances of Imprida HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide.

– Imprida HCT 10 mg/160 mg/12.5 mg film-coated tablets: Each film-coated tablet contains 10 mg amlodipine (as amlodipine besylate), 160 mg valsartan, and 12.5 mg hydrochlorothiazide. The other ingredients are cellulose microcrystalline; crospovidone; silica, colloidal anhydrous; magnesium stearate; hypromellose, macrogol 4000, talc, titanium dioxide (E171), yellow iron oxide (E172), red iron oxide (E172).

What Imprida HCT looks like and contents of the pack

– Imprida HCT 10 mg/160 mg/12.5 mg film-coated tablets are pale yellow, oval tablets with “NVR” on one side and “VDL” on the other side.

Imprida HCT is available in packs containing 14, 28, 30, 56, 90, 98 or 280 film-coated tablets, in multipacks of 280 tablets (comprising 4 cartons, each containing 70 tablets, or 20 cartons, each containing 14 tablets), and in hospital packs containing 56, 98 or 280 tablets in single unit blisters. Not all pack sizes may be available in your country.
Marketing Authorisation Holder
Novartis Europharm Limited
Wimblehurst Road
Horsham
West Sussex, RH12 5AB
United Kingdom

Manufacturer
Novartis Pharma GmbH
Roonstraße 25
D-90429 Nuremberg
Germany

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

België/Belgique/Belgien
Novartis Pharma N.V.
Tél/Tel: +32 2 246 16 11

България
Novartis Pharma Services Inc.
Тел.: +359 2 976 98 28

Česká republika
Novartis s.r.o.
Tel: +420 225 775 111

Danmark
Novartis Healthcare A/S
Tlf: +45 39 16 84 00

Deutschland
Novartis Pharma GmbH
Tel: +49 911 273 0

Eestī
Novartis Pharma Services Inc.
Tel: +372 66 30 810

Ελλάδα
Novartis (Hellas) A.E.B.E.
Τηλ.: +30 210 281 17 12

España
Lacer, S.A.
Tel: +34 93 446 53 00

France
Novartis Pharma S.A.S.
Tél: +33 1 55 47 66 00

Ireland
Novartis Ireland Limited
Tel: +353 1 260 12 55

Luxembourg/Luxemburg
Novartis Pharma N.V.
Tél/Tel: +32 2 246 16 11

Magyarország
Novartis Hungária Kft. Pharma
Tel.: +36 1 457 65 00

Malta
Novartis Pharma Services Inc.
Tel: +356 2298 3217

Nederland
Novartis Pharma B.V.
Tel: +31 26 37 82 111

Norge
Novartis Norge AS
Tlf: +47 23 05 20 00

Österreich
Novartis Pharma GmbH
Tel: +43 1 86 6570

Polska
Novartis Poland Sp. z o.o.
Tel.: +48 22 375 4888

Portugal
Novartis Farma - Produtos Farmacêuticos, S.A.
Tel: +351 21 000 8600

România
Novartis Pharma Services Romania SRL
Tel: +40 21 31299 01

Slovenija
Novartis Pharma Services Inc.
Tel: +386 1 300 75 50
Ísland
Vistor hf.
Sími: +354 535 7000

Slovenská republika
Novartis Slovakia s.r.o.
Tel: +421 2 5542 5439

Italia
Novartis Farma S.p.A.
Tel: +39 02 96 54 1

Suomi/Finland
Novartis Finland Oy
Puh/Tel: +358 (0)10 6133 200

Κύπρος
Novartis Pharma Services Inc.
Τηλ: +357 22 690 690

Sverige
Novartis Sverige AB
Tel: +46 8 732 32 00

Latvija
Novartis Pharma Services Inc.
Tel: +371 67 887 070

United Kingdom
Novartis Pharmaceuticals UK Ltd.
Tel: +44 1276 698370

Lietuva
Novartis Pharma Services Inc.
Tel: +370 5 269 16 50

This leaflet was last approved in

Detailed information on this medicine is available on the European Medicines Agency web site:
http://www.ema.europa.eu
1. WHAT IMPRIDA HCT IS AND WHAT IT IS USED FOR

Imprida HCT tablets contain three substances called amlodipine, valsartan and hydrochlorothiazide. All of these substances help to control high blood pressure.

- Amlodipine belongs to a group of substances called “calcium channel blockers”. Amlodipine stops calcium from moving into the blood vessel wall, which stops the blood vessels from tightening.
- Valsartan belongs to a group of substances called “angiotensin-II receptor antagonists”. Angiotensin II is produced by the body and makes the blood vessels tighten, thus increasing the blood pressure. Valsartan works by blocking the effect of angiotensin II.
- Hydrochlorothiazide belongs to a group of substances called “thiazide diuretics”. Hydrochlorothiazide increases urine output, which also lowers blood pressure.

As a result of all three mechanisms, the blood vessels relax and blood pressure is lowered.

Imprida HCT is used to treat high blood pressure in adult patients who are already taking amlodipine, valsartan and hydrochlorothiazide and who may benefit from taking one tablet containing all three substances.

2. BEFORE YOU TAKE IMPRIDA HCT

Do not take Imprida HCT

- if you are more than 3 months pregnant. (It is also better to avoid Imprida HCT in early pregnancy – see Pregnancy section).
- if you are allergic (hypersensitive) to amlodipine, valsartan, hydrochlorothiazide, sulphonamide-derived medicines (medicines used to treat chest or urinary infections), or any of the other ingredients of Imprida HCT (see section 6, “What Imprida HCT contains”).
- if you think you may be allergic, do not take Imprida HCT and talk to your doctor.
- if you have liver disease, destruction of the small bile ducts within the liver (biliary cirrhosis) leading to the build up of bile in the liver (cholestasis).
- if you have severe kidney problems or if you are having dialysis.
- if you are unable to produce urine (anuria).
– if the level of potassium or sodium in your blood is too low despite treatment.
– if the level of calcium in your blood is too high despite treatment.
– if you have gout (uric acid crystals in the joints).

If any of the above applies to you, do not take Imprida HCT and talk to your doctor.

Take special care with Imprida HCT
– if you have a low level of potassium or magnesium in your blood (with or without symptoms such as muscle weakness, muscle spasms, abnormal heart rhythm).
– if you have a low level of sodium in your blood (with or without symptoms such as tiredness, confusion, muscle twitching, convulsions).
– if you have a high level of calcium in your blood (with or without symptoms such as nausea, vomiting, constipation, stomach pain, frequent urination, thirst, muscle weakness and twitching).
– if you are taking medicines or substances that increase the amount of potassium in your blood. These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines and heparin. It may be necessary to check the amount of potassium in your blood at regular intervals.
– if you have kidney problems, have had a kidney transplant or if you had been told that you have a narrowing of your kidney arteries.
– if you have liver problems.
– if you have or have had heart failure or coronary artery disease, particularly if you are taking the maximum dose of Imprida HCT (10 mg/320 mg/25 mg).
– if your doctor has told you that you have a narrowing of the valves in your heart (called “aortic or mitral stenosis”) or that the thickness of your heart muscle is abnormally increased (called “obstructive hypertrophic cardiomyopathy”).
– if you suffer from aldosteronism. This is a disease in which the adrenal glands make too much of the hormone aldosterone. If this applies to you, the use of Imprida HCT is not recommended.
– if you suffer from a disease called systemic lupus erythematosus (also called “lupus” or “SLE”).
– if you have diabetes (high level of sugar in your blood).
– if you have high levels of cholesterol or triglycerides in your blood.
– if you experience skin reactions such as rash after sun exposure.
– if you had an allergic reaction to other high blood pressure medicines or diuretics (a type of medicine also known as “water tablets”), especially if you suffer from asthma and allergies.
– if you have been sick (vomiting or diarrhoea).
– if you experience dizziness and/or fainting during treatment with Imprida HCT, tell your doctor as soon as possible.
– if you experience a decrease in vision or eye pain. These could be symptoms of an increase of pressure in your eye and can happen within hours to a week of taking Imprida HCT. This can lead to permanent vision impairment, if not treated.

If any of these apply to you, talk to your doctor.

You must tell your doctor if you think that you are (or might become) pregnant. Imprida HCT is not recommended in early pregnancy and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at this stage (see section “Pregnancy and breast-feeding”).

The use of Imprida HCT in children and adolescents under 18 years of age is not recommended.

Imprida HCT and older people (age 65 years and older)
Imprida HCT can be used by people aged 65 years and over at the same dose as for other adults and in the same way as they have already taken the three substances called amlodipine, valsartan and hydrochlorothiazide. Elderly patients, particularly those taking the maximum dose of Imprida HCT (10 mg/320 mg/25 mg), should have their blood pressure checked regularly.
Using other medicines
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. Your doctor may need to change the dose or take other precautions. In some cases you may have to stop using one of the medicines. This is especially important if you are using any of the medicines listed below:

Do not take together with:
- lithium (a medicine used to treat some types of depression);
- medicines or substances that increase the amount of potassium in your blood. These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines and heparin.

Caution should be used with:
- alcohol, sleeping pills and anaesthetics (medicines allowing patients to undergo surgery and other procedures);
- amantadine (anti-Parkinson therapy, also used to treat or prevent certain illnesses caused by viruses);
- anticholinergic agents (medicines used to treat a variety of disorders such as gastrointestinal cramps, urinary bladder spasm, asthma, motion sickness, muscular spasm, Parkinson's disease and as an aid to anaesthesia);
- anticonvulsant medicines and mood-stabilising medicines used to treat epilepsy and bipolar disorder (e.g. carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone);
- cholestryramine, colestipol or other resins (substances used mainly to treat high levels of lipids in the blood);
- simvastatin (a medicine used to control high cholesterol levels);
- ciclosporin (a medicine used in transplantation to prevent organ rejection or for other conditions, e.g.: rheumatoid arthritis or atopic dermatitis);
- cytotoxic medicines (used to treat cancer), such as methotrexate or cyclophosphamide;
- digoxin or other digitalis glycosides (medicines used to treat heart problems);
- verapamil, diltiazem (heart medicines);
- iodine contrast media (agents used for imaging examinations);
- medicines for the treatment of diabetes (oral agents such as metformin or insulins);
- medicines for the treatment of gout, such as allopurinol;
- medicines that may increase blood sugar levels (beta blockers, diazoxide);
- medicines that may induce, “torsades de pointes” (irregular heart beat), such as antiarrhythmics (medicines used to treat heart problems) and some antipsychotics;
- medicines that may reduce the amount of sodium in your blood, such as antidepressants, antipsychotics, antiepileptics;
- medicines that may reduce the amount of potassium in your blood, such as diuretics (water tablets), corticosteroids, laxatives, amphotericin or penicillin G;
- medicines to increase blood pressure such as adrenaline or noradrenaline;
- medicines used for HIV/AIDS (e.g. ritonavir, indinavir, nelfinavir);
- medicines used to treat fungal infections (e.g. ketoconazole, itraconazole);
- medicines used for oesophageal ulceration and inflammation (carbenoxolone);
- medicines used to relieve pain or inflammation, especially non-steroidal anti-inflammatory agents (NSAIDs), including selective cyclooxygenase-2 inhibitors (Cox-2 inhibitors);
- muscle relaxants (medicines to relax the muscles which are used during operations);
- nitroglycerin and other nitrates, or other substances called “vasodilators”;
- other medicines to treat high blood pressure, including methyldopa;
- rifampicin (used, for example, to treat tuberculosis);
- St. John’s wort;
- dantrolene (infusion for severe body temperature abnormalities);
- vitamin D and calcium salts.

Talk to your doctor before drinking alcohol. Alcohol may make your blood pressure fall too much and/or increase the possibility of dizziness or fainting.
Taking Imprida HCT with food and drink
You can take Imprida HCT with or without food. Grapefruit and grapefruit juice should not be consumed by people who are taking Imprida HCT. This is because grapefruit and grapefruit juice can lead to an increase in the blood levels of the active substance amlodipine, which can cause an unpredictable increase in the blood pressure lowering effect of Imprida HCT.

Pregnancy and breast-feeding
Pregnancy
You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking Imprida HCT before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Imprida HCT. Imprida HCT is not recommended in early pregnancy and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.

Breast-feeding
Tell your doctor if you are breast-feeding or about to start breast-feeding. Imprida HCT is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is a newborn, or was born prematurely.

Ask your doctor or pharmacist for advice before taking any medicine.

Driving and using machines
As with many other medicines used to treat high blood pressure, this medicine may make you feel dizzy. If you experience this symptom, do not drive or use tools or machines.

3. HOW TO TAKE IMPRIDA HCT

Always take this medicine exactly as your doctor has told you. You should check with your doctor if you are not sure. This will help you get the best results and lower the risk of side effects.

The usual dose of Imprida HCT is one tablet per day.

- It is best to take the tablet at the same time each day. Morning is the best time.
- Swallow the tablet whole with a glass of water.
- You can take Imprida HCT with or without food. Do not take Imprida HCT with grapefruit or grapefruit juice.

Depending on how you respond to the treatment, your doctor may suggest a higher or lower dose.

If you take more Imprida HCT than you should
If you have accidentally taken too many Imprida HCT tablets, talk to a doctor immediately. You may require medical attention.

If you forget to take Imprida HCT
If you forget to take a dose of this medicine, take it as soon as you remember and then take the next dose at its usual time. If it is almost time for your next dose you should simply take the next tablet at the usual time. Do not take a double dose (two tablets at once) to make up for a forgotten tablet.

If you stop taking Imprida HCT
Stopping your treatment with Imprida HCT may cause your disease to get worse. Do not stop taking your medicine unless your doctor tells you to.
Always take this medicine, even if you are feeling well
People who have high blood pressure often do not notice any signs of the problem. Many feel normal. It is very important that you take this medicine exactly as your doctor tells you to get the best results and reduce the risk of side effects. Keep your appointments with the doctor even if you are feeling well.

If you have any further questions on the use of this product ask your doctor or pharmacist.

4. POSSIBLE SIDE EFFECTS

Like all medicines, Imprida HCT can cause side effects, although not everybody gets them. These side effects may occur with certain frequencies, which are defined as follows:
very common: affects more than 1 user in 10
common: affects 1 to 10 users in 100
uncommon: affects 1 to 10 users in 1,000
rare: affects 1 to 10 users in 10,000
very rare: affects less than 1 user in 10,000
not known: frequency cannot be estimated from the available data

Some side effects can be serious and need immediate medical attention:
You should see your doctor immediately if you experience any of the following symptoms:

Common
- dizziness
- low blood pressure (feeling of faintness, light-headedness, sudden loss of consciousness)

Uncommon
- severely decreased urine output (decreased kidney function)

Rare
- spontaneous bleeding
- irregular heart beat
- liver disorder

Very rare
- allergic reaction with symptoms such as rash, itching
- angioedema: swelling of face or lips or tongue, difficulty of breathing
- crushing/tight chest pain that gets worse or that does not go away
- weakness, bruising, fever and frequent infections
- stiffness

Other possible side effects of Imprida HCT:
Common
- stomach discomfort after meal
- tiredness
- swelling
- low level of potassium in the blood
- headache
- frequent urination
**Uncommon**
- fast heart beat
- spinning sensation
- vision disorder
- stomach discomfort
- chest pain
- increase of urea nitrogen, creatinine and uric acid in the blood
- high level of calcium, fat or sodium in the blood
- decrease of potassium in the blood
- breath odour
- diarrhoea
- dry mouth
- nausea
- vomiting
- abdominal pain
- weight increase
- loss of appetite
- disturbed sense of taste
- back pain
- joint swelling
- muscle cramps/weakness/pain
- pain in extremity
- inability to either stand or walk in a normal manner
- weakness
- abnormal coordination
- dizziness on standing up or after exercising
- lack of energy
- sleep disturbances
- tingling or numbness
- neuropathy
- sleepiness
- sudden, temporary loss of consciousness
- low blood pressure on standing up
- impotence
- cough
- breathlessness
- throat irritation
- excessive sweating
- itching
- swelling, reddening and pain along a vein
- skin reddening
- trembling

**Not known**
- changes in blood tests for kidney function, increase of potassium in your blood, low level of red blood cells
Side effects reported with amlodipine or valsartan or hydrochlorothiazide alone, but not observed with Imprida HCT or observed in a higher frequency:

**Amlodipine**

*Common*
- palpitations
- abdominal pain
- nausea
- sleepiness
- hot flushes

*Uncommon*
- ringing noise in ears
- change of bowel habit
- pain
- weight decrease
- joint pain
- trembling
- mood swings
- urination disorders
- urination at night
- breast enlargement in men
- runny nose
- hair loss
- skin eruption
- purple skin patches
- rash
- skin discoloration

*Very rare*
- low level of white blood cells and blood platelets
- irregular heart beat
- heart attack
- inflammation of the stomach lining or of the pancreas, gingival overgrowth, abnormal liver function test
- liver disorder which can occur together with yellow skin and eyes, or dark-coloured urine
- allergic reaction including swelling deeper in the skin and difficulty breathing
- high level of sugar in the blood
- increased muscle stiffness
- skin reaction with skin reddening and peeling, blistering of lips, eyes or mouth
- itchy rash
- inflammation of blood vessels

*Not known*
- stiff limbs and trembling hands
Valsartan

*Not known*

- abnormal red blood cell test
- low level of a certain type of white blood cell and blood platelet
- increase of potassium in the blood
- increase of creatinine in the blood
- abnormal liver function test
- allergic reaction including swelling deeper in the skin and difficulty breathing
- muscle pain
- severely decreased urine output
- itching
- rash
- inflammation of blood vessels

Hydrochlorothiazide

*Very common*

- low level of potassium in the blood
- increase of lipids in the blood

*Common*

- high level of uric acid in the blood
- low level of magnesium in the blood
- low level of sodium in the blood
- dizziness, fainting on standing up
- reduced appetite
- nausea and vomiting
- itchy rash and other types of rash
- inability to achieve or maintain erection

*Rare*

- low level of blood platelets (sometimes with bleeding or bruising underneath the skin)
- sugar in the urine
- high level of sugar in the blood
- worsening of the diabetic metabolic state
- sad mood (depression)
- irregular heart beat
- abdominal discomfort
- constipation
- liver disorders which can occur together with yellow skin and eyes, or dark-coloured urine (haemolytic anaemia)
- increased sensitivity of skin to sun
- purple skin patches
- kidney disorders

*Very rare*

- fever, sore throat or mouth ulcers, more frequent infections (lack or low level of white blood cells)
- pale skin, tiredness, breathlessness, dark-coloured urine (haemolytic anaemia, abnormal breakdown of red blood cells either in the blood vessels or elsewhere in the body)
- confusion, tiredness, muscle twitching and spasm, rapid breathing (hypochloraemic alkalosis)
- severe upper stomach ache (inflammation of the pancreas)
- rash, itching, hives, difficulty breathing or swallowing, dizziness (hypersensitivity reactions)
- difficulty breathing with fever, coughing, wheezing, breathlessness (respiratory distress, pulmonary oedema, pneumonitis)
facial rash, joint pain, muscle disorder, fever (lupus erythematosus)
• inflammation of blood vessels with symptoms such as rash, purplish-red spots, fever (vasculitis)
• severe skin disease that causes rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever (toxic epidermal necrolysis)

Not known
• weakness, bruising and frequent infections (aplastic anaemia)
• decrease in vision or pain in your eyes due to high pressure (possible signs of acute angle-closure glaucoma)
• breathlessness
• severely decreased urine output (possible signs of renal disorder or renal failure)
• severe skin disease that causes rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever (erythema multiforme)
• muscle spasm
• fever (pyrexia)

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

5. HOW TO STORE IMPRIDA HCT

Keep out of the reach and sight of children.
Do not use Imprida HCT after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.
Do not store above 30°C.
Store in the original package in order to protect from moisture.
Do not use any Imprida HCT pack that is damaged or shows signs of tampering.

6. FURTHER INFORMATION

What Imprida HCT contains
– The active substances of Imprida HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide.
– Imprida HCT 5 mg/160 mg/25 mg film-coated tablets: Each film-coated tablet contains 5 mg amlodipine (as amlodipine besylate), 160 mg valsartan and 25 mg hydrochlorothiazide. The other ingredients are cellulose microcrystalline; crospovidone; silica, colloidal anhydrous, magnesium stearate, hypromellose, macrogol 4000, talc, titanium dioxide (E171), yellow iron oxide (E172).

What Imprida HCT looks like and contents of the pack
– Imprida HCT 5 mg/160 mg/25 mg film-coated tablets are yellow, oval tablets with “NVR” on one side and “VEL” on the other side.

Imprida HCT is available in packs containing 14, 28, 30, 56, 90, 98 or 280 film-coated tablets, in multipacks of 280 tablets (comprising 4 cartons, each containing 70 tablets, or 20 cartons, each containing 14 tablets), and in hospital packs containing 56, 98 or 280 tablets in single unit blisters. Not all pack sizes may be available in your country.
Marketing Authorisation Holder
Novartis Europharm Limited
Wimblehurst Road
Horsham
West Sussex, RH12 5AB
United Kingdom

Manufacturer
Novartis Pharma GmbH
Roonstraße 25
D-90429 Nuremberg
Germany

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

België/Belgique/Belgien
Novartis Pharma N.V.
Tél/Tel: +32 2 246 16 11

Belgaria
Novartis Pharma Services Inc.
Tel.: +359 2 976 98 28

Česká republika
Novartis s.r.o.
Tel: +420 225 775 111

Danmark
Novartis Healthcare A/S
Tlf: +45 39 16 84 00

Deutschland
Novartis Pharma GmbH
Tel: +49 911 273 0

Eesti
Novartis Pharma Services Inc.
Tel: +372 66 30 810

Ελλάδα
Novartis (Hellas) A.E.B.E.
Τηλ.: +30 210 281 17 12

España
Lacer, S.A.
Tel: +34 93 446 53 00

France
Novartis Pharma S.A.S.
Tél: +33 1 55 47 66 00

Ireland
Novartis Ireland Limited
Tel: +353 1 260 12 55

Luxembourg/Luxemburg
Novartis Pharma N.V.
Tél/Tel: +32 2 246 16 11

Magyarország
Novartis Hungária Kft. Pharma
Tel.: +36 1 457 65 00

Malta
Novartis Pharma Services Inc.
Tel: +356 2298 3217

Nederland
Novartis Pharma B.V.
Tel: +31 26 37 82 111

Norge
Novartis Norge AS
Tlf: +47 23 05 20 00

Österreich
Novartis Pharma GmbH
Tel: +43 1 86 6570

Polska
Novartis Poland Sp. z o.o.
Tel.: +48 22 375 4888

Portugal
Novartis Farma - Produtos Farmacêuticos, S.A.
Tel: +351 21 000 8600

România
Novartis Pharma Services Romania SRL
Tel: +40 21 31299 01

Slovenija
Novartis Pharma Services Inc.
Tel: +386 1 300 75 50
This leaflet was last approved in

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu
Imprida HCT tablets contain three substances called amlodipine, valsartan and hydrochlorothiazide. All of these substances help to control high blood pressure.

- Amlodipine belongs to a group of substances called “calcium channel blockers”. Amlodipine stops calcium from moving into the blood vessel wall, which stops the blood vessels from tightening.
- Valsartan belongs to a group of substances called “angiotensin-II receptor antagonists”. Angiotensin II is produced by the body and makes the blood vessels tighten, thus increasing the blood pressure. Valsartan works by blocking the effect of angiotensin II.
- Hydrochlorothiazide belongs to a group of substances called “thiazide diuretics”. Hydrochlorothiazide increases urine output, which also lowers blood pressure.

As a result of all three mechanisms, the blood vessels relax and blood pressure is lowered.

Imprida HCT is used to treat high blood pressure in adult patients who are already taking amlodipine, valsartan and hydrochlorothiazide and who may benefit from taking one tablet containing all three substances.

2. BEFORE YOU TAKE IMPRIDA HCT

Do not take Imprida HCT

- if you are more than 3 months pregnant. (It is also better to avoid Imprida HCT in early pregnancy – see Pregnancy section).
- if you are allergic (hypersensitive) to amlodipine, valsartan, hydrochlorothiazide, sulphonamide-derived medicines (medicines used to treat chest or urinary infections), or any of the other ingredients of Imprida HCT (see section 6, “What Imprida HCT contains”).
- If you think you may be allergic, do not take Imprida HCT and talk to your doctor.
- if you have liver disease, destruction of the small bile ducts within the liver (biliary cirrhosis) leading to the build up of bile in the liver (cholestasis).
- if you have severe kidney problems or if you are having dialysis.
- if you are unable to produce urine (anuria).
– if the level of potassium or sodium in your blood is too low despite treatment.
– if the level of calcium in your blood is too high despite treatment.
– if you have gout (uric acid crystals in the joints).

**If any of the above applies to you, do not take Imprida HCT and talk to your doctor.**

**Take special care with Imprida HCT**
– if you have a low level of potassium or magnesium in your blood (with or without symptoms such as muscle weakness, muscle spasms, abnormal heart rhythm).
– if you have a low level of sodium in your blood (with or without symptoms such as tiredness, confusion, muscle twitching, convulsions).
– if you have a high level of calcium in your blood (with or without symptoms such as nausea, vomiting, constipation, stomach pain, frequent urination, thirst, muscle weakness and twitching).
– if you are taking medicines or substances that increase the amount of potassium in your blood. These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines and heparin. It may be necessary to check the amount of potassium in your blood at regular intervals.
– if you have kidney problems, have had a kidney transplant or if you had been told that you have a narrowing of your kidney arteries.
– if you have liver problems.
– if you have or have had heart failure or coronary artery disease, particularly if you are taking the maximum dose of Imprida HCT (10 mg/320 mg/25 mg).
– if your doctor has told you that you have a narrowing of the valves in your heart (called “aortic or mitral stenosis”) or that the thickness of your heart muscle is abnormally increased (called “obstructive hypertrophic cardiomyopathy”).
– if you suffer from aldosteronism. This is a disease in which the adrenal glands make too much of the hormone aldosterone If this applies to you, the use of Imprida HCT is not recommended.
– if you suffer from a disease called systemic lupus erythematosus (also called “lupus” or “SLE”).
– if you have diabetes (high level of sugar in your blood).
– if you have high levels of cholesterol or triglycerides in your blood.
– if you experience skin reactions such as rash after sun exposure.
– if you had an allergic reaction to other high blood pressure medicines or diuretics (a type of medicine also known as “water tablets”), especially if you suffer from asthma and allergies.
– if you have been sick (vomiting or diarrhoea).
– if you experience dizziness and/or fainting during treatment with Imprida HCT, tell your doctor as soon as possible.
– if you experience a decrease in vision or eye pain. These could be symptoms of an increase of pressure in your eye and can happen within hours to a week of taking Imprida HCT. This can lead to permanent vision impairment, if not treated.

**If any of these apply to you, talk to your doctor.**

You must tell your doctor if you think that you are (or might become) pregnant. Imprida HCT is not recommended in early pregnancy and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at this stage (see section “Pregnancy and breast-feeding”).

The use of Imprida HCT in children and adolescents under 18 years of age is not recommended.

**Imprida HCT and older people (age 65 years and older)**
Imprida HCT can be used by people aged 65 years and over at the same dose as for other adults and in the same way as they have already taken the three substances called amlodipine, valsartan and hydrochlorothiazide. Elderly patients, particularly those taking the maximum dose of Imprida HCT (10 mg/320 mg/25 mg), should have their blood pressure checked regularly.
Using other medicines
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. Your doctor may need to change the dose or take other precautions. In some cases you may have to stop using one of the medicines. This is especially important if you are using any of the medicines listed below:

Do not take together with:
- lithium (a medicine used to treat some types of depression);
- medicines or substances that increase the amount of potassium in your blood. These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines and heparin.

Caution should be used with:
- alcohol, sleeping pills and anaesthetics (medicines allowing patients to undergo surgery and other procedures);
- amantadine (anti-Parkinson therapy, also used to treat or prevent certain illnesses caused by viruses);
- anticholinergic agents (medicines used to treat a variety of disorders such as gastrointestinal cramps, urinary bladder spasm, asthma, motion sickness, muscular spasm, Parkinson's disease and as an aid to anaesthesia);
- anticonvulsant medicines and mood-stabilising medicines used to treat epilepsy and bipolar disorder (e.g. carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone);
- cholestyramine, colestipol or other resins (substances used mainly to treat high levels of lipids in the blood);
- simvastatin (a medicine used to control high cholesterol levels);
- ciclosporin (a medicine used in transplantation to prevent organ rejection or for other conditions, e.g: rheumatoid arthritis or atopic dermatitis);
- cytotoxic medicines (used to treat cancer), such as methotrexate or cyclophosphamide;
- digoxin or other digitalis glycosides (medicines used to treat heart problems);
- verapamil, diltiazem (heart medicines);
- iodine contrast media (agents used for imaging examinations);
- medicines for the treatment of diabetes (oral agents such as metformin or insulins);
- medicines for the treatment of gout, such as allopurinol;
- medicines that may increase blood sugar levels (beta blockers, diazoxide);
- medicines that may induce, “torsades de pointes” (irregular heart beat), such as antiarrhythmics (medicines used to treat heart problems) and some antipsychotics;
- medicines that may reduce the amount of sodium in your blood, such as antidepressants, antipsychotics, antiepileptics;
- medicines that may reduce the amount of potassium in your blood, such as diuretics (water tablets), corticosteroids, laxatives, amphotericin or penicillin G;
- medicines to increase blood pressure such as adrenaline or noradrenaline;
- medicines used for HIV/AIDS (e.g. ritonavir, indinavir, nelfinavir);
- medicines used to treat fungal infections (e.g. ketoconazole, itraconazole);
- medicines used for oesophageal ulceration and inflammation (carbenoxolone);
- medicines used to relieve pain or inflammation, especially non-steroidal anti-inflammatory agents (NSAIDs), including selective cyclooxygenase-2 inhibitors (Cox-2 inhibitors);
- muscle relaxants (medicines to relax the muscles which are used during operations);
- nitroglycerin and other nitrates, or other substances called “vasodilators”;
- other medicines to treat high blood pressure, including methyldopa;
- rifampicin (used, for example, to treat tuberculosis);
- St. John’s wort;
- dantrolene (infusion for severe body temperature abnormalities);
- vitamin D and calcium salts.

Talk to your doctor before drinking alcohol. Alcohol may make your blood pressure fall too much and/or increase the possibility of dizziness or fainting.
Taking Imprida HCT with food and drink
You can take Imprida HCT with or without food. Grapefruit and grapefruit juice should not be consumed by people who are taking Imprida HCT. This is because grapefruit and grapefruit juice can lead to an increase in the blood levels of the active substance amlodipine, which can cause an unpredictable increase in the blood pressure lowering effect of Imprida HCT.

Pregnancy and breast-feeding

Pregnancy
You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking Imprida HCT before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Imprida HCT. Imprida HCT is not recommended in early pregnancy and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.

Breast-feeding
Tell your doctor if you are breast-feeding or about to start breast-feeding. Imprida HCT is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is a newborn, or was born prematurely.

Ask your doctor or pharmacist for advice before taking any medicine.

Driving and using machines
As with many other medicines used to treat high blood pressure, this medicine may make you feel dizzy. If you experience this symptom, do not drive or use tools or machines.

3. HOW TO TAKE IMPRIDA HCT

Always take this medicine exactly as your doctor has told you. You should check with your doctor if you are not sure. This will help you get the best results and lower the risk of side effects.

The usual dose of Imprida HCT is one tablet per day.
− It is best to take the tablet at the same time each day. Morning is the best time.
− Swallow the tablet whole with a glass of water.
− You can take Imprida HCT with or without food. Do not take Imprida HCT with grapefruit or grapefruit juice.

Depending on how you respond to the treatment, your doctor may suggest a higher or lower dose.

If you take more Imprida HCT than you should
If you have accidentally taken too many Imprida HCT tablets, talk to a doctor immediately. You may require medical attention.

If you forget to take Imprida HCT
If you forget to take a dose of this medicine, take it as soon as you remember and then take the next dose at its usual time. If it is almost time for your next dose you should simply take the next tablet at the usual time. Do not take a double dose (two tablets at once) to make up for a forgotten tablet.

If you stop taking Imprida HCT
Stopping your treatment with Imprida HCT may cause your disease to get worse. Do not stop taking your medicine unless your doctor tells you to.
Always take this medicine, even if you are feeling well
People who have high blood pressure often do not notice any signs of the problem. Many feel normal. It is very important that you take this medicine exactly as your doctor tells you to get the best results and reduce the risk of side effects. Keep your appointments with the doctor even if you are feeling well.

If you have any further questions on the use of this product ask your doctor or pharmacist.

4. POSSIBLE SIDE EFFECTS

Like all medicines, Imprida HCT can cause side effects, although not everybody gets them. These side effects may occur with certain frequencies, which are defined as follows:
very common: affects more than 1 user in 10
common: affects 1 to 10 users in 100
uncommon: affects 1 to 10 users in 1,000
rare: affects 1 to 10 users in 10,000
very rare: affects less than 1 user in 10,000
not known: frequency cannot be estimated from the available data

Some side effects can be serious and need immediate medical attention:

You should see your doctor immediately if you experience any of the following symptoms:

Common
• dizziness
• low blood pressure (feeling of faintness, light-headedness, sudden loss of consciousness)

Uncommon
• severely decreased urine output (decreased kidney function)

Rare
• spontaneous bleeding
• irregular heart beat
• liver disorder

Very rare
• allergic reaction with symptoms such as rash, itching
• angioedema: swelling of face or lips or tongue, difficulty of breathing
• crushing/tight chest pain that gets worse or that does not go away
• weakness, bruising, fever and frequent infections
• stiffness

Other possible side effects of Imprida HCT:

Common
• stomach discomfort after meal
• tiredness
• swelling
• low level of potassium in the blood
• headache
• frequent urination
Uncommon
- fast heart beat
- spinning sensation
- vision disorder
- stomach discomfort
- chest pain
- increase of urea nitrogen, creatinine and uric acid in the blood
- high level of calcium, fat or sodium in the blood
- decrease of potassium in the blood
- breath odour
- diarrhoea
- dry mouth
- nausea
- vomiting
- abdominal pain
- weight increase
- loss of appetite
- disturbed sense of taste
- back pain
- joint swelling
- muscle cramps/weakness/pain
- pain in extremity
- inability to either stand or walk in a normal manner
- weakness
- abnormal coordination
- dizziness on standing up or after exercising
- lack of energy
- sleep disturbances
- tingling or numbness
- neuropathy
- sleepiness
- sudden, temporary loss of consciousness
- low blood pressure on standing up
- impotence
- cough
- breathlessness
- throat irritation
- excessive sweating
- itching
- swelling, reddening and pain along a vein
- skin reddening
- trembling

Not known
- changes in blood tests for kidney function, increase of potassium in your blood, low level of red blood cells
Side effects reported with amlodipine or valsartan or hydrochlorothiazide alone, but not observed with Imprida HCT or observed in a higher frequency:

**Amlodipine**

*Common*
- palpitations
- abdominal pain
- nausea
- sleepiness
- hot flushes

*Uncommon*
- ringing noise in ears
- change of bowel habit
- pain
- weight decrease
- joint pain
- trembling
- mood swings
- urination disorders
- urination at night
- breast enlargement in men
- runny nose
- hair loss
- skin eruption
- purple skin patches
- rash
- skin discoloration

*Very rare*
- low level of white blood cells and blood platelets
- irregular heart beat
- heart attack
- inflammation of the stomach lining or of the pancreas, gingival overgrowth, abnormal liver function test
- liver disorder which can occur together with yellow skin and eyes, or dark-coloured urine
- allergic reaction including swelling deeper in the skin and difficulty breathing
- high level of sugar in the blood
- increased muscle stiffness
- skin reaction with skin reddening and peeling, blistering of lips, eyes or mouth
- itchy rash
- inflammation of blood vessels

*Not known*
- stiff limbs and trembling hands
Valsartan
Not known
• abnormal red blood cell test
• low level of a certain type of white blood cell and blood platelet
• increase of potassium in the blood
• increase of creatinine in the blood
• abnormal liver function test
• allergic reaction including swelling deeper in the skin and difficulty breathing
• muscle pain
• severely decreased urine output
• itching
• rash
• inflammation of blood vessels

Hydrochlorothiazide
Very common
• low level of potassium in the blood
• increase of lipids in the blood

Common
• high level of uric acid in the blood
• low level of magnesium in the blood
• low level of sodium in the blood
• dizziness, fainting on standing up
• reduced appetite
• nausea and vomiting
• itchy rash and other types of rash
• inability to achieve or maintain erection

Rare
• low level of blood platelets (sometimes with bleeding or bruising underneath the skin)
• sugar in the urine
• high level of sugar in the blood
• worsening of the diabetic metabolic state
• sad mood (depression)
• irregular heart beat
• abdominal discomfort
• constipation
• liver disorders which can occur together with yellow skin and eyes, or dark-coloured urine (haemolytic anaemia)
• increased sensitivity of skin to sun
• purple skin patches
• kidney disorders

Very rare
• fever, sore throat or mouth ulcers, more frequent infections (lack or low level of white blood cells)
• pale skin, tiredness, breathlessness, dark-coloured urine (haemolytic anaemia, abnormal breakdown of red blood cells either in the blood vessels or elsewhere in the body)
• confusion, tiredness, muscle twitching and spasm, rapid breathing (hypochloraeemic alkalosis)
• severe upper stomach ache (inflammation of the pancreas)
• rash, itching, hives, difficulty breathing or swallowing, dizziness (hypersensitivity reactions)
• difficulty breathing with fever, coughing, wheezing, breathlessness (respiratory distress, pulmonary oedema, pneumonitis)
- facial rash, joint pain, muscle disorder, fever (lupus erythematosus)
- inflammation of blood vessels with symptoms such as rash, purplish-red spots, fever (vasculitis)
- severe skin disease that causes rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever (toxic epidermal necrolysis)

Not known
- weakness, bruising and frequent infections (aplastic anaemia)
- decrease in vision or pain in your eyes due to high pressure (possible signs of acute angle-closure glaucoma)
- breathlessness
- severely decreased urine output (possible signs of renal disorder or renal failure)
- severe skin disease that causes rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever (erythema multiforme)
- muscle spasm
- fever (pyrexia)

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

5. HOW TO STORE IMPRIDA HCT

Keep out of the reach and sight of children.
Do not use Imprida HCT after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.
Do not store above 30°C.
Store in the original package in order to protect from moisture.
Do not use any Imprida HCT pack that is damaged or shows signs of tampering.

6. FURTHER INFORMATION

What Imprida HCT contains
- The active substances of Imprida HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide.
- Imprida HCT 10 mg/160 mg/25 mg film-coated tablets: Each film-coated tablet contains 10 mg amlodipine (as amlodipine besylate), 160 mg valsartan, and 25 mg hydrochlorothiazide. The other ingredients are cellulose microcrystalline; crospovidone; silica, colloidal anhydrous, magnesium stearate, hypromellose, macrogol 4000, talc, yellow iron oxide (E172).

What Imprida HCT looks like and contents of the pack
- Imprida HCT 10 mg/160 mg/25 mg film-coated tablets are brown-yellow, oval tablets with “NVR” on one side and “VHL” on the other side.

Imprida HCT is available in packs containing 14, 28, 30, 56, 90, 98 or 280 film-coated tablets, in multipacks of 280 tablets (comprising 4 cartons, each containing 70 tablets, or 20 cartons, each containing 14 tablets), and in hospital packs containing 56, 98 or 280 tablets in single unit blisters. Not all pack sizes may be available in your country.
Marketing Authorisation Holder
Novartis Europharm Limited
Wimblehurst Road
Horsham
West Sussex, RH12 5AB
United Kingdom

Manufacturer
Novartis Pharma GmbH
Roonstraße 25
D-90429 Nuremberg
Germany

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

Belgie/Belgique/Belgien
Novartis Pharma N.V.
Tél/Tel: +32 2 246 16 11

България
Novartis Pharma Services Inc.
Tel.: +359 2 976 98 28

Česká republika
Novartis s.r.o.
Tel: +420 225 775 111

Danmark
Novartis Healthcare A/S
Tlf: +45 39 16 84 00

Deutschland
Novartis Pharma GmbH
Tel: +49 911 273 0

Eesti
Novartis Pharma Services Inc.
Tel: +372 66 30 810

Ελλάδα
Novartis (Hellas) A.E.B.E.
Τηλ.: +30 210 281 17 12

España
Lacer, S.A.
Tel: +34 93 446 53 00

France
Novartis Pharma S.A.S.
Tél: +33 1 55 47 66 00

Ireland
Novartis Ireland Limited
Tel: +353 1 260 12 55

Luxembourg/Luxemburg
Novartis Pharma N.V.
Tél/Tel: +32 2 246 16 11

Magyarország
Novartis Hungária Kft. Pharma
Tel.: +36 1 457 65 00

Malta
Novartis Pharma Services Inc.
Tel: +356 2298 3217

Nederland
Novartis Pharma B.V.
Tel: +31 26 37 82 111

Norge
Novartis Norge AS
Tlf: +47 23 05 20 00

Österreich
Novartis Pharma GmbH
Tel: +43 1 86 6570

Polska
Novartis Poland Sp. z o.o.
Tel.: +48 22 375 4888

Portugal
Novartis Farma - Produtos Farmacêuticos, S.A.
Tel: +351 21 000 8600

România
Novartis Pharma Services Romania SRL
Tel: +40 21 31299 01

Slovenija
Novartis Pharma Services Inc.
Tel: +386 1 300 75 50
Ísland
Vistor hf.
Sími: +354 535 7000

Slovenská republika
Novartis Slovakia s.r.o.
Tel: +421 2 5542 5439

Italia
Novartis Farma S.p.A.
Tel: +39 02 96 54 1

Suomi/Finland
Novartis Finland Oy
Puh/Tel: +358 (0)10 6133 200

Képroς
Novartis Pharma Services Inc.
Τηλ: +357 22 690 690

Sverige
Novartis Sverige AB
Tel: +46 8 732 32 00

Latvija
Novartis Pharma Services Inc.
Tel: +371 67 887 070

United Kingdom
Novartis Pharmaceuticals UK Ltd.
Tel: +44 1276 698370

Lietuva
Novartis Pharma Services Inc.
Tel: +370 5 269 16 50

This leaflet was last approved in

Detailed information on this medicine is available on the European Medicines Agency web site:
http://www.ema.europa.eu

Medicinal product no longer authorised
PACKAGE LEAFLET: INFORMATION FOR THE USER

Imprida HCT 10 mg/320 mg/25 mg film-coated tablets
amlodipine/valsartan/hydrochlorothiazide

Read all of this leaflet carefully before you start taking this medicine.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

In this leaflet:
1. What Imprida HCT is and what it is used for
2. Before you take Imprida HCT
3. How to take Imprida HCT
4. Possible side effects
5. How to store Imprida HCT
6. Further information

1. WHAT IMPRIDA HCT IS AND WHAT IT IS USED FOR

Imprida HCT tablets contain three substances called amlodipine, valsartan and hydrochlorothiazide. All of these substances help to control high blood pressure.
- Amlodipine belongs to a group of substances called “calcium channel blockers”. Amlodipine stops calcium from moving into the blood vessel wall, which stops the blood vessels from tightening.
- Valsartan belongs to a group of substances called “angiotensin-II receptor antagonists”. Angiotensin II is produced by the body and makes the blood vessels tighten, thus increasing the blood pressure. Valsartan works by blocking the effect of angiotensin II.
- Hydrochlorothiazide belongs to a group of substances called “thiazide diuretics”. Hydrochlorothiazide increases urine output, which also lowers blood pressure.
As a result of all three mechanisms, the blood vessels relax and blood pressure is lowered.

Imprida HCT is used to treat high blood pressure in adult patients who are already taking amlodipine, valsartan and hydrochlorothiazide and who may benefit from taking one tablet containing all three substances.

2. BEFORE YOU TAKE IMPRIDA HCT

Do not take Imprida HCT
- if you are more than 3 months pregnant. (It is also better to avoid Imprida HCT in early pregnancy – see Pregnancy section).
- if you are allergic (hypersensitive) to amlodipine, valsartan, hydrochlorothiazide, sulphonamide-derived medicines (medicines used to treat chest or urinary infections), or any of the other ingredients of Imprida HCT (see section 6, “What Imprida HCT contains”).
If you think you may be allergic, do not take Imprida HCT and talk to your doctor.
- if you have liver disease, destruction of the small bile ducts within the liver (biliary cirrhosis) leading to the build up of bile in the liver (cholestasis).
- if you have severe kidney problems or if you are having dialysis.
- if you are unable to produce urine (anuria).
- if the level of potassium or sodium in your blood is too low despite treatment.
- if the level of calcium in your blood is too high despite treatment.
- if you have gout (urate crystals in the joints).

If any of the above applies to you, do not take Imprida HCT and talk to your doctor.

Take special care with Imprida HCT
- if you have a low level of potassium or magnesium in your blood (with or without symptoms such as muscle weakness, muscle spasms, abnormal heart rhythm).
- if you have a low level of sodium in your blood (with or without symptoms such as tiredness, confusion, muscle twitching, convulsions).
- if you have a high level of calcium in your blood (with or without symptoms such as nausea, vomiting, constipation, stomach pain, frequent urination, thirst, muscle weakness and twitching).
- if you are taking medicines or substances that increase the amount of potassium in your blood. These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines and heparin. It may be necessary to check the amount of potassium in your blood at regular intervals.
- if you have kidney problems, have had a kidney transplant or if you had been told that you have a narrowing of your kidney arteries.
- if you have liver problems.
- if you have or have had heart failure or coronary artery disease, particularly if you are taking the maximum dose of Imprida HCT (10 mg/320 mg/25 mg).
- if your doctor has told you that you have a narrowing of the valves in your heart (called “aortic or mitral stenosis”) or that the thickness of your heart muscle is abnormally increased (called “obstructive hypertrophic cardiomyopathy”).
- if you suffer from aldosteronism. This is a disease in which the adrenal glands make too much of the hormone aldosterone. If this applies to you, the use of Imprida HCT is not recommended.
- if you suffer from a disease called systemic lupus erythematosus (also called “lupus” or “SLE”).
- if you have diabetes (high level of sugar in your blood).
- if you have high levels of cholesterol or triglycerides in your blood.
- if you experience skin reactions such as rash after sun exposure.
- if you had an allergic reaction to other high blood pressure medicines or diuretics (a type of medicine also known as “water tablets”), especially if you suffer from asthma and allergies.
- if you have been sick (vomiting or diarrhoea).
- if you experience dizziness and/or fainting during treatment with Imprida HCT, tell your doctor as soon as possible.
- if you experience a decrease in vision or eye pain. These could be symptoms of an increase of pressure in your eye and can happen within hours to a week of taking Imprida HCT. This can lead to permanent vision impairment, if not treated.

If any of these apply to you, talk to your doctor.

You must tell your doctor if you think that you are (or might become) pregnant. Imprida HCT is not recommended in early pregnancy and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at this stage (see section “Pregnancy and breast-feeding”).

The use of Imprida HCT in children and adolescents under 18 years of age is not recommended.

Imprida HCT and older people (age 65 years and older)
Imprida HCT can be used by people aged 65 years and over at the same dose as for other adults and in the same way as they have already taken the three substances called amlodipine, valsartan and hydrochlorothiazide. Elderly patients, particularly those taking the maximum dose of Imprida HCT (10 mg/320 mg/25 mg), should have their blood pressure checked regularly.
Using other medicines

Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. Your doctor may need to change the dose or take other precautions. In some cases you may have to stop using one of the medicines. This is especially important if you are using any of the medicines listed below:

Do not take together with:
- lithium (a medicine used to treat some types of depression);
- medicines or substances that increase the amount of potassium in your blood. These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines and heparin.

Caution should be used with:
- alcohol, sleeping pills and anaesthetics (medicines allowing patients to undergo surgery and other procedures);
- amantadine (anti-Parkinson therapy, also used to treat or prevent certain illnesses caused by viruses);
- anti-cholinergic agents (medicines used to treat a variety of disorders such as gastrointestinal cramps, urinary bladder spasm, asthma, motion sickness, muscular spasms, Parkinson's disease and as an aid to anaesthesia);
- anticonvulsant medicines and mood-stabilising medicines used to treat epilepsy and bipolar disorder (e.g. carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone);
- cholestyramine, colestipol or other resins (substances used mainly to treat high levels of lipids in the blood);
- simvastatin (a medicine used to control high cholesterol levels);
- ciclosporin (a medicine used in transplantation to prevent organ rejection or for other conditions, e.g: rheumatoid arthritis or atopic dermatitis);
- cytotoxic medicines (used to treat cancer), such as methotrexate or cyclophosphamide;
- digoxin or other digitalis glycosides (medicines used to treat heart problems);
- verapamil, diltiazem (heart medicines);
- iodine contrast media (agents used for imaging examinations);
- medicines for the treatment of diabetes (oral agents such as metformin or insulins);
- medicines for the treatment of gout, such as allopurinol;
- medicines that may increase blood sugar levels (beta blockers, diazoxide);
- medicines that may induce "torsades de pointes" (irregular heart beat), such as antiarrhythmics (medicines used to treat heart problems) and some antipsychotics;
- medicines that may reduce the amount of sodium in your blood, such as antidepressants, antipsychotics, antiepileptics;
- medicines that may reduce the amount of potassium in your blood, such as diuretics (water tablets), corticosteroids, laxatives, amphotericin or penicillin G;
- medicines to increase blood pressure such as adrenaline or noradrenaline;
- medicines used for HIV/AIDS (e.g. ritonavir, indinavir, nelfinavir);
- medicines used to treat fungal infections (e.g. ketoconazole, itraconazole);
- medicines used for oesophageal ulceration and inflammation (carbenoxolone);
- medicines used to relieve pain or inflammation, especially non-steroidal anti-inflammatory agents (NSAIDs), including selective cyclooxygenase-2 inhibitors (CoX-2 inhibitors);
- muscle relaxants (medicines to relax the muscles which are used during operations);
- nitroglycerin and other nitrates, or other substances called “vasodilators”;
- other medicines to treat high blood pressure, including methyldopa;
- rifampicin (used, for example, to treat tuberculosis);
- St. John’s wort;
- dantrolene (infusion for severe body temperature abnormalities);
- vitamin D and calcium salts.

Talk to your doctor before drinking alcohol. Alcohol may make your blood pressure fall too much and/or increase the possibility of dizziness or fainting.
Taking Imprida HCT with food and drink
You can take Imprida HCT with or without food. Grapefruit and grapefruit juice should not be consumed by people who are taking Imprida HCT. This is because grapefruit and grapefruit juice can lead to an increase in the blood levels of the active substance amlodipine, which can cause an unpredictable increase in the blood pressure lowering effect of Imprida HCT.

Pregnancy and breast-feeding

Pregnancy
You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking Imprida HCT before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Imprida HCT. Imprida HCT is not recommended in early pregnancy and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.

Breast-feeding
Tell your doctor if you are breast-feeding or about to start breast-feeding. Imprida HCT is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is a newborn, or was born prematurely.

Ask your doctor or pharmacist for advice before taking any medicine.

Driving and using machines
As with many other medicines used to treat high blood pressure, this medicine may make you feel dizzy. If you experience this symptom, do not drive or use tools or machines.

3. HOW TO TAKE IMPRIDA HCT

Always take this medicine exactly as your doctor has told you. You should check with your doctor if you are not sure. This will help you get the best results and lower the risk of side effects.

The usual dose of Imprida HCT is one tablet per day.
- It is best to take the tablet at the same time each day. Morning is the best time.
- Swallow the tablet whole with a glass of water.
- You can take Imprida HCT with or without food. Do not take Imprida HCT with grapefruit or grapefruit juice.

Depending on how you respond to the treatment, your doctor may suggest a higher or lower dose.

If you take more Imprida HCT than you should
If you have accidentally taken too many Imprida HCT tablets, talk to a doctor immediately. You may require medical attention.

If you forget to take Imprida HCT
If you forget to take a dose of this medicine, take it as soon as you remember and then take the next dose at its usual time. If it is almost time for your next dose you should simply take the next tablet at the usual time. Do not take a double dose (two tablets at once) to make up for a forgotten tablet.

If you stop taking Imprida HCT
Stopping your treatment with Imprida HCT may cause your disease to get worse. Do not stop taking your medicine unless your doctor tells you to.
Always take this medicine, even if you are feeling well
People who have high blood pressure often do not notice any signs of the problem. Many feel normal.
It is very important that you take this medicine exactly as your doctor tells you to get the best results
and reduce the risk of side effects. Keep your appointments with the doctor even if you are feeling
well.

If you have any further questions on the use of this product ask your doctor or pharmacist.

4. POSSIBLE SIDE EFFECTS

Like all medicines, Imprida HCT can cause side effects, although not everybody gets them. These side effects may occur with certain frequencies, which are defined as follows:
very common: affects more than 1 user in 10
common: affects 1 to 10 users in 100
uncommon: affects 1 to 10 users in 1,000
rare: affects 1 to 10 users in 10,000
very rare: affects less than 1 user in 10,000
not known: frequency cannot be estimated from the available data

Some side effects can be serious and need immediate medical attention:
You should see your doctor immediately if you experience any of the following symptoms:
Common
- dizziness
- low blood pressure (feeling of faintness, light-headedness, sudden loss of consciousness)

Uncommon
- severely decreased urine output (decreased kidney function)

Rare
- spontaneous bleeding
- irregular heart beat
- liver disorder

Very rare
- allergic reaction with symptoms such as rash, itching
- angioedema: swelling of face or lips or tongue, difficulty of breathing
- crushing/tight chest pain that gets worse or that does not go away
- weakness, bruising, fever and frequent infections
- stiffness

Other possible side effects of Imprida HCT:
Common
- stomach discomfort after meal
- tiredness
- swelling
- low level of potassium in the blood
- headache
- frequent urination
Uncommon

- fast heart beat
- spinning sensation
- vision disorder
- stomach discomfort
- chest pain
- increase of urea nitrogen, creatinine and uric acid in the blood
- high level of calcium, fat or sodium in the blood
- decrease of potassium in the blood
- breath odour
- diarrhoea
- dry mouth
- nausea
- vomiting
- abdominal pain
- weight increase
- loss of appetite
- disturbed sense of taste
- back pain
- joint swelling
- muscle cramps/weakness/pain
- pain in extremity
- inability to either stand or walk in a normal manner
- weakness
- abnormal coordination
- dizziness on standing up or after exercising
- lack of energy
- sleep disturbances
- tingling or numbness
- neuropathy
- sleepiness
- sudden, temporary loss of consciousness
- low blood pressure on standing up
- impotence
- cough
- breathlessness
- throat irritation
- excessive sweating
- itching
- swelling, reddening and pain along a vein
- skin reddening
- trembling

Not known

- changes in blood tests for kidney function, increase of potassium in your blood, low level of red blood cells
Side effects reported with amlodipine or valsartan or hydrochlorothiazide alone, but not observed with Imprida HCT or observed in a higher frequency:

**Amlodipine**

*Common*
- palpitations
- abdominal pain
- nausea
- sleepiness
- hot flushes

*Uncommon*
- ringing noise in ears
- change of bowel habit
- pain
- weight decrease
- joint pain
- trembling
- mood swings
- urination disorders
- urination at night
- breast enlargement in men
- runny nose
- hair loss
- skin eruption
- purple skin patches
- rash
- skin discoloration

*Very rare*
- low level of white blood cells and blood platelets
- irregular heart beat
- heart attack
- inflammation of the stomach lining or of the pancreas, gingival overgrowth, abnormal liver function test
- liver disorder which can occur together with yellow skin and eyes, or dark-coloured urine
- allergic reaction including swelling deeper in the skin and difficulty breathing
- high level of sugar in the blood
- increased muscle stiffness
- skin reaction with skin reddening and peeling, blistering of lips, eyes or mouth
- itchy rash
- inflammation of blood vessels

*Not known*
- stiff limbs and trembling hands
Valsartan

*Not known*

- abnormal red blood cell test
- low level of a certain type of white blood cell and blood platelet
- increase of potassium in the blood
- increase of creatinine in the blood
- abnormal liver function test
- allergic reaction including swelling deeper in the skin and difficulty breathing
- muscle pain
- severely decreased urine output
- itching
- rash
- inflammation of blood vessels

Hydrochlorothiazide

*Very common*

- low level of potassium in the blood
- increase of lipids in the blood

*Common*

- high level of uric acid in the blood
- low level of magnesium in the blood
- low level of sodium in the blood
- dizziness, fainting on standing up
- reduced appetite
- nausea and vomiting
- itchy rash and other types of rash
- inability to achieve or maintain erection

*Rare*

- low level of blood platelets (sometimes with bleeding or bruising underneath the skin)
- sugar in the urine
- high level of sugar in the blood
- worsening of the diabetic metabolic state
- sad mood (depression)
- irregular heart beat
- abdominal discomfort
- constipation
- liver disorders which can occur together with yellow skin and eyes, or dark-coloured urine (haemolytic anaemia)
- increased sensitivity of skin to sun
- purple skin patches
- kidney disorders

*Very rare*

- fever, sore throat or mouth ulcers, more frequent infections (lack or low level of white blood cells)
- pale skin, tiredness, breathlessness, dark-coloured urine (haemolytic anaemia, abnormal breakdown of red blood cells either in the blood vessels or elsewhere in the body)
- confusion, tiredness, muscle twitching and spasm, rapid breathing (hypochloraemic alkalosis)
- severe upper stomach ache (inflammation of the pancreas)
- rash, itching, hives, difficulty breathing or swallowing, dizziness (hypersensitivity reactions)
- difficulty breathing with fever, coughing, wheezing, breathlessness (respiratory distress, pulmonary oedema, pneumonitis)
facial rash, joint pain, muscle disorder, fever (lupus erythematosus)
inflammation of blood vessels with symptoms such as rash, purplish-red spots, fever (vasculitis)
severe skin disease that causes rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever (toxic epidermal necrolysis)

Not known
weakness, bruising and frequent infections (aplastic anaemia)
decrease in vision or pain in your eyes due to high pressure (possible signs of acute angle-closure glaucoma)
breathlessness
severely decreased urine output (possible signs of renal disorder or renal failure)
severe skin disease that causes rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever (erythema multiforme)
muscle spasm
fever (pyrexia)

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

5. HOW TO STORE IMPRIDA HCT

Keep out of the reach and sight of children.
Do not use Imprida HCT after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.
Do not store above 30°C.
Store in the original package in order to protect from moisture.
Do not use any Imprida HCT pack that is damaged or shows signs of tampering.

6. FURTHER INFORMATION

What Imprida HCT contains
– The active substances of Imprida HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide.

– Imprida HCT 10 mg/320 mg/25 mg film-coated tablets: Each film-coated tablet contains 10 mg amlodipine (as amlodipine besylate), 320 mg valsartan, and 25 mg hydrochlorothiazide. The other ingredients are cellulose microcrystalline; crospovidone; silica, colloidal anhydrous, magnesium stearate, hypromellose, macrogol 4000, talc, yellow iron oxide (E172).

What Imprida HCT looks like and contents of the pack
– Imprida HCT 10 mg/320 mg/25 mg film-coated tablets are brown-yellow, oval tablets with “NVR” on one side and “VFL” on the other side.

Imprida HCT is available in packs containing 14, 28, 30, 56, 90, 98 or 280 film-coated tablets, in multipacks of 280 tablets (comprising 4 cartons, each containing 70 tablets, or 20 cartons, each containing 14 tablets), and in hospital packs containing 56, 98 or 280 tablets in single unit blisters. Not all pack sizes may be available in your country.
Marketing Authorisation Holder
Novartis Europharm Limited
Wimblehurst Road
Horsham
West Sussex, RH12 5AB
United Kingdom

Manufacturer
Novartis Pharma GmbH
Roonstraße 25
D-90429 Nuremberg
Germany

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

België/Belgique/Belgien
Novartis Pharma N.V.
Tél/Tel: +32 2 246 16 11

България
Novartis Pharma Services Inc.
Тел.: +359 2 976 98 28

Česká republika
Novartis s.r.o.
Tel: +420 225 775 111

Danmark
Novartis Healthcare A/S
Tlf: +45 39 16 84 00

Deutschland
Novartis Pharma GmbH
Tel: +49 911 273 0

Ελλάδα
Novartis (Hellas) A.E.B.E.
Τηλ.: +30 210 281 17 12

España
Lacer, S.A.
Tel: +34 93 446 53 00

France
Novartis Pharma S.A.S.
Tél: +33 1 55 47 66 00

Ireland
Novartis Ireland Limited
Tel: +353 1 260 12 55

Luxembourg/Luxemburg
Novartis Pharma N.V.
Tél/Tel: +32 2 246 16 11

Magyarország
Novartis Hungária Kft. Pharma
Tel.: +36 1 457 65 00

Malta
Novartis Pharma Services Inc.
Tel: +356 2298 3217

Nederland
Novartis Pharma B.V.
Tel: +31 26 37 82 111

Norge
Novartis Norge AS
Tlf: +47 23 05 20 00

Österreich
Novartis Pharma GmbH
Tel: +43 1 86 6570

Polska
Novartis Poland Sp. z o.o.
Tel.: +48 22 375 4888

Portugal
Novartis Farma - Produtos Farmacêuticos, S.A.
Tel: +351 21 000 8600

România
Novartis Pharma Services Romania SRL
Tel: +40 21 31299 01

Slovenija
Novartis Pharma Services Inc.
Tel: +386 1 300 75 50
Ísland
Vistor hf.
Sími: +354 535 7000

Italia
Novartis Farma S.p.A.
Tel: +39 02 96 54 1

Slovenská republika
Novartis Slovakia s.r.o.
Tel: +421 2 5542 5439

Suomi/Finland
Novartis Finland Oy
Puh/Tel: +358 (0)10 6133 200

Κύπρος
Novartis Pharma Services Inc.
Τηλ: +357 22 690 690

Sverige
Novartis Sverige AB
Tel: +46 8 732 32 00

Latvija
Novartis Pharma Services Inc.
Tel: +371 67 887 070

United Kingdom
Novartis Pharmaceuticals UK Ltd.
Tel: +44 1276 698370

Lietuva
Novartis Pharma Services Inc.
Tel: +370 5 269 16 50

This leaflet was last approved in

Detailed information on this medicine is available on the European Medicines Agency web site:
http://www.ema.europa.eu